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CHAPTER
Complex I  deficiency:  Causes, 
consequences and treatment 
options with focus towards the 
NDUFS4 subunit
Partially published in 
Roestenberg, P., Manjeri, G.R., Valsecchi, F., Smeitink, J.A., 
Willems, P.H., and Koopman, W.J. (2012). Pharmacological targeting 
of mitochondrial complex I deficiency: the cellular level and beyond. 
Mitochondrion 12, 57-65. 
Valsecchi, F., Koopman, W.J., Manjeri, G.R., Rodenburg, R.J., 
Smeitink, J.A., and Willems, P.H. (2010). Complex I disorders: causes, 
mechanisms, and development of treatment strategies at the cellular 
level. Developmental disabilities research reviews 16, 175-182.
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Introduction
Mitochondrial Complex I (CI)
Complex I (CI), or NADH: ubiquinone oxidoreductase, is the first multisubunit 
enzyme complex of the mitochondrial oxidative phosphorylation (OXPHOS) system. 
In most cells, the OXPHOS system is responsible for the vast majority of cellular 
ATP production, with ATP being the primary source of energy to power the cell’s 
activities. CI liberates electrons from NADH and passes them via a series of protein-
coupled redox centres to the electron acceptor ubiquinone (Hirst and Roessler 2016, 
Wirth, Brandt et al. 2016). In well-coupled mitochondria, the electron flux through 
the respiratory chain (RC) part of the OXPHOS system leads to the building of an 
electrochemical proton gradient across the mitochondrial inner membrane (MIM), 
the proton motive force (PMF), which is used by the fifth complex of the system, 
complex V or F1F0-ATP synthase, to generate ATP. The complex is composed of 44 
subunits, 14 of which are the so-called core subunits (Fiedorczuk, Letts et al. 2016, 
Lenaz, Tioli et al. 2016, Sanchez-Caballero, Guerrero-Castillo et al. 2016, Wirth, Brandt 
et al. 2016). Seven of these core subunits are encoded by the mitochondrial (mt)
DNA (ND1, ND2, ND3, ND4, ND4L, ND5, ND6 and ND7) and 7 by the nuclear (n)DNA 
(NDUFV1, NDUFV2, NDUFS1, NDUFS2, NDUFS3, NDUFS7, and NDUFS8). The function 
of the remaining 30 subunits, the accessory subunits, which all are encoded by the 
nDNA, is still incompletely understood but it is believed that they play a crucial role 
in CI assembly, biogenesis stabilization, and/or functional regulation (Valsecchi, 
Koopman et al. 2010, Balsa, Marco et al. 2012, Roestenberg, Manjeri et al. 2012).
Genetics of inherited isolated CI deficiency 
Inherited isolated CI deficiency can result from mutations in either mtDNA- or nDNA-
encoded CI structural subunits or nDNA-encoded CI assembly factors (Smeitink, 
Sengers et al. 2001, Smeitink, van den Heuvel et al. 2001, Koopman, Willems et al. 
2012). The first mtDNA mutation associated with human disease was described in 
1988 (Wallace, Zheng et al. 1988). Individual mitochondria contain multiple mtDNA 
copies and mutations are generally inherited via the mother (maternal inheritance). 
Mutations can be present in a variable amount of mtDNA copies, a phenomenon 
referred to as heteroplasmy. The degree of heteroplasmy is an important contributor 
to the severity of the disease. To date, genetic defects causing inherited isolated 
CI deficiency have been reported for all 7 mtDNA-encoded CI subunits. Mutations 
in nDNA-encoded CI subunits are frequently inherited in an autosomal recessive 
fashion, meaning that both parents have to be heterozygous carriers. For successful 
14
1
C
o
m
ple
x
 I d
efIC
Ien
C
y
prenatal diagnosis, it is necessary that causative nuclear gene mutations are known. In 
this respect, disease-causing mutations have been demonstrated in genes encoding 
the following CI subunits: NDUFV1 (Schuelke, Smeitink et al. 1999), NDUFV2 (Benit, 
Beugnot et al. 2003), NDUFS1(Benit, Chretien et al. 2001, Martin, Blazquez et al. 2005, 
Iuso, Scacco et al. 2006, Hoefs, Skjeldal et al. 2010) , NDUFS2 (Loeffen, Elpeleg et al. 
2001), NDUFS3 (Benit, Slama et al. 2004), NDUFS4 (van den Heuvel, Ruitenbeek et 
al. 1998), NDUFS6 (Kirby, Salemi et al. 2004), NDUFS7 (Triepels, van den Heuvel et al. 
1999), NDUFS8 (Loeffen, Smeitink et al. 1998), NDUFA1 (Fernandez-Vizarra, Bugiani et 
al. 2007), NDUFA2 (Hoefs, Dieteren et al. 2008), NDUFA9 (van den Bosch, Gerards et 
al. 2012), NDUFA10 (Hoefs, van Spronsen et al. 2011), NDUFA11 (Berger, Hershkovitz et 
al. 2008), NDUFA12 (Ostergaard, Rodenburg et al. 2011), NDUFA13 (Angebault, Charif 
et al. 2015), NDUFB3 (Alston, Howard et al. 2016) and NDUFB9 (Haack, Madignier et 
al. 2012). In addition inherited isolated CI deficiency can be caused by mutations in 
nDNA-encoded proteins involved in CI assembly and/or stabilization. Mutations have 
been found in NDUFAF1 (Dunning, McKenzie et al. 2007), NDUFAF2 (Hoefs, Dieteren 
et al. 2008), NDUFAF3 (Saada, Vogel et al. 2009), NDUFAF4 (Saada, Edvardson et al. 
2008), C8orf38 (Pagliarini, Calvo et al. 2008), C20orf7 (Sugiana, Pagliarini et al. 2008), 
ACAD9 (Garone, Donati et al. 2013), FOXRED1 (Zurita Rendon, Antonicka et al. 2016) 
and NUBPL (Kevelam, Rodenburg et al. 2013). 
The NDUFS4 gene and its product 
NADH dehydrogenase [ubiquinone] iron-sulphur protein 4 or NDUFS4 is an accessory 
subunit of CI encoded by the nDNA. Its gene encodes an 18kDa protein also referred 
to as the AQDQ subunit and is localized on chromosome 5q11.1 (Emahazion, Beskow 
et al. 1998, van den Heuvel, Ruitenbeek et al. 1998, Scacco, Petruzzella et al. 2003). 
The subunit is located at a strategic position within CI at the junction between 
the peripheral mass protruding into the matrix and the membrane moiety of CI 
(Petruzzella, Vergari et al. 2001). The NDUFS4 gene consists of 5 exons interspersed 
by large introns spanning in total over 122 kb. The gene encodes 175 amino acids and 
displays a high degree of conservation in all known mammalian sequences (Papa 2002, 
Budde, van den Heuvel et al. 2003, De Rasmo, Panelli et al. 2008). The human precursor 
NDUFS4 protein contains two phosphorylation consensus sites, one at position 36-38 
(RTS) in the 42 amino acids long leader sequence and the other one at position 171-173 
(RVS) in the 133 amino acids long mature protein (Budde, van den Heuvel et al. 2002). 
Phosphorylation of the Serine 173 in the RVS site by cAMP-dependent protein kinase, 
or protein kinase A (PKA), increases its affinity for cytosolic Hsp70 (De Rasmo, Panelli 
et al. 2008). This, in turn, facilitates its import and subsequent cleavage to the mature 
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form and incorporation in CI. Thus, PKA-mediated phosphorylation of the NDUFS4 
subunit leads to an increase in CI activity (Schwoch, Trinczek et al. 1990, Papa, Rasmo 
et al. 2012, Valsecchi, Ramos-Espiritu et al. 2013).
Pathogenic NDUFS4 mutations
The NDUFS4 gene is regarded as a mutational hotspot in human CI deficiency 
(Petruzzella and Papa 2002, Scacco, Petruzzella et al. 2003, Panelli, Petruzzella et 
al. 2008). To date, nine disease causing NDUFS4 mutations have been reported 
(Pagniez-Mammeri, Loublier et al. 2012). These include a 5-bp duplication, resulting 
in a frameshift at codon K158 (K158fs) extending the mature protein by 14 amino acids 
and destroying the PKA phosphorylation consensus site (RVS) at position 171-173 (van 
den Heuvel, Ruitenbeek et al. 1998), three nonsense mutations, resulting in a marked 
decrease (W96X and R106X) (Budde, van den Heuvel et al. 2000, Benit, Steffann 
et al. 2003, Ugalde, Janssen et al. 2004) or even the complete absence (W15X) 
(Petruzzella, Panelli et al. 2005) of fully assembled CI, a splice acceptor site mutation 
of intron 1 (c.99-1G>A), resulting in complete skipping of exon 2 and accumulation of 
a truncated protein of 39 amino acids (S34fs) (Benit, Steffann et al. 2003), a deletion 
resulting in a frameshift (K154fs) (Anderson, Chung et al. 2008), a point mutation 
(D119H) (Leshinsky-Silver, Lebre et al. 2009), a c.351-2A>G mutation, predicted to 
alter NDUFS4 splicing resulting in mRNA instability (Calvo, Tucker et al. 2010) and a 
c.393dupA frameshift mutation (Lamont, Beaulieu et al. 2016).
Patient characteristics
Neurodevelopmental disorders with major implications on survival rates are 
observed in patients suffering from mutations in nuclear genes encoding structural 
subunits of CI (Shoubridge 2001, Distelmaier, Koopman et al. 2009). Children 
with NDUFS4 mutations present with Leigh or Leigh-like syndrome, which is 
characterized by symmetrical bilateral necrotic lesions and capillary proliferation in 
different regions of the central nervous system. Clinical signs and symptoms include 
muscular hypotonia, dystonia, developmental delay, abnormal eye movements, 
seizures, respiratory irregularities, lactic acidemia and neonatal cardiomyopathy 
(Loeffen, Smeitink et al. 2000). Recently, Assouline et al summarized general 
phenotypes observed in patients with NDUFS4 mutations, which included apart 
from the abovementioned signs and symptoms, pyramidal syndrome, psychomotor 
retardation / regression, depressed tendon reflexes and hepatomegaly. Intra-
uterine growth retardation, in some patients accompanied by premature birth 
and vomiting, was also occasionally observed. Muscle impairment with atrophy, 
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rhabdomyolysis or abnormal electromyography (EMG), liver impairment, peripheral 
neuropathy, anaemia, hyperkinesia’s/dystonia/athetoid movements and deafness/
sensorineural hearing loss were not described in these patients. Death, in patients 
with a shorter life expectancy, was always caused due to cardio-respiratory failure 
(Assouline, Jambou et al. 2012). 
Cell biological consequences of pathogenic NDUFS4 mutations
CI expression and intrinsic catalytic activity – Blue native polyacrylamide gel 
electrophoresis (BN-PAGE) of mitochondrial-enriched fractions from primary skin 
fibroblasts of patients with a pathogenic mutation in the NDUFS4 gene invariably 
showed a single ~830-kDA subcomplex that lacked in gel activity (Scacco, Petruzzella 
et al. 2003, Ugalde, Janssen et al. 2004, Petruzzella, Panelli et al. 2005, Verkaart, 
Koopman et al. 2007a). Intriguingly, the same fractions displayed a marked rotenone-
sensitive NADH: ubiquinone oxidoreductase, or CI, activity in a spectrophotometric 
assay using freeze-thawing rather than mild detergent solubilisation (Budde, van 
den Heuvel et al. 2003, Scacco, Petruzzella et al. 2003, Ugalde, Janssen et al. 2004). 
These data suggest that the ~830-kDa subcomplex lacks the dehydrogenase 
moiety. Analysis of the amount of immunoreactive ~830-kDa subcomplex in patient 
fibroblasts with a mutation in the NDUFS4 gene showed a significant decrease as 
compared to the amount of ~1-MDa holocomplex in healthy control fibroblasts. 
Regression analysis of data from 13 CI deficient patients including 4 patients with 
a pathogenic NDUFS4 mutation revealed a positive linear correlation between the 
spectrophotometrically measured CI activity and the amount of holocomplex or 
its ~830-kDa subcomplex (Valsecchi, Koopman et al. 2010). This linear relationship 
was interpreted to suggest that CI deficiency is primarily a CI expression problem 
rather than a CI intrinsic catalytic problem. Furthermore, it was concluded that 
the role of the NDUFS4 subunit is to reinforce the physical coupling between the 
~830-kDa subcomplex and the dehydrogenase moiety. The latter conclusion is 
in agreement with the general idea that the NDUFS4 subunit plays an important 
role in maintaining CI stability (Kruse, Watt et al. 2008). In the case of the W96X 
and R106X mutation, a parallel decrease in complex III (CIII) activity was observed, 
suggesting a functional interaction between CI and CIII (Ugalde, Janssen et al. 2004). 
More recently, evidence was provided that in the absence of the NDUFS4 subunit CI 
activity is preserved in a supercomplex that also includes CIII (Calvaruso, Willems et 
al. 2012). This finding may explain the presence of a significant amount of CI activity, 
referred to as residual CI activity, in skin fibroblasts and muscle biopsies of patients 
with a pathogenic NDUFS4 mutation. 
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Mitochondrial membrane potential, cellular ROS production and intracellular Ca2+ 
homeostasis – Primary skin fibroblasts of patients with a pathogenic mutation in the 
NDUFS4 gene invariably showed increased oxidation rates of HEt and CM-H
2
DCFDA 
(Verkaart, Koopman et al. 2007a). When the rate of ROS production grossly exceeds 
the capacity of the cell’s antioxidant systems their level will increase to such a degree 
that cellular molecules will be damaged leading to cellular dysfunction and, eventually, 
cell death. However, patient skin fibroblasts maintained in standard culture medium 
failed to show any increase in lipid peroxidation (Verkaart, Koopman et al. 2007b). In 
sharp contrast, healthy control fibroblasts treated with rotenone displayed a significant 
increase in lipid peroxidation which was completely prevented by the mitochondrial-
targeted antioxidant MitoQ. Patient fibroblasts neither showed a change in cytosolic 
and/or mitochondrial thiol redox state (Koopman, Verkaart et al. 2005, Verkaart, 
Koopman et al. 2007b). Taken together, these data demonstrate that CI deficient 
fibroblasts maintained in standard culture medium are adequately adapted to the 
increased rate of ROS production. In addition to an increase in ROS production rate, 
fibroblasts of patients with a pathogenic mutation in the NDUFS4 gene invariably 
showed a less negative mitochondrial membrane potential (Δψ) (Distelmaier, Visch et 
al. 2009). Regression analysis of data from 10 CI deficient patients including 3 patients 
with a pathogenic mutation in the NDUFS4 gene revealed a negative linear correlation 
between the mitochondrial membrane potential and the rate of CM-DCF formation. A 
similar negative linear correlation was observed between the mitochondrial membrane 
potential and the Ca2+ content of the endoplasmic reticulum (ER). ER Ca2+, through 
its stimulus-induced release from the ER into the ER-mitochondrial contact sites and 
its consequent uptake by the mitochondria, is responsible for the stimulus-induced 
increase in mitochondrial ATP production (Willems, Valsecchi et al. 2008, Valsecchi, 
Esseling et al. 2009). Indeed, CI deficient patient fibroblasts showed a significant 
decrease in stimulus-induced mitochondrial Ca2+ mobilization and ATP production 
(Visch, Rutter et al. 2004, Visch, Koopman et al. 2006). Treatment of patient fibrioblasts 
with the water-soluble vitamin E analog, Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-
2-carboxylic acid), lowered the rate of CM-DCF formation, normalized Δψ and increased 
the ER Ca2+ content. Subsequent stimulation showed an enhanced increase in cytosolic 
Ca2+ concentration and a normalized increase in mitochondrial Ca2+ concentration, 
NADH level and ATP production (Distelmaier, Visch et al. 2009). These findings 
exemplify the feasibility that certain aspects of the cell’s physiology may be altered in 
complex I deficiency as a consequence of the increased rate of reactive oxygen species 
(ROS) production. Consequences of nDNA-encoded mutations in CI are schematically 
represented in (Figure 1).
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Figure 1: Consequences of nDNA-encoded mutations in CI. The total amount of fully assembled 
and active CI within the cell (a) is determined by the balance between CI biogenesis (b) and 
degradation (c). Mutations in nDNA-encoded CI subunits (d) lead to functional impairment of CI (e) 
and induce changes in cellular physiology (f, h). If these changes are not properly counterbalanced by 
adaptive responses (j), including alterations in mitochondrial morphology and glycolysis upregulation 
(k), cell death can occur (g). This is likely reflected by the fact that fibroblasts from patients with 
isolated CI deficiency display increased ROS levels but no increased cellular lipid peroxidation or 
changes in thiol redox state (i). This figure is based upon experimental data obtained in fibroblasts of 
patients with nDNA-encoded isolated CI deficiency. Primary and possible adaptive pathways are 
indicated in red and green, respectively. Abbreviations: Δψ, mitochondrial membrane potential; 
Figure 1. Consequences of nDNA-encoded mutations in CI. The total amount of fully 
assembled and active CI within the cell (a) is determined by the balance between CI biogenesis 
(b) and degradation (c). Mutations in nDNA-encoded CI subunits (d) lead to functional 
impairment of CI (e) and induce changes in cellular physiology (f, h). If these changes are not 
properly counterbalanced by adaptive responses ( j), including alterations in mitochondrial 
morphology and glycolysis upregulation (k), cell death can ccur (g). This is likely reflected 
by the fact that fibroblasts f om patients with isolat d CI deficiency dis lay increased ROS 
levels but no increased cellular lip d peroxidation or cha g  in thiol re ox state (i). This figure 
is based upon xperim ntal data obtained in fibroblasts of patients with nDNA-encoded 
isolated CI deficiency. Primary and possible adaptive pathways are indicated in red and 
green, respectiv ly. Abbreviations: Dy, mitochondrial membrane potential; NADH, reduced 
nicotinamide adenine dinucleotide; NADPH,   reduced nicotinamide adenine dinucleotide 
phosphate; nDNA, nuclear DNA; ROS, reactive oxygen species. 
Mouse models for Ndufs4 deficiency 
The Whole-body (WB) Ndufs4-/- mouse – The WB Ndufs4-/- mouse was generated by 
deletion of exon 2, resulting in a frame shift and undetectable levels of the Ndufs4 
protein (Kruse, Watt et al. 2008). During the first ~30 days of life, i.e. until ~P30, 
behaviour of Ndufs4-/- mice was similar to that of their wild type and heterozygous 
littermates (Fig. 2). However, already at ~P12, Ndufs4-/- mice were smaller and lighter 
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than their wild type littermates. At day 20 of life, most Ndufs4-/- animals lost their 
body hair, which grew back during the next hair-growth cycle. Between P35 and P50, 
Ndufs4-/- animals stopped gaining weight and started to display weight loss. This was 
accompanied by worsening ataxia, stopped grooming and, finally, death from a fatal 
encephalomyopathy. Further phenotypic features of the Ndufs4-/- mice include a 
decreased body temperature (2°C), cataracts, blindness, hearing loss, loss of motor 
skills and lethargy (Kruse, Watt et al. 2008). Ndufs4-/- animals displayed significantly 
higher serum lactate levels than wild type mice. On the other hand, in vivo 31P-NMR 
spectroscopy analysis of ATP turnover reactions in hindlimb muscle revealed the 
lack of any difference in resting ATP demand and maximal rate of mitochondrial ATP 
production between Ndufs4-/- and wild type mice. A similar observation was reached 
for the resting O
2
 consumption rate determined by in vivo optical spectroscopy of 
haemoglobin and myoglobin saturation levels. Mitochondrial ultrastructure appeared 
normal although large subsarcolemmal clusters of mitochondria were present in the 
soleus but not in the extensor digitorum longus muscle fibers of Ndufs4-/- mice. 
Figure 2. Onset of aberrant clinical symptoms in Ndufs4-/- mice. Ndufs4-/- mice (n=23) 
were phenotypically characterized by comparing them to their WT litter mates (n=23). The 
“X-axis” is denoted by day of life, when the symptom was first observed in the Ndufs4-/- mice as 
compared to its WT counterpart. The “Y-axis” represents the phenotype / symptom observed 
in the Ndufs4-/- mouse.
NADH, reduced nicotinamide adenine dinucleotide; NADPH,   reduced nicotinamide adenine 
dinucleotide phosphate; nDNA, nuclear DNA; ROS, reactive oxygen species.  
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Furthermore, a marked decrease in CI activity was observed in Ndufs4-/- mice while 
cytochrome c oxidase (COX) activity was similar to wild type. Progressive neuronal 
deterioration and gliosis were observed in specific brain areas of the Ndufs4-/- mice. 
These observations corresponded to behavioural changes during disease advance, 
with early involvement of the olfactory bulb, cerebellum, and vestibular nuclei 
(Quintana, Kruse et al. 2010). Neurons, particularly in those brain regions, showed 
aberrant mitochondrial morphology. Electron microscopy analysis revealed that 
mitochondria were swollen and/or displayed a compact cristae structure. Activation 
of caspase 8, but not caspase 9, in the affected brain regions of Ndufs4-/- mice was 
suggested to reflect initiation of the extrinsic apoptotic pathway. The limited caspase 
3 activation and the predominance of ultrastructural features of necrotic cell death 
suggest a switch from apoptosis to necrosis in affected neurons. From these data it 
was suggested that dysfunctional CI in specific brain regions results in progressive 
glial activation that, in turn, promotes neuronal death and ultimately mortality of 
the mouse. CI activity in submitochondrial particles from liver of Ndufs4-/- mice was 
undetectable using spectrophotometric assays. However, CI-driven O
2
 consumption 
in intact liver cells was about half that of wild type. Native gel electrophoresis 
revealed reduced levels of intact CI. In our laboratory BN-PAGE has been performed 
on different tissues of the Ndufs4-/- mouse. Instead of fully assembled CI an inactive 
830-kDa subcomplex was observed (Calvaruso, Willems et al. 2012, Valsecchi, Grefte 
et al. 2013).  A similarly sized 830-kDa CI subcomplex has been reported in patients 
with NDUFS4 mutations (Ugalde, Janssen et al. 2004, Ogilvie, Kennaway et al. 2005, 
Vogel, Dieteren et al. 2007, Papa, Petruzzella et al. 2009, Valsecchi, Koopman et al. 
2010). Taken together, these findings suggest that when the Ndufs4 subunit is absent, 
CI fails to assemble properly or is instable.
The whole body Ndufs4fky/fky mouse – Leong et al (Leong, Komen et al. 2012) inserted 
a transposable element into the Ndufs4 gene causing aberrant transcript splicing and 
absence of the Ndufs4 protein in all tissues of the homozygous Ndufs4fky/fky mouse. 
The physical and behavioral symptoms displayed by the Ndufs4fky/fky mouse included 
temporary fur loss, growth retardation, unsteady gait and abnormal body posture 
when suspended from the tail. Similar phenotypic changes were observed in the 
Ndufs4-/- mouse (Kruse, Watt et al. 2008). Ndufs4 protein was not detected in any 
of the tissues analysed namely, brain, heart, muscle, liver and kidney. CI enzymatic 
activity was significantly reduced in all tissues tested. ATP synthesis capacity, which 
was determined in the presence of glutamate and malate, was significantly reduced 
in brain and heart of the Ndufs4fky/fky mutant. Analysis of CI in the Ndufs4fky/fky 
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mutant by BN-PAGE revealed a faster migrating crippled subcomplex. This crippled 
subcomplex lacked subunits of the N-module that contains the NADH binding 
site. This subcomplex contained two assembly factors which were not present 
in fully assembled CI. Further, metabolomic analysis in blood by tandem mass 
spectrometry established increased hydroxyacylcarnitine, glycine, phenylalanine 
and homocitrulline. The increased level of hydroxyacylcarnitine was interpreted to 
suggest that CI dysfunction causes an imbalance of NADH and NAD+ resulting in 
inhibited mitochondrial fatty acid β-oxidation.
The Nes Ndufs4-/- and PC Ndufs4-/- mouse – Two different brain-specific Ndufs4-/- 
mouse models have been generated (Quintana, Kruse et al. 2010). Mice that brain-
specifically lack Ndufs4 were generated by crossing Ndufs4lox/lox mice with mice 
expressing Cre recombinase from the Nestin locus. The phenotype of the resulting 
“Nes Ndufs4-/-” mouse generally resembled that of the WB Ndufs4-/- mouse including 
retarded growth, loss of motor ability, breathing abnormalities, and a maximum life 
span of approximately 7 weeks. Because both the WB and Nes Ndusf4-/- mouse showed 
cell death of Purkinje cells in the lobules of the cerebellum, also a Purkinje cell specific 
Ndufs4-/- mouse was generated. This PC Ndufs4-/- mouse displayed only mild behavioural 
and neuropathological abnormalities. Combined with the results obtained in the WB 
Ndufs4-/- and Nes Ndufs4-/- mouse models, this suggests that death of Purkinje cells in 
Nes Ndufs4-/- animals is likely a secondary effect possibly due to dysregulation of the 
cerebellar circuitry or hypersensitivity to hypoxia (Quintana, Kruse et al. 2010).
The Conditional WB Ndufs4-/- mouse – Conditional knockout of the Ndufs4 gene was 
achieved by crossing Ndufs4 lox/lox mice with mice bearing an inducible Cre recombinase 
gene. The latter gene can be induced in most cells by tamoxifen (Quintana, Kruse et 
al. 2010). Tamoxifen treatment at day ~P60 induced a large decrease in abundance 
of the Ndufs4 protein in most brain regions. Effects in other tissues have not been 
reported. Seven months after tamoxifen treatment the mice displayed a phenotype 
that resembled that of early stage WB Ndufs4-/- mice. This rather mild phenotype, 
also in comparison to Nes Ndufs4-/- mice, might be explained by incomplete or 
absent recombination in some brain regions, despite intensive tamoxifen treatment. 
Alternatively, complete absence of Ndufs4 during animal development might have 
more severe consequences than its (partial) absence at a later stage of development.
The Ndufs4-PM mouse – This mouse model was generated by introducing a point 
mutation in the Ndufs4 gene, resulting in loss of the last 10-15 amino acids of the 
last exon of the protein (Ingraham, Burwell et al. 2009). Interestingly, heterozygous 
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mice showed expression and even integration of mutant Ndufs4 protein in holo- CI. 
In heart mitochondria, the amount of wild type Ndufs4 protein present in holo-CI 
was 2.5-fold higher than that of the mutant subunit. The presence of the mutant 
subunit resulted in a significant decrease in CI activity and CI-linked O
2
 consumption 
and increased lactate levels. The clinical phenotype of the heterozygous Ndufs4-PM 
mouse was not reported. In sharp contrast to the other four mouse models, 
homozygote Ndufs4-PM mice were not viable and their presence in the early 
embryonic state (<E9) could not be demonstrated. This suggests that in homozygous 
animals the presence of a mutated Ndufs4 protein leads to a much more severe 
phenotype than its complete absence. 
The (Conditional) Heart-specific Ndufs4-/- mouse – Sterky et al (Sterky, Hoffman et 
al. 2012) generated a heart specific Ndufs4-/- mouse by disrupting the Ndufs4 gene 
in heart tissue. Although they observed a dramatic reduction of CI activity, oxidation 
of CI-linked substrates was only mildly reduced in intact heart mitochondria. 
As previously reported by Calvaruso et al (Calvaruso, Willems et al. 2012), they 
demonstrated the formation of supercomplexes with CI activity. Chouchani et 
al (Chouchani, Methner et al. 2014) showed that heart-specific Ndufs4-/- mice 
developed a severe hypertrophic cardiomyopathy which occurred in the absence 
of increased levels of mitochondrial hydrogen peroxide, accumulation of oxidative 
damage makers and induction of apoptosis or tissue fibrosis. This suggests that CI 
dysfunction alone might be sufficient to drive the hypertrophic cardio-myopathy 
independently of elevated levels of mitochondrial hydrogen peroxide and increased 
oxidative damage. Karamanlidis et al (Karamanlidis, Lee et al. 2013), created a 
conditional heart specific Ndufs4-/- mouse and observed a 60% decrease in CI-linked 
respiration. However, the conditional heart specific Ndufs4-/- mouse maintained a 
normal cardiac function in vivo and a high energy phosphate content in the isolated 
perfused heart. They developed accelerated heart failure with pressure overload. 
The increased NADH/NAD+ ratio, due to inhibition of CI, caused inhibition of Sirt3 
resulting in protein acetylation and sensitization of the mitochondrial permeability 
transition pore (mPTP). NAD+ precursor supplementation partially normalized the 
NADH/NAD+ ratio, protein acetylation and mPTP sensitivity. The authors concluded 
that NAD+ precursor supplementation could be a potential therapeutic approach for 
mitochondrial dysfunction.
The Conditional Hematopoietic-, Liver- and TLR 2/4-specific Ndufs4-/- mouse models 
– Jin et al (Jin, Wei et al. 2014) used the WB Ndufs4-/- mouse to investigate the effect 
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of CI deficiency on innate immunity and bone remodelling and  observed systemic 
inflammation and osteoporosis. They then created a conditional hematopoietic 
system-specific Ndufs4-/- mouse and observed an intrinsic change in lineage from 
osteoclast to macrophage. Next, they created a conditional liver-specific Ndufs4-/- 
mouse and observed an increase in fatty acid and lactate concentration in the 
circulation, causing a further activation of the Ndufs4-/- macrophages by the induction 
of ROS and a decrease in osteoclast lineage commitment in Ndufs4-/- progenitors. 
Finally, they showed that inflammation and osteoporosis could be abated in a 
conditional Toll like receptor 2/4 (TLR2/4)-specific Ndufs4-/- mouse. It was concluded 
that healthy mitochondria suppress macrophage activation and inflammation while 
promoting osteoclast differentiation and bone resorption via cell-autonomous and 
systemic regulation.
Pharmacological intervention in complex I deficiency 
In vivo treatment of CI deficiency is tremendously challenging because a possible 
beneficial drug effect also depends on the way of administration, concentration, (bio) 
distribution, turnover and clearance. In addition, (long term) drug effectiveness and 
toxicity have to be considered. The possibilities of pharmacological intervention in 
the case of mitochondrial disorders have been extensively reviewed (Finsterer and 
Segall 2010, Hersh 2010, Jin, Randazzo et al. 2010, Moncada 2010, Valsecchi, Koopman 
et al. 2010, Wallace, Fan et al. 2010, Wenz, Williams et al. 2010, Koopman, Beyrath 
et al. 2016). In our research, we have successfully applied an antioxidant (Trolox) 
and a benzothiazepine (CGP37157) to mitigate several cellular consequences of CI 
deficiency. Below, we briefly present several strategies that might prove useful for 
mitigation of the clinical consequences of CI deficiency. 
The non-mitochondria-targeted antioxidants vitamin E, vitamin C and N-acetyl 
cysteine amide (AD4) – Because of its lipophilic nature, vitamin E or α-tocopherol 
can effectively detoxify lipid peroxyl radicals (Niki 1991). Chronic oral administration 
of vitamin E significantly reduced the increase in mitochondrial oxidative damage, the 
decrease in mitochondrial manganese-dependent superoxide dismutase (MnSOD or 
SOD2) and the decrease in mitochondrial state 3 respiration in brain of aging mice 
(Navarro, Gomez et al. 2005). These effects were paralleled by an increased lifespan 
and preservation of neurological performance and exploratory activity. Importantly, 
the levels of α-tocopherol in mouse brain increased from 11.5 to 26.2 nmol/g brain, 
showing that it was able to cross the blood brain barrier. In humans there is still 
controversy on the use of vitamin E supplementation (Navarro and Boveris 2010). For 
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instance, a meta-analysis claimed that vitamin E supplementation increases human 
mortality (Bjelakovic, Nikolova et al. 2007). However, these results are challenged by 
clinical evidence that vitamin E supplements are safe at high dosages (Hathcock, Azzi 
et al. 2005) and by the reported effects of vitamins E and C in the reduction of the 
prevalence/incidence of Alzheimer disease in an elderly population (Zandi, Anthony 
et al. 2004). Vitamin C, or ascorbate, is well known for its antioxidant capacity. 
Because of its aqueous nature, vitamin C cannot detoxify lipid peroxyl radicals (Niki 
1991). However, it is very effective in regenerating active vitamin E from its radicals 
formed during the detoxification of lipid peroxyl radicals. Human skin fibroblasts 
have the ability to import vitamin C via a Na+-dependent carrier (Welch, Bergsten et 
al. 1993). In human skin fibroblasts from patients with respiratory chain deficiencies, 
vitamin C was able to reduce superoxide production while increasing respiratory 
chain function (Sharma and Mongan 2001). In aging human fibroblasts in  vitro, 
ascorbate prevented the age-dependent decline in respiratory chain activities 
(Ghneim and Al-Sheikh 2010). N-acetyl cysteine amide or AD4 is a blood-brain-
barrier penetrating antioxidant that can decrease oxidative stress both in vitro and 
in vivo. Ndufs4-/- mice were injected intraperitoneally with AD4 (150mg/kg/day) from 
postnatal day 21 to 28. This short period of administration was sufficient to delay the 
onset of the neurodegenerative phenotype and improve the motor defects observed 
in Ndufs4-/- mice, stressing a role for elevated ROS in the development of the disease 
phenotype (Liu, Zhang et al. 2015).
The mitochondria-targeted antioxidants mitoquinone (MitoQ), SkQ and Szeto-
Schiller (SS)-31 peptide – Currently, there are several strategies that allow oxidants to 
be targeted to mitochondria in living cells (Finsterer and Segall 2010, Hersh 2010, Jin, 
Randazzo et al. 2010, Moncada 2010, Valsecchi, Koopman et al. 2010, Wallace, Fan et 
al. 2010, Wenz, Williams et al. 2010). Here, we will discuss the triphenylphosphonium 
(TPP) compounds and Szeto-Schiller (SS) peptides in more detail. One group of 
compounds which specifically accumulate in mitochondria consists of antioxidants 
that are covalently linked to the triphenylphosphonium (TPP) cation. These 
molecules are engineered in such a way that they pass phospholipid bilayers without 
requiring a specific uptake mechanism. Because of their positive charge, they 
preferentially accumulate (500-1000 fold) within mitochondria in a Δψ-dependent 
manner (Murphy and Smith 2007). A potential drawback of these compounds might 
be their dependence on Δψ, which, as we have reported (Distelmaier, Visch et al. 
2009), is less negative in human CI deficiency. As a consequence, their concentration 
might not reach the sufficiently high values in cells of CI deficient patients. A well-
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studied member of the TPP family is [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-
cyclohexadien-1-yl)decyl]triphenylphosphonium, referred to as mitoquinone or 
MitoQ. Given its relatively large hydrophobicity, MitoQ is preferentially adsorbed to 
the matrix-facing leaflet of the MIM, with its TPP moiety at the membrane surface at 
the level of the fatty acid carbonyls and its alkyl chain and ubiquinol moiety inserted 
into the hydrophobic core of the lipid bilayer (Murphy and Smith 2007). In healthy 
fibroblasts treated with rotenone (100 nM, 72 h), MitoQ prevented rotenone-induced 
mitochondrial elongation and lipid peroxidation but did not block rotenone-induced 
HEt oxidation regarded as a measure of mitochondrial superoxide production 
(Koopman, Verkaart et al. 2005). This is compatible with MitoQ being localized inside 
the MIM and thereby preventing oxidation of mitochondrial lipids. Our results show 
that MitoQ can accumulate to sufficiently high levels in complex I deficient patient 
fibroblasts. Use of MitoQ in mouse models as well as patients in vivo, revealed that 
its use is safe in vivo, even during long term use. Administration in the drinking water 
of mice resulted in measurable levels of MitoQ in all tissues, including brain, although 
the concentrations differed between organs (Rodriguez-Cuenca, Cocheme et al. 
2010). This illustrates that MitoQ is able to cross the blood-brain barrier which is an 
important hurdle in therapies for CI deficiency. Furthermore, MitoQ was excreted 
in the urine and bile as unchanged MitoQ or with sulfation or glucuronidation of 
the quinol ring with no indication of other metabolites (Li, Zhang et al. 2007, Ross, 
Prime et al. 2008). In addition to MitoQ also other antioxidant variants like MitoVitE, 
MitoTEMPOL and MitoPBN have been developed (Murphy and Smith 2007). The 
detailed in vivo characteristics of these compounds and their effects in CI deficiency 
require further investigation. Skulachev et al developed [10-(6’-plastoquinonyl)
decyl]triphenylphosphonium, referred to as SkQ (Skulachev, Anisimov et al. 2009). 
SkQ consists of a plastoquinone moiety linked to TPP. When compared to MitoQ, 
SkQ displayed a higher permeability in a variety of in vitro, ex vivo and in vivo models 
(Antonenko, Avetisyan et al. 2008). Moreover, SkQ was shown to possess a strong 
antioxidant activity at relatively low (nM) concentrations, whereas at relatively 
high (µM) concentrations SkQ was shown to act as a pro-oxidant. Applied in vivo, 
SkQ displayed beneficial effects during hydrogen peroxide- and ischemia-induced 
heart arrhythmia, heart infarction, kidney ischemia and stroke (Bakeeva, Barskov 
et al. 2008). Currently, no data of SkQ in relation to CI deficiency are available. 
However, it would be interesting to determine whether SkQ is able to influence 
the downstream effects of CI deficiency. Another group of mitochondria-targeted 
antioxidants are the so called Szeto-Schiller (SS) peptides. This is a novel class 
of small cell permeable peptide antioxidants that target to mitochondria in a Δψ-
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independent manner. The structural motif of these peptides centres on alternating 
aromatic residues and basic amino acids (Szeto 2006). SS-peptides are small and 
relatively easy to synthesize, readily soluble in water, and resistant to peptidase 
degradation. Besides, they display a high blood-brain barrier permeability and a 
relatively long elimination half-life in sheep and rats, which allows their testing in 
neurological disease models (Szeto 2006). In cell experiments, SS-31 accumulated 
5000-fold in the mitochondrial fraction. SS-31 was localized close to the site(s) 
of mitochondrial ROS production and protected against mitochondrial oxidative 
damage and further ROS production (Zhao, Zhao et al. 2004). SS-31 prevented Δψ 
depolarization, reduced cellular ROS and inhibited apoptosis in neurons treated 
with the pro-oxidant tert-butyl-hydroperoxide (Zhao, Luo et al. 2005). The effects 
of SS-peptides in CI deficiency models are currently unknown. 
The benzothiazepine CGP37157 – CGP37157, a benzothiazepine, is an inhibitor of 
mitochondrial Na+/Ca2+ exchange (Cox and Matlib 1993). CGP37157 normalized aberrant 
mitochondrial Ca2+ handling during hormone stimulation of cybrid cells carrying the 
tRNAlys mutation associated with MERRF (Myclonic Epilepsy with Ragged Red Fibres) 
syndrome (Brini, Pinton et al. 1999). To directly interfere with aberrant mitochondrial 
Ca2+ signalling, we investigated the effect of CGP37157 in fibroblasts from patients 
with isolated CI deficiency (Visch, Rutter et al. 2004). Short-term pre-treatment 
with CGP37157 (1 µM, 2 min) fully normalized the amplitude of the hormone-induced 
mitochondrial Ca2+ signal, without altering this parameter in healthy fibroblasts. Also 
the hormone-induced increase in mitochondrial and cytosolic ATP concentration, 
which were significantly lowered in these patient fibroblasts, were fully normalized 
by CGP37157 treatment. The effect of CGP37157 was independent of the presence 
of extracellular Ca2+, excluding a stimulatory effect on Ca2+ entry across the plasma 
membrane. These findings suggest that the mitochondrial Na+/Ca2+ exchanger is a 
potential target for drugs aiming to restore or improve Ca2+-stimulated mitochondrial 
ATP synthesis.
Riboflavin – Riboflavin, or vitamin B2, is a precursor of flavin mononucleotide (FMN) 
and flavin adenine dinucleotide (FAD), which function as cofactors in CI and CII, 
respectively. In vitro, riboflavin treatment of CI-deficient patient fibroblasts virtually 
normalized the rate of ATP production (Bar-Meir, Elpeleg et al. 2001). In vivo, riboflavin 
supplementation, with or without co-administration of carnitine, was reported to 
be effective in a number of patients with CI deficiency. Primary effects included 
improvement of muscle tone, exercise capacity/tolerance and serum lactate levels, 
although the results of the treatment substantially differed between different 
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studies [reviewed by (Marriage, Clandinin et al. 2003)]. A mechanism was proposed 
in which riboflavin inhibits the proteolytic breakdown of CI, leading to an increase 
in CI enzymatic activity (Vergani, Barile et al. 1999, Gold and Cohen 2001, Marriage, 
Clandinin et al. 2003). Dosages of riboflavin used in treatment of OXPHOS patients 
ranged between 9-300 mg/day without observation of adverse effects (Marriage, 
Clandinin et al. 2003). Although the results obtained with riboflavin vary, they 
clearly demonstrate that in some patients with CI deficiency, riboflavin alone or in 
combination with other supplements is beneficial (Marriage, Clandinin et al. 2003, 
Panetta, Smith et al. 2004).
The modulators of PGC-1a activity fibrates and resveratrol – Peroxisome proliferator-
activated receptor (PPAR) co-activator 1a (PGC-1a), is a transcriptional factor regulator 
that stimulates transcription of genes involved in cellular energy metabolism 
(Scarpulla 2008, Wenz 2009). PGC-1a  influences mitochondrial biogenesis and 
function by modulating the transcription of the mtDNA transcription factor A (Tfam) 
gene (Wu, Puigserver et al. 1999).  Several ways to therapeutically modulate PGC-1α 
have been reported. The pan (i.e. a, d  and g) PPAR agonist bezafibrate has been 
demonstrated to increase the activity of CI and other ETC enzymes (complex III and 
complex IV) in healthy and OXPHOS-deficient cells through PGC-1α upregulation 
(Bastin, Aubey et al. 2008). In COX10 KO mice displaying progressive myopathy, 
bezafibrate stimulated OXPHOS gene expression in skeletal muscle and induced 
a global increase in oxidative metabolism (Wenz, Diaz et al. 2008). Resveratrol is 
a polyphenolic phytoalexin that is abundantly present in grapes, peanuts and red 
wine. It stimulates sirtuin activity and thereby transcription of nDNA-encoded genes 
involved in energy metabolism (Shin, Cho et al. 2009, Ungvari, Labinskyy et al. 2009). 
Dietary delivery of resveratrol increased mitochondrial abundance and aerobic 
capacity in cultured endothelial cells and mice (Baur, Pearson et al. 2006, Lagouge, 
Argmann et al. 2006, Robb, Winkelmolen et al. 2008, Csiszar, Labinskyy et al. 2009). 
Resveratrol also affects the cellular antioxidant system. Both oral and subcutaneously 
injected resveratrol altered the activities of the key antioxidant enzymes glutathione 
peroxidase (GPx), catalase (CAT) and (mitochondrial) manganese superoxide 
dismutase (MnSOD) and increased the mitochondrial content in heart, brain and 
liver (Robb, Winkelmolen et al. 2008). A double blind healthy volunteer study showed 
that frequent administration of resveratrol is well-tolerated, but results in low plasma 
concentrations even at a 4-hr oral administration regime (Almeida, Vaz-da-Silva et al. 
2009). As far as we know, no data are currently available on side effects of continuous 
resveratrol administration. PGC-1α levels in skeletal muscle can also be stimulated 
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by endurance exercise via a mechanism involving repetitive changes in cytosolic 
free Ca2+ concentration and AMP-activated protein kinase (AMPK) activation (Wu, 
Kanatous et al. 2002, Ojuka 2004, Benton, Wright et al. 2008). It was suggested that, 
in healthy subjects, endurance exercise increases skeletal muscle oxidative capacity 
by improving the metabolic flux through CI (Daussin, Zoll et al. 2008). Endurance 
exercise improved the physiological and biochemical features in muscles of patients 
with mtDNA mutations (Taivassalo and Haller 2004, Taivassalo and Haller 2005). 
Rapamycin – Rapamycin is a specific inhibitor of the mechanistic target of rapamycin 
(mTOR) signalling pathway. Johnson and co-workers investigated the use of rapamycin 
as a potential therapeutic strategy in the WB Ndufs4-/- mice and observed a delay in 
onset of neurological symptoms, reduction in neuroinflammation, prevention of 
brain lesions and increase in median and maximum survival age (Kruse, Watt et al. 
2008, Johnson, Yanos et al. 2013). The median survival age in males and females was 
reported to be (114 and 111 days) respectively. Although, they could not delineate the 
exact mechanism of rescue, they observed that rapamycin induced a metabolic shift 
from glycolysis to amino acid catabolism thus alleviating the buildup of glycolytic 
intermediates.
Nicotinamide Riboside – Nicotinamide Riboside (NR) is used as a precursor for 
nicotinamide adenine dinucleotide or NAD+. Karamanlidis et al treated the conditional 
heart specific Ndufs4-/- mouse with NR and observed partial normalization of 
the NAD+/NADH ratio, the protein acetylation level and the sensitivity of the 
mitochondrial permeability transition pore (mPTP) (Karamanlidis, Lee et al. 2013). 
The poly (adenine diphosphate-ribose) polymerase (PARP)-1 inhibitor PJ34 – PARP 
proteins are involved in DNA repair and programmed cell death. Felici et al treated 
Ndufs4-/- mice with the PARP inhibitor N-(6-oxo-5,6-dihydrophenanthridin-2-yl)-
(N,Ndimethylamino) acetamide hydrochloride (PJ34) from postnatal day 30 to 50 and 
observed increased exploratory behaviour and motor skills (Felici, Cavone et al. 2014). 
PJ34 treatment reduced astrogliosis in the olfactory bulb and motor cortex but did 
not reduce neuronal loss. Finally, PJ34 did not delay death. Recently, it was speculated 
that NR and PJ34 improve mitochondrial function by increasing the intracellular levels 
of NAD+ (Cerutti, Pirinen et al. 2014). 
Stabilization of CI – Observations in patient and mouse cells indicate that CI is 
stabilized by its physical interaction with CIII (Acin-Perez, Bayona-Bafaluy et al. 2004, 
Fernandez-Vizarra, Bugiani et al. 2007). Even when the stability of CI is seriously 
compromised as is the case in the absence of the NDUFS4 subunit, partially assembled 
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CI can associate with CIII into supercomplexes resulting in rotenone-sensitive CI 
activity (Ogilvie, Kennaway et al. 2005, Lazarou, McKenzie et al. 2007, Calvaruso, 
Willems et al. 2012, Sterky, Hoffman et al. 2012). Another important determinant of 
the structural and functional integrity of CI is the MIM lipid cardiolipin (Schlame, Rua 
et al. 2000, Sharpley, Shannon et al. 2006, Houtkooper and Vaz 2008). Cardiolipin is 
very sensitive to peroxidation by mitochondrial ROS and cardiolipin peroxidation was 
demonstrated to decrease CI activity in bovine heart and rat heart/liver mitochondria 
(Petrosillo, Matera et al. 2009). This means that prevention of mitochondrial ROS 
production and/or ensuing cardiolipin peroxidation might be a good strategy to 
increase CI stability in patient cells as well as in vivo. This idea is in agreement with 
the above-discussed observation that MitoQ prevents superoxide-mediated lipid 
peroxidation and consequent changes in mitochondrial morphology in rotenone-
treated healthy skin fibroblasts (Verkaart, Koopman et al. 2007b).
Nutritional intervention: the ketogenic diet 
Nutritional approaches like a ketogenic diet may be very useful. Ketogenic diets 
have a high fat content, are adequate in protein and low in carbohydrates. During 
the regime of a ketogenic diet, ketone bodies are used as a substitute for glucose 
to generate energy for the brain. Intriguingly, ketone bodies appear to be a more 
efficient source of energy per unit of oxygen than glucose (Veech, Chance et al. 
2001). Evidence has been provided that a ketogenic diet induces a coordinated 
upregulation of mitochondrial genes involved in energy metabolism and might 
stimulate mitochondrial biogenesis as well (Yudkoff, Daikhin et al. 2001).  
Environmental strategy: Hypoxia
Recently, Jain and co-workers used hypoxia as an alternative strategy to target 
mitochondrial dysfunction in WB Ndufs4-/- mice (Jain, Zazzeron et al. 2016). They 
observed that Ndufs4-/- mice exposed to chronic hypoxia (11% Oxygen) displayed 
a marked improvement in survival. In sharp contrast, Ndufs4-/- mice exposed to 
chronic hyperoxia (55% Oxygen) died within 2-11 days of exposure. Hypoxia improved 
body weight gain, maintenance of core body temperature and neurologic behavior. 
Moreover, hypoxia dramatically reduced the development of lesions accompanied 
with microglial proliferation in the olfactory bulb, cerebellum and brainstem. Hypoxia 
furthermore reduced α-hydroxybutyrate, which is a circulating plasma marker for 
Leigh disease (Thompson Legault, Strittmatter et al. 2015), and plasma lactate. 
Hypoxia did not improve the dramatically reduced activity of CI in brain mitochondria. 
The authors speculated that chronic hypoxia leads to hypoxia inducible factor 
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(HIF)-dependent transcriptional regulation, which is known to activate important 
biochemical pathways including redox-neutral ATP production and a decreased flux 
through pyruvate dehydrogenase thus preventing mitochondrial ROS generation. 
In addition, the lower availability of oxygen under hypoxia lowers the availability of 
oxygen as a substrate in the generation of ROS. 
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Aims and Scope of this  thesis
As already discussed above, treatment of patient fibroblasts with the water-soluble 
vitamin E analog, Trolox, lowered the rate of CM-DCF formation, normalized Δψ 
and normalized the ER Ca2+ content, the latter thought to underly the observed 
normalization of the stimulus-induced increase in mitochondrial ATP production 
(Distelmaier, Visch et al. 2009). Also discussed above is our finding that Trolox 
increased the expression of fully assembled CI in fibroblasts from a panel of 13 
CI deficient patients including 4 patients with a pathogenic NDUFS4 mutation 
(Valsecchi, Koopman et al. 2010). The latter observation lead to the fundamentally 
important conclusion that CI deficiency is primarily a CI expression problem rather 
than a CI intrinsic catalytic problem and that therefore therapeutic strategies aimed 
at stabilizing CI and thus at increasing the expression of CI are a promising avenue.
The main aim of this thesis was to understand the pathophysiological 
consequences of isolated mitochondrial CI deficiency by using the Ndufs4-/- mouse. 
To this end, I compared the phenotypic manifestations in 23 Ndufs4-/- mice to their 
wild type littermates starting from postnatal day 0 to their predefined humane 
endpoint as defined by the Ethical Committee of Animal Welfare (Figure 2). In 
Chapter 2, I determined the biochemical consequences of isolated CI deficiency on 
mitochondrial ATP generating capacity and activity of individual OXPHOS complexes 
in tissues of high energy demand, namely skeletal muscle, heart and brain. In 
Chapter 3, I use the skeletal muscle data of chapter 2 in a systems biology approach to 
explore the consequences of isolated CI deficiency on skeletal muscle bioenergetics. 
In Chapter 4, through a longitudinal investigation, I discuss the consequences of 
isoflurane anaesthesia in Ndufs4-/- mice. In Chapter 5, I study the effect of isoflurane 
anaesthesia of Ndufs4-/- mice on the mitochondrial ATP production capacity and 
activity of individual OXPHOS complexes in brain. I show that, contrary to previous 
hypotheses, increased sensitivity to isoflurane anaesthesia in CI deficient mice is 
not due to reduction in brain mitochondrial ATP production capacity. In Chapter 6, 
I discuss the special position of neurons, whose deterioration, because they are 
highly susceptible to oxidative damage, might underlie most of the clinical signs and 
symptoms observed in Ndufs4-/- mice. In Chapter 7, I present the results of my in vivo 
study with Ndufs4-/- mice regarding the therapeutic potential of Trolox. In Chapter 8, 
I present the general conclusions of my thesis and discuss future directions of the 
field of research of which it forms part.
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Abstract 
We reported before that the maximal rate of mitochondrial ATP production 
expressed per mg of protein or mitochondrial ATP production capacity is not altered 
in a mitochondrial-enriched fraction from skeletal muscle, whereas it is decreased 
in a mitochondrial-enriched fraction from whole brain of mice lacking the NDUFS4 
subunit of complex I (CI) of the respiratory chain (RC). Here, we show that this rate 
is also not altered in a mitochondrial-enriched fraction from heart. To investigate 
the mechanism underlying the ability of skeletal muscle and heart, but not brain, to 
maintain their mitochondrial ATP production capacity, we determined the maximal 
rate of pyruvate oxidation and the maximal activities of the RC complexes II, III and 
IV and the mitochondrial matrix marker citrate synthase (CS) in a mitochondrial-
enriched fraction. When expressed per mg of protein, the maximal rate of pyruvate 
oxidation showed a tendency to increase in skeletal muscle and heart, but not in 
brain, the maximal activity of CII was increased in skeletal muscle with a tendency to 
increase in heart, that of CIII showed a tendency to increase in skeletal muscle and 
heart and that of CIV was increased in both skeletal muscle and heart. For none of the 
RC complexes the maximal activity was changed in brain. Finally, maximal CS activity 
per mg protein was increased in skeletal muscle and heart but not in brain. Together, 
these data suggest that the mitochondrial ATP production capacity is maintained in 
skeletal muscle and heart of CI-deficient mice through an increase in abundance of 
components of the mitochondrial ATP generating system and that this process does 
not occur in the brain of these mice. 
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Introduction
The oxidative phosphorylation (OXPHOS) system is organized into five multisubunit 
protein complexes (I, II, III, IV and V) and two electron carriers (cytochrome c and 
coenzyme Q). Together with cytochrome c and coenzyme Q, the complexes I, II, III 
and IV form the electron transport chain (ETC). The ETC oxidizes NADH and FADH
2
 
to generate an electrochemical proton gradient across the mitochondrial inner 
membrane, the potential energy of which is used by complex V to convert ADP to 
ATP (Hatefi 1985). 
Except for CII, whose subunits are encoded entirely by the nuclear DNA (nDNA), 
all other OXPHOS complexes are built of subunits that are encoded either by the 
nDNA or the mitochondrial DNA (mtDNA). Genetic defects resulting in OXPHOS 
dysfunction are now recognized as causal to a clinically heterogeneous group of 
diseases, generally referred to as mitochondrial disorders (Zeviani and Di Donato 
2004, Taylor and Turnbull 2005). Defects in the mtDNA may affect protein synthesis 
genes (22 transfer RNA genes and 2 ribosomal RNA genes) and protein encoding 
genes (13 OXPHOS subunit genes). Nuclear DNA mutations may affect genes 
encoding the remainder of the OXPHOS subunits, OXPHOS assembly factors, factors 
involved in mtDNA maintenance, replication and transcription and mitochondrial 
RNA translation and genes encoding biosynthetic enzymes for lipids or cofactors 
(Smeitink, Zeviani et al. 2006).
Isolated CI deficiency is the most commonly encountered single enzyme 
deficiency in patients with a mitochondrial disorder. CI is built of 44 subunits, 
7 encoded by the mtDNA and 37 by the nDNA and pathogenic mutations have been 
identified in all 7 mtDNA genes and 19 of the nDNA genes (Koopman, Beyrath et 
al. 2016). In addition to these structural building blocks of CI, there are numerous 
proteins required for the assembly of the enzyme. Pathogenic mutations have also 
been identified in genes encoding these assembly factors (Mimaki, Wang et al. 2012, 
Nouws, Nijtmans et al. 2012, Pagniez-Mammeri, Rak et al. 2012). 
CI deficiency is routinely established by determining its activity in a 600g 
supernatant, referred to as mitochondrial-enriched fraction, of a muscle tissue 
homogenate or a homogenate of cultured primary skin fibroblasts using a 
spectrophotometric assay (Janssen, Trijbels et al. 2007, Rodenburg 2011). The 
assay uses NADH as a substrate which requires mitochondrial lysis by sonication, 
detergent treatment or freeze-thawing. It is generally observed that the activity of 
CI, albeit lower than the lowest healthy control value, differs greatly among patients 
with isolated CI-deficiency (Distelmaier, Koopman et al. 2009). Information on the 
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amount of fully assembled CI present in a mitochondrial-enriched fraction can be 
obtained through Blue Native gel-electrophoresis (BN-PAGE) followed by Western 
blotting. Linear regression analysis revealed a positive linear correlation between the 
activity and amount of CI, both expressed as percentage of the same lowest control, 
in mitochondrial-enriched fractions from cultured skin fibroblasts of 13 patients with 
isolated CI deficiency (Valsecchi, Koopman et al. 2010). The slope of the regression 
line did not significantly differ from the line of identity, suggesting that the decrease 
in CI activity is primarily due to a reduced amount of fully assembled CI and not, 
or to a much lesser extent, to a decrease in intrinsic activity of the fully assembled 
complex. Intriguingly, this analysis included 4 patients with a mutation in the Ndufs4 
gene showing an obvious, albeit significantly reduced, residual CI activity in the 
spectrophotometric assay but no fully assembled CI on the BN-PAGE Western blot. 
Instead, a ~830 kDa subcomplex was observed that failed to show in-gel activity. 
However, the residual CI activity in the spectrophotometric assay showed a good 
correlation with the amount of this subcomplex on the Western blot, suggesting 
that this subcomplex is part of the NADH oxidizing and ubiquinone reducing enzyme 
in the spectrophotometric assay. Based on these results it was suggested that the 
primary role of the NDUFS4 subunit is a regulatory one by controlling the stability 
and, thus, the cellular expression of the fully assembled complex. Here, it is important 
to note that BN-PAGE cannot replace the spectrophotometric assay as evidenced by 
the observation that it failed to identify a specific mutation in the Ndufs2 gene, which 
caused a marked reduction in CI activity in the spectrophotometric assay but showed 
a normal amount of fully assembled CI on the BN-PAGE Western blot and a normal 
in-gel activity (Ngu, Nijtmans et al. 2012). 
The ATP production capacity is routinely measured in a freshly prepared 600g 
supernatant of muscle tissue or cultured fibroblasts containing intact mitochondria 
(Janssen, Trijbels et al. 2006). The maximal rate of CI-dependent ATP production is 
measured in the presence of excess pyruvate, malate, ADP, PO
4
3- and creatine. It is 
generally observed that the ATP production rate is decreased in patients with isolated 
CI deficiency. Finally, cellular oxygen consumption is another paradigm through which 
CI deficiency can be analyzed. Moran and co-workers observed that CI-driven cellular 
oxygen consumption was diminished in patients with genetic defects in NDUFV1 and 
NDUFA1 (Moran, Rivera et al. 2010). 
The first mouse model with an isolated CI deficiency was a ubiquitous Ndufs4 
deletion created by Kruse et al (Kruse, Watt et al. 2008). The authors reported that 
these Ndufs4-/- mice, which lack the NDUFS4 subunit, displayed a progressive lethal 
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phenotype characterized by encephalomyopathy and early death around week 7. 
Their maximal body weight was attained around day 30 after which it declined 
again. From day 35 onwards, they became lethargic and hypothermic. Moreover, 
they displayed a progressive loss of gross motor skills as was deduced from an ataxic 
gait and the inability to perform on a Rotarod. Around day 40, a first increase in 
serum lactate occurred. Quintana et al, created a mouse with conditional deletion 
of Ndufs4 in neurons and glial cells (Quintana, Kruse et al. 2010). This brain-specific 
Ndufs4-/- mouse was demonstrated to display the same progressive phenotype as 
the ubiquitous Ndufs4-/- mouse. Mice engineered to specifically lack NDUFS4 in 
dopaminergic neurons did not show any sign of neurodegeneration, loss of striatal 
innervation or Parkinson’s related symptoms (Sterky, Hoffman et al. 2012). However, 
decreased dopamine release and increased levels of dopamine metabolites pointed 
to a significant effect on dopamine homeostasis. Moreover, dopaminergic neurons 
of these mice appeared more sensitive to methyl-4-phenyl-1,2,3,6-tetrahyropyridine 
(MPTP) toxicity, suggesting that that a decrease in CI activity may contribute to drug-
induced Parkinson’s disease Finally, Sterky et al and Karamanlidis et al independently 
generated a conditional heart-specific Ndufs4-/- mouse and demonstrated that 
the absence of NDUFS4 had no effect on lifespan (Sterky, Hoffman et al. 2012, 
Karamanlidis, Lee et al. 2013). 
Kruse et al did not observe any detectable rotenone sensitive CI activity in 
submitochondrial particles obtained after sonication, freeze-thawing or Triton X-100 
lysis of a mitochondrial-enriched fraction from liver of the ubiquitous Ndufs4-/- mouse 
(Kruse, Watt et al. 2008). Analysis of a mitochondrial-enriched fraction from several 
tissues of this Ndufs4-/- mouse after mitochondrial lysis by freeze-thawing showed CI 
activities normalized to that of CIV ranging from 9% (lung) to 44% (heart) of control 
(Calvaruso, Willems et al. 2012). The near absence of CI activity in skeletal muscle 
and brain of these mice was confirmed by Alam et al ((Alam, Manjeri et al. 2015); 
Chapter 3 of this thesis) and Manjeri et al ((Manjeri, Rodenburg et al. 2016);Chapter 
5 of this thesis). Intriguingly, the latter two studies revealed that the maximal rate 
of CI-dependent ATP production expressed per mg of protein or overall tissue CI-
dependent ATP production capacity, measured in an intact mitochondrial-enriched 
fraction in the presence of excess pyruvate, malate, ADP, PO
4
3- and creatine, was 
not altered in skeletal muscle (Alam, Manjeri et al. 2015), whereas it was decreased 
in brain (Manjeri, Rodenburg et al. 2016). These results indicate that the absence 
of the NDUFS4 subunit does prohibit CI-dependent ATP production and that the 
reduction in overall tissue CI-dependent ATP production capacity as observed in 
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brain is overcome in skeletal muscle. In the present study, we add additional data 
on the heart of this ubiquitous Ndufs4-/- mouse in order to elucidate the mechanism 
underlying the differences in CI-dependent ATP production capacity between the 
three tissues.
Materials  and Methods
All experiments were approved by the Regional Animal Ethics Committee (Nijmegen, 
The Netherlands) and performed under the guidelines of the Dutch Council for 
Animal Care. All efforts were made to reduce animal suffering and number of animals 
used in this study.
Animals. This study is a comparative study using skeletal muscle, heart and brain 
obtained from 5 WT (Ndufs4+/+) and 5 KO (Ndufs4-/-) mice with the understanding 
that the experimental data on skeletal muscle and brain of these mice have been 
published elsewhere (Alam, Manjeri et al. 2015); (Manjeri, Rodenburg et al. 2016). The 
genotype of the mice was confirmed by polymerase chain reaction and both male 
and female mice were included. Mice were group-housed at the central animal facility 
(CDL) of the Radboud University at 22°C on a day and night rhythm of 12 hours. The 
animals had ad libitum access to food and water and were fed on a standard animal 
diet (Ssniff GmbH, Soest, 76. Germany. V1534-300 R/M-H).
Tissue harvesting for biochemical analyses. Animals were sacrificed at PN 
(postnatal) 31-34 days by cervical dislocation. Skeletal muscle from the hind limbs 
and heart tissue were harvested and immediately put in ice-cold SETH buffer 
(0.25  mol/L sucrose, 2mmol/L EDTA, 10 mmol/L Tris, 5x104 U heparin/L, pH 7.4). 
Whole brains were transferred to ice-cold SEF buffer (0.25 mol/L sucrose, 2mmol/L 
EDTA, 10 mmol/L Potassium phosphate, pH 7.4), minced with a Sorvall TC2 tissue 
chopper and homogenized with a glass/Teflon Potter Elvehjem homogenizer within 
1 h of harvest. The homogenates were centrifuged at 600g and a portion of the 
supernatant was used for measurement of the maximal rates of pyruvate oxidation and 
ATP production. The remainder of the 600g supernatant was frozen in 10 µl aliquots 
in liquid nitrogen and kept at -80º C for maximal enzymatic activity measurements. 
The protein concentration was measured according to Rodenburg (Rodenburg 2011). 
Pyruvate oxidation and ATP production measurements. To determine the maximal 
pyruvate oxidation rate, the freshly prepared 600g supernatant was incubated with 
radiolabeled substrate ([1-14C] pyruvate). After 20 min, the reaction was stopped 
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and the amount of liberated radioactive CO
2
 (14CO
2
) was quantified (Janssen, Trijbels 
et al. 2006). The assay medium (pH 7.4) contained K+- phosphate buffer (30 mM; 
source of Pi), KCl (75 mM), Tris (8 mM), K-EDTA (1.6 mM), P1,P5-Di (adenosine-5′) 
pentaphosphate (Ap5A; 0.2 mM), MgCl
2
 (0.5 mM), ADP (2 mM), creatine (20 mM), 
malate (1 mM) and [1-14C] pyruvate (1 mM). AP5A is a potent adenylate kinase 
(AK) inhibitor required to prevent interference of the AK reaction with the levels 
of produced ATP, as well as with the excess of ADP required for this assay. For 
measurement of the maximal rate of ATP production, the same assay medium was 
used but with pyruvate instead of [1-14C] pyruvate. After 20 min, the reaction was 
stopped by addition of 0.1 M HClO
4
. The reaction mixture was centrifuged at 14000g 
for 2 min at 2 °C. To the supernatant, 1.2 vol (V/V) of 0.333 M KHCO
3
 was added, and 
this mixture was diluted 2-fold. The amount of ATP and phosphocreatine formed 
during the reaction were measured in the supernatant using a Konelab 20XT auto-
analyzer (Thermo Scientific). Mitochondrial ATP production rate was corrected 
using a parallel assay in which residual glycolysis was blocked by arsenite (2 mM) 
(Janssen, Trijbels et al. 2006). 
Respiratory chain enzyme assays. The liquid nitrogen frozen portion of the 600g 
supernatant was thawed and used for measurement of the (MCA) of the complexes 
I (CI), II (CII), III (CIII) and IV (CIV) and citrate synthase (CS), as described by Rodenburg 
(Rodenburg 2011). 
Electron microscopy analyses. Brains from 3 KO animals and 3 WT mice were 
harvested at PN 31-34 days after perfusion fixation in 2% (w/v) glutaraldehyde in 
phosphate buffer (PB) (pH 7.4). Brains were rinsed several times in PB and post fixed 
for 1h in 1% osmium tetroxide and 1% potassium ferrocyanide in 0.1M cacodylate 
buffer. Brains were dehydrated in an ascending series of aqueous ethanol solutions 
and subsequently transferred via a mixture of ethanol and Epon to pure Epon 812 
embedding medium. Ultrathin gray sections (60-80 nm) were cut, contrasted with 
aqueous 3% uranyl acetate, rinsed and counter-stained with lead citrate, air dried and 
examined in a JEOL JEM1010 electron microscope (JEOL, Welwyn Garden City, UK) 
operating at 60 kV.
Statistical Analysis. Statistical analysis was performed using Prism 5 (GraphPad 
Software Inc., La Jolla, Ca). Results were expressed as mean ± SD and comparisons 
between groups were performed using the nonparametric Mann-Whitney test. 
Statistical significance was set at (p<0.05).
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Results
Linear relationship between the maximal rates of pyruvate oxidation and ATP 
production in skeletal muscle, heart and brain from WT and KO mice. The 
maximal rates of pyruvate oxidation and ATP production were determined in the 
presence of excess pyruvate, malate, ADP, PO
4
3- and creatine in a 600g supernatant 
of a homogenate of skeletal muscle, heart and brain from wild type (WT) and NDUFS4 
knockout (KO) mice and expressed per mg of protein. Linear regression analysis 
revealed a highly significant relationship between the maximal rates of pyruvate 
oxidation and ATP production (Figure 1; R=0.89, p<0.0001). This result indicates that 
the conversion of pyruvate into ATP occurs equally efficiently in mitochondria of 
skeletal muscle, heart and brain and that this process is not compromised by the 
absence of the NUFS4 subunit of complex I (Figure 1). 
Citrate synthase activity is higher in skeletal muscle and heart but unaltered 
in brain of KO mice. The maximal activity of citrate synthase (CS) is widely used 
as an indicator of mitochondrial mass (Trounce, Kim et al. 1996, Kirby, Thorburn et 
al. 2007). CS activity was determined in a 600g supernatant of a homogenate of 
skeletal muscle, heart and brain from WT and KO mice after freeze-thawing and 
expressed per mg of protein. Both in WT (open bars) and KO (closed bars) mice, 
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Figure 1. Regression analysis of the relationship between the maximal rates of pyruvate 
oxidation and ATP production. The maximal rates of pyruvate oxidation and ATP production 
were determined in the presence of excess pyruvate, malate, ADP, PO
4
3- and creatine in 
a 600g supernatant of a homogenate of skeletal muscle (circles; n=5 and 4 for WT and KO, 
respectively), heart (triangles; n=5 and 4 for WT and KO, respectively) and brain (squares; n=5 
for both WT and KO) from WT (open symbols) and KO (closed symbols) mice and expressed per 
mg of protein. Thin lines represent the upper and lower 95% confidence limit.
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CS activity was highest in heart and lowest in muscle (Figure 2). Compared to WT 
mice, KO mice displayed significantly higher levels of CS in muscle (72%; p=0.017) 
and heart (49%; p=0.002). In sharp contrast, CS levels did not differ between WT 
and KO brain. 
Maximal rate of ATP production is unaltered in skeletal muscle and heart 
but lower in brain of KO mice. The maximal rate of ATP production can be 
expressed per unit of CS or per mg of protein. When expressed per unit of CS, 
ATP production was 51% (p=0.04), 32% (p=0.088) and 25% (p=0.019) lower in 
skeletal muscle, heart and brain, respectively, from KO mice as compared to WT 
mice (Figure 3). This result indicates that the absence of the NDUFS4 subunit 
decreases the ATP production capacity of the individual mitochondria and that 
this effect is most pronounced in skeletal muscle. However, when expressed 
per mg of protein, ATP production was not altered in KO skeletal muscle and 
KO heart, but 26% (p=0.028) lower in KO brain. This result suggests that in KO 
mice, the decrease in ATP production capacity of the individual mitochondria is 
compensated for by an increase in mitochondrial mass in skeletal muscle and 
heart, but not in brain.      
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Figure 2. Citrate synthase activity. The maximal activity of citrate synthase (CS) was 
determined in a 600g supernatant of a homogenate of skeletal muscle (n=5 for both WT and 
KO mice), heart (n=5 for both WT and KO mice) and brain (n=5 for both WT and KO mice) 
from WT (open bars) and KO (closed bars) mice after freeze-thawing and expressed per mg of 
protein. CS activity in WT heart was significantly higher than in WTmuscle (p<0.001) and in WT 
brain (p=0.020) and significantly higher in WT brain than in WT muscle (p<0.001). Similarly, 
CS activity in KO heart was significantly higher than in KO muscle (p<0.001) and in KO brain 
(p<0.001) and significantly higher in KO brain than in KO muscle (p<0.001). WTm=WT muscle, 
WTh=WT heart, WTb=WT brain. Statistics for comparison between WT and KO are given in 
the text.
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Maximal activity of the respiratory chain complexes II, III and IV is higher in 
skeletal muscle and heart but unaltered in brain of KO mice. The maximal activity 
of the respiratory chain (RC) complexes was determined in the presence of complex-
specific substrates in a 600g supernatant of a homogenate of skeletal muscle, heart 
and brain from WT and KO mice after freeze-thawing and expressed per unit of CS 
or mg of protein. Compared to WT mice, KO mice displayed a dramatically lower CI 
activity in all three tissues (Figure 4). However, when expressed per mg of protein, 
a residual activity of 28% was observed in KO heart. When expressed per unit of CS, 
no significant differences in CII, CIII and SCC activity were observed between WT and 
corresponding KO tissues (Figures 5a-c). On the other hand, when expressed per mg of 
protein, CII activity was 56% (p=0.033) higher in KO muscle as compared to WT muscle 
(Figure 5a), while the maximal activity of CIII tended to be higher in KO skeletal muscle 
(45%; p=0.069) and KO heart (11%; p=0.071) (Figure 5b). Measurement of the combined 
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Figure 3. Maximal rate of mitochondrial ATP production. The maximal rate of mitochondrial 
ATP production was determined in a 600g supernatant of a homogenate of skeletal muscle 
(circles; n=5 for both WT and KO mice), heart (triangles; n=5 for both WT and KO mice) and 
brain (squares; n=5 for both WT and KO mice) from WT (open symbols) and KO (closed 
symbols) mice as described in the caption to figure 1. The values obtained were expressed as 
nmol per U of CS (Y-axis) or mg of protein (X-axis). When expressed per U of CS, the rate of ATP 
production was significantly higher in WT brain than in WT muscle (p=0.005) and WT heart 
(P<0.001), significantly higher in WT muscle than in WT heart (p=0.009) and significantly higher 
in KO brain than in KO muscle (p=0.001) and in KO heart (p<0.001). Similarly, when expressed 
per mg of protein, the ATP production rate was significantly higher in WT brain than in WT 
muscle (p<0.001) and WT heart (p=0.032), significantly higher in WT heart than in WT muscle 
(P=0.011), significantly higher in KO brain than in KO muscle (p<0.001) and significantly higher 
in KO heart than in KO muscle (p=0.001). Statistics for comparison between WT and KO are 
given in the text.
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activity of the complexes II and III, referred to as succinate: cyt c oxidoreductase 
(SCC) activity, corroborated the picture that emerged from the measurement of their 
individual activities (Figure 5c). Expression per mg of protein revealed 64% and 50% 
higher values in KO skeletal muscle (p=0.042) and KO heart (p=0.001), respectively. The 
KO brain did not show any alteration in CII, CIII and SCC activity.
The picture was completed by measurement of the maximal activity of CIV. When 
expressed per CS, no significant difference in CIV activity was observed between 
WT and corresponding KO tissues (Figure 6). However, when expressed per mg of 
protein, CIV activity was 70% and 51% higher in KO skeletal muscle (p=0.024) and KO 
heart (p=0.005), respectively, whereas this activity was unaltered in KO brain.
Aberrant mitochondrial cristae structures in the cerebellum of Ndufs4 KO mice. 
Quintana et al., 2010, reported the cerebellum to be one of the most affected brain 
regions in the conditional brain specific Ndufs4-/- mice. In the present study, the 
mitochondria from cerebellar cells were analyzed on an ultrastructural level. Figure 7A 
depicts two WT cerebellar Purkinje cells characterized by a large nucleus and a clear 
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Figure 4. Maximal CI activity. The maximal activity of CI was determined in a 600g supernatant 
of a homogenate of skeletal muscle (circles; n=5 for both WT and KO mice), heart (triangles; 
n=5 for both WT and KO mice) and brain (squares; n=5 for both WT and KO mice) from WT 
(open symbols) and KO (closed symbols) mice after freeze-thawing. The values obtained were 
expressed as mU per U of CS (Y-axis) or mg of protein (X-axis). When expressed per U of CS, 
CI activity was significantly higher in WT brain than in WT muscle (p=0.013) and significantly 
higher in KO heart than in KO brain (p=0.045). Similarly, when expressed per mg of protein, CI 
activity was significantly higher in WT heart than in WT muscle (p<0.001), significantly higher 
in WT brain than in WT muscle (p<0.001) and significantly higher in KO heart than in KO muscle 
(p=0.012) and in KO brain (p=0.012). 
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Figure 5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Maximal CII, CIII and succinate: cyt c oxidoreductase (SCC) activity. The 
maximal CII, CIII and SCC activity was determined in a 600g supernatant of a homogenate of 
skeletal muscle (circles; n=5 for both WT and KO mice), heart (triangles; n=5 for both WT and 
KO mice) and brain (squares; n=5 for both WT and KO mice) from WT (open symbols) and KO 
(closed symbols) mice after freeze-thawing. The values obtained were expressed as mU per 
U of CS (Y-axis) or mg of protein (X-axis). a. When expressed per mg of protein, CII activity 
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was significantly higher in WT heart than in WT muscle (p<0.001) and in WT brain (p=0.010), 
significantly higher in WT brain than in WT muscle (p<0.001), significantly higher in KO heart 
than in KO muscle (p<0.001) and in KO brain (p<0.001) and significantly higher in KO brain than 
in KO muscle (p=0.003). Statistics for comparison between WT and KO are given in the text. 
b. When expressed per U of CS, CIII activity was significantly higher in KO muscle (p<0.001) 
and KO brain (p<0.001) than in KO heart. When expressed per mg of protein, CIII activity was 
significantly higher in WT heart than in WT muscle (p<0.001), significantly higher in WT brain 
than in WT muscle (p<0.001), significantly higher in KO heart than in KO muscle (p<0.001) 
and in KO brain (p<0.001) and significantly higher in KO brain than in KO muscle (p=0.005). 
Statistics for comparison between WT and KO are given in the text. c. When expressed per 
U of CS, SCC activity was significantly higher in WT brain than in WT heart (p=0.017). When 
expressed per mg of protein, SCC activity was significantly higher in WT heart than in WT 
muscle (p<0.001) and WT brain (P=0.054), significantly higher in WT brain than in WT muscle 
(p<0.001), significantly higher in KO heart than in KO muscle (p<0.001) and KO brain (p<0.001) 
and significantly higher in KO brain than in KO muscle (p<0.001). Statistics for comparison 
between WT and KO are given in the text.
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Figure 6. Maximal CIV activity. The maximal activity of CIV was determined in a 600g 
supernatant of a homogenate of skeletal muscle (circles; n=5 for both WT and KO mice), heart 
(triangles; n=5 for both WT and KO mice) and brain (squares; n=5 for both WT and KO mice) from 
WT (open symbols) and KO (closed symbols) mice after freeze-thawing. The values obtained 
were expressed as mU per U of CS (Y-axis) or mg of protein (X-axis). When expressed per U of 
CS, maximal CIV activity was significantly higher in WT brain than in WT muscle (p<0.001) and 
in WT heart (P<0.001) and significantly higher in KO brain than in KO muscle (p<0.001) and in 
KO heart (p<0.001). When expressed per mg of protein, maximal CIV activity was significantly 
higher in WT brain than in WT muscle (p<0.001), significantly higher in WT heart than in WT 
muscle (p<0.001), significantly higher in KO heart than in KO muscle (p<0.001) and in KO 
brain (p<0.001) and significantly higher in KO brain than in KO muscle (p<0.001). Statistics for 
comparison between WT and KO are given in the text.
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Figure 7. Abnormal mitochondria with condensed cristae in basket cell extensions 
surrounding the Purkinje cells in the brain of KO mice.  Electron micrographs displaying the 
cerebellum Purkinje cell layer (pcl), the granular cell layer (gcl), and the cerebellum molecular 
layer (mol) in (A) WT and (B) KO mouse brain. Some of the small nuclei in the vicinity of the 
Purkinje cells are basket cells (seen at higher magnification in C-G). Magnification (in A, B) 
is 1000x. (C) WT cerebellum with on the left the large nucleus (Nu) of a Purkinje cell, to the 
right the cytoplasm containing normal healthy organelles like rough endoplasmic reticulum 
(rer), Golgi apparatus (G), and normal healthy mitochondria (m). In the right bottom area a 
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nucleolus. Also present are several nuclei of adjacent granule cells. Comparison of 
figures 7A and 7B shows that the buildup of the cerebellar cortex layers is similar 
between WT and KO. Clearly visible are the granular cell layer, the molecular layer 
and the Purkinje cells surrounded by axo-somatic collaterals of inhibitory GABAergic 
basket cells. However, electron micrographs at higher magnification reveal the 
presence of abnormal mitochondria with condensed cristae in the basket cell 
extensions (Figures 7 D, F and G).
Discussion
The present study describes a comparative analysis on the CI-dependent ATP 
production capacity per mitochondrial mass (after normalization to the maximal 
activity of CS) and per tissue mass (after normalization to the amount of protein) 
for three tissues of high energy demand, namely brain, heart and skeletal muscle, 
of a mouse model of ubiquitous CI deficiency and shows that the capacity per 
mitochondrial mass is significantly decreased in all three tissues, whereas the 
capacity per tissue mass is unaltered in heart and skeletal muscle but decreased 
in brain. The mouse model is engineered to globally lack the NDUFS4 subunit 
of the first complex of the mitochondrial ATP generating system. Ubiquitous 
Ndufs4-/- mice remain healthy until ~35 days after which they show a progressive 
clinical phenotype leading to early death at ~7 weeks. Tissues were removed at 
31-34 days, homogenized and centrifuged at 600g to obtain a fraction enriched in 
intact mitochondria. CI-dependent ATP production was measured in the presence of 
pyruvate, malate, ADP, PO
4
3- and creatine and expressed both per U of CS and per mg 
of protein. The data presented suggest that up to day 35, mitochondrial biogenesis 
can compensate for the decrease in CI-dependent ATP production capacity per 
mitochondrial mass in heart and skeletal muscle, but not in brain. Using intact 
heart mitochondria from a heart-specific Ndufs4-/- mouse, Sterky et al observed a 
tendency to decrease of the ATP production rate normalized to CS and measured 
basket cell (bc) extension is seen, containing normal mitochondria (m). (D) KO cerebellum 
depicting normal Purkinje cell features with healthy organelles, and to the far right 3 basket 
cell (bc) extensions containing abnormal mitochondria with condensed cristae (indicated with 
an asterisk). (E) Details of basket cell (bc) mitochondria (m) show normal cristae in WT mice, 
while (F) depicts mitochondria with abnormal cristae (indicated with an asterisk) in the KO 
mice. Magnification (in E, F) is 8000x. (G) A higher magnification in the KO mouse at 15000x is 
clearly demonstrating the mitochondria with condensed cristae (indicated with an asterisk) in 
the basket cell (bc). Bars in (C), (D), (E), and (G) are 1µm.
60
2
B
io
c
h
e
m
ic
a
l c
h
a
r
a
c
ter
iz
a
tio
n
 o
f th
e o
x
id
a
tiv
e ph
o
sph
o
ry
la
tio
n
 sy
ste
m
in the presence of either pyruvate and malate or glutamate and malate (Sterky, 
Hoffman et al. 2012). In addition, they observed a tendency to increase of the activity 
of CS. Based on these data they tentatively concluded that the Ndufs4-/--deficient 
heart underwent a compensatory increase in mitochondrial mass in order to ensure 
a normal overall tissue ATP production capacity. This idea, which is substantiated in 
the present study, provides a logical explanation for the observation that the rate 
of phosphocreatine recovery was not different between ubiquitous Ndufs4-/- mice 
and their wildtype counterparts in the ischemic hind limb reperfusion paradigm 
(Kruse, Watt et al. 2008). Moreover, our results demonstrate the functionality of 
the increase in mitochondrial clusters in the subsarcolemma of the soleus muscle 
reported by these authors.
Increased mitochondrial biogenesis involves the activation of peroxisome-
proliferator-activated receptor γ co-activator-1α (PGC-1α);(Jornayvaz and Shulman 
2010).The activity of PGC-1α is controlled by several factors including the cellular 
energy sensor AMP-activated protein kinase (AMPK). Upon activation, PGC-1α 
activates several transcription factors including nuclear respiratory factor 1 (NRF-1) and 
nuclear respiratory factor 2 (NRF-2), which activate mitochondrial transcription factor 
A (Tfam). Expression of PGC-1α has been shown to be decreased under conditions 
of chronic stress (Farhoud, Nijtmans et al. 2012). On the other hand, degradation 
of PGC-1α by the ubiquitin-proteasome system was found to be slowed down in 
cultured primary skin fibroblasts from CI-deficient patients (Farhoud, Nijtmans et al. 
2012). Studies with cultured primary skin fibroblasts from CI-deficient patients have 
shown the increased oxidation of probes sensitive to reactive oxygen species (ROS); 
(Koopman, Nijtmans et al. 2010). If unbalanced by the antioxidant systems of the cell, 
this increase in ROS production results in the condition of chronic oxidative stress. It is 
tempting to speculate that the effect of chronic oxidative stress predominates in brain 
keeping PGC-1α low thus preventing increased mitochondrial biogenesis, whereas in 
skeletal muscle and heart the effect of degradation inhibition predominates resulting 
in increased levels of PGC-1α and thus increased mitochondrial biogenesis. Evidence 
favoring a beneficial effect of activation of the AMPK/PGC-1α pathway comes from 
studies with primary skin fibroblasts of CI-deficient patients cultured in the presence 
of galactose showing that the AMPK activator 5-Aminoimidazole-4-carboxamide 
ribotide (AICAR) decreased the production of ROS and increased mitochondrial 
biogenesis, cell growth and cellular ATP content (Golubitzky, Dan et al. 2011). 
In addition to measuring the ATP production capacity, we measured the maximal 
rate of pyruvate oxidation in the tissue fractions enriched in intact mitochondria. 
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The assay medium was exactly the same for both measurements and regression 
analysis revealed a linear correlation for all three tissues and regardless whether 
they were from the Ndufs4-/- mice or their wildtype counterparts. From the slope it 
can be calculated that ~5-6 mol of ATP is produced per mol of pyruvate. The major 
conclusion that can be drawn from this result is that in none of the three tissues 
the absence of the NDUFS4 subunit alters the efficiency with which the uptake and 
oxidation of pyruvate is coupled to the production and release of ATP.
As already reported by many other researchers, the absence of the NDUFS4 
subunit did not lead to the absence of CI-dependent pyruvate oxidation and ATP 
production in an intact mitochondrial-enriched fraction. BN-PAGE analysis revealed 
the presence of a CI subcomplex of ~830 kDa rather than the fully assembled complex 
of 1 MDa (Valsecchi, Monge et al. 2012). This subcomplex failed to show in-gel activity, 
indicating that it lacks the functional NADH dehydrogenase module. However, in a 
recent study we provided evidence that CIII may functionally stabilize the ~830 kDa 
subcomplex and the NADH dehydrogenase module in the absence of NDUFS4 
(Calvaruso, Willems et al. 2012). Apparently, this stabilization is disturbed during the 
freeze-thawing procedure required to measure the activity of the complex. 
The above idea that mitochondrial biogenesis compensates for the decrease in 
CI-dependent ATP production capacity per mitochondrial mass in heart and skeletal 
muscle of Ndufs4-/- mice implicates that apart from the maximal activity of CS also 
the maximal activity of the individual RC complexes is increased in these tissues and 
that this is not the case in brain. Analysis of the maximal activity of the individual RC 
complexes was performed in a freeze-thawed aliquot of the mitochondrial-enriched 
fraction used for measurement of the ATP production capacity. The overall picture 
that emerges from these measurements is that of an increase in maximal activity of 
CII, CIII and CIV per tissue mass in KO skeletal muscle and heart. In sharp contrast, 
the activity per tissue mass remained unaltered in KO brain. These data indicate that 
normalization of the ATP production capacity to either one of the above three RC 
complex activities yields the wrong picture. For instance, Leong et al normalized 
the CI-dependent ATP production measured in the presence of glutamate and 
malate to the CII-dependent ATP production and concluded a significant decrease 
in heart and brain of NDUFS4-deficient Ndufs4fky/fky mice (Leong, Komen et al. 2012). 
Extrapolation of our result of an increase in CII activity in skeletal muscle but not 
brain most probably leads to the same conclusion as obtained in the present study 
that the ATP production capacity per tissue mass is not altered in skeletal muscle but 
decreased in brain. 
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When expressed per mitochondrial mass, the maximal activity of CII and CIII 
tended to be lower in skeletal muscle and heart but this was not reflected by the 
maximal SCC activity, measuring the combined activity of these two complexes, 
which showed no change. Thus, when expressed per mitochondrial mass neither 
of the three tissues showed a change in maximal activity of CII, CIII and CIV. Kruse 
et al reported a significant increase in maximal activity of CII, but not CIII and CIV, 
when normalized to CS in submitochondrial particles from liver of the ubiquitous 
Ndufs4-/- mouse (Kruse, Watt et al. 2008). This result suggests that in liver, CII is 
selectively upregulated to a larger extent than CS and, therefore, mitochondrial 
mass. This emphasizes our above remark that the ATP production capacity should 
not be expressed per activity of one of the RC complexes. In contrast to our findings, 
Karamanlidis et al reported no change in CII, CIV and CS activity in submitochondrial 
particles isolated from a heart-specific Ndufs4-/- mouse (Karamanlidis, Lee et al. 
2013). Although details on normalization are lacking it is likely that activities were 
normalized to mg of protein. On the other hand, Sterky et al showed a significant 
reduction in CII activity normalized to CS in a detergent-permeabilized mitochondrial 
preparation from heart tissue of a heart-specific Ndufs4-/- mouse (Sterky, Hoffman 
et al. 2012). Although we also observe a tendency to decrease of this activity in heart, 
our SCC measurement shows that the combined activity of CII and CIII is not altered. 
In agreement with our findings no differences in maximal activity were observed 
for CII, CIII and CIV normalized to CS in brain of the NDUFS4-deficient Ndufs4fky/fky 
mouse (Leong, Komen et al. 2012). Taken together, the results of the present study 
substantiate the idea that the absence of the NDUFS4 does not significantly affect 
the maximal activity per mitochondrial mass of CII, CIII and CIV in brain, heart and 
skeletal muscle.
In contrast to the above conclusion that mitochondrial biogenesis can compensate 
for the decrease in ATP production capacity per mitochondrial mass, CI-driven oxygen 
consumption appeared to be halved in intact liver cells of the ubiquitous Ndufs4-/- 
mouse (Kruse, Watt et al. 2008). The same results were obtained with brain tissue 
of the brain-specific Ndufs4-/- mouse (Quintana, Kruse et al. 2010). In the present 
study we did not include liver but the above result obtained with brain tissue from 
the brain-specific Ndufs4-/- mouse is in agreement with our observation that this 
tissue lacks compensatory mitochondrial biogenesis. Also in contrast to the above 
conclusion that mitochondrial biogenesis can compensate for the decrease in ATP 
production capacity per mitochondrial mass, permeabilized cardiac myofibers from 
the heart-specific Ndufs4-/- mouse showed a reduction in CI-driven mitochondrial 
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respiration (Karamanlidis, Lee et al. 2013). However, in the same study no increase in 
CS and therefore mitochondrial biogenesis was observed (see above). It remains to 
be established whether these discrepancies are due to the fact that unstressed heart-
specific Ndufs4-/- mice, unlike ubiquitous Ndufs4-/- mice, show no clinical phenotype. 
It has been suggested that the pathophysiological consequences of isolated CI 
deficiency are neurological (Kruse, Watt et al. 2008, Quintana, Kruse et al. 2010, 
Leong, Komen et al. 2012, Quintana, Zanella et al. 2012). It is tempting to speculate that 
this has to do with the present observation that brain tissue is unable to perform a 
compensatory increase in ATP production capacity. However, our analysis involves the 
whole brain. Quintana et al reported the cerebellum to be one of the most affected 
brain regions in the conditional brain-specific Ndufs4-/- mouse (Quintana, Kruse et al. 
2010). To gain more insight we studied the mitochondrial ultrastructure in cerebellar 
cells. As already reported by Quintana et al analysis of the electron micrographs 
demonstrated the presence of abnormal mitochondria with condensed cristae in 
the axo-somatic collaterals of the inhibitory GABAergic basket cells surrounding the 
Purkinje cells.
As discussed above ROS production is increased in cultured primary skin 
fibroblasts of CI-deficient patients (Koopman, Nijtmans et al. 2010). If unbalanced 
by the antioxidant systems of the cell, this increase in ROS production may result 
in an increase in lipid peroxidation as demonstrated by the addition of rotenone in 
the absence and presence of the mitochondria-targeted antioxidant mitoquinone 
(Koopman, Verkaart et al. 2005). It has been speculated that lipid peroxidation 
products such as malondialdehyde and 4-hydroxynonenal (HNE) may induce 
damage to vulnerable brain cells (Kayser, Sedensky et al. 2016). However, the latter 
authors showed that covalent modification of mitochondrial proteins by HNE was 
not increased in olfactory bulb, brainstem and cerebellum, brain regions showing 
increased degeneration in Ndufs4-/- mice. Similarly, Chouchani et al did not find any 
sign of oxidative damage in heart tissue of a heart-specific Ndufs4-/- mouse during 
development of severe hypertrophic cardiomyopathy (Chouchani, Methner et al. 
2014). The induction of dopamine neuron death by rotenone has implicated CI in 
Parkinson’s disease (Choi, Palmiter et al. 2011). However, these authors provided 
evidence that the increase in NADH-mediated dopamine production and ROS 
formation induced by CI inhibition alone is not sufficient to induce dopamine 
neuron death and that the latter requires the additional increase in microtubule 
depolimerization as obtained with rotenone but not with piericidin A (Choi, Palmiter 
et al. 2011). Leong et al observed increased levels of hydroxyacylcarnitine species 
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and inferred that CI dysfunction increases the NADH/NAD+ ratio thus inhibiting 
mitochondrial fatty acid oxidation (Leong, Komen et al. 2012). The heart-specific 
Ndufs4-/- mouse generated by Karamanlidis et al also displayed an increased NADH/
NAD+ ratio, which was associated with inhibition of Sirtuin-3 resulting in increased 
protein acetylation and sensitization of the mitochondrial permeability transition 
pore (Karamanlidis, Lee et al. 2013). NAD+ precursor supplementation partially 
normalized the NADH/NAD+ ratio, protein acetylation and mPTP sensitivity. 
In conclusion, the present study demonstrates that skeletal muscle and heart 
respond to a decrease in CI-dependent ATP production capacity per mitochondrial 
mass with an increase in mitochondrial biogenesis resulting in maintenance of the 
overall tissue CI-dependent ATP production capacity. The absence of such an adaptive 
response in brain may explain the increased degeneration observed in olfactory bulb, 
brainstem and cerebellum of Ndufs4-/- mice. Given the fact that ubiquitous and brain-
specific Ndufs4-/- mice display the same clinical phenotype, this means that these 
brain regions are the primary target for therapeutic intervention (Koopman, Beyrath 
et al. 2016).
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Abstract
Mitochondrial ATP production is mediated by the oxidative phosphorylation 
(OXPHOS) system, which consists of four multi-subunit complexes (CI-CIV) and the 
F
o
F
1
-ATP synthase (CV). Mitochondrial disorders including Leigh Syndrome often 
involve CI dysfunction, the pathophysiological consequences of which still remain 
incompletely understood. Here we combined experimental and computational 
strategies to gain mechanistic insight into the energy metabolism of isolated skeletal 
muscle mitochondria from 5 weeks old wild-type (WT) and CI-deficient NDUFS4-/- 
(KO) mice. Enzyme activity measurements in KO mitochondria revealed a reduction 
of 79% in maximal CI activity (V
max
), which was paralleled by 45-72% increase in 
V
max 
of CII, CIII, CIV and citrate synthase. Mathematical modeling of mitochondrial 
metabolism predicted that these V
max
 changes do not affect the maximal rates of 
pyruvate (PYR) oxidation and ATP production in KO mitochondria. This prediction 
was empirically confirmed by flux measurements. In silico analysis further predicted 
that CI deficiency altered the concentration of intermediate metabolites, modestly 
increased mitochondrial NADH/NAD+ ratio and stimulated the lower half of the TCA 
cycle, including CII. Several of the predicted changes were previously observed 
in experimental models of CI-deficiency. Interestingly, model predictions further 
suggested that CI deficiency only has major metabolic consequences when its activity 
decreases below 90% of normal levels, compatible with a biochemical threshold 
effect. Taken together, our results suggest that mouse skeletal muscle mitochondria 
possess a substantial CI overcapacity, which minimizes the effects of CI dysfunction 
on mitochondrial metabolism in this otherwise early fatal mouse model.
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Introduction
Mitochondria are among the prime producers of cellular ATP and consist of a matrix 
compartment surrounded by an inner (MIM) and outer membrane (MOM), with in 
between an inter-membrane space (IMS) (Kroemer 1999, Newmeyer and Ferguson-
Miller 2003, Duchen 2004, Balaban, Nemoto et al. 2005, McBride, Neuspiel et 
al. 2006, Detmer and Chan 2007, Dieteren, Gielen et al. 2011). Mitochondrial ATP 
production is fueled by pyruvate (PYR), two molecules of which are generated from 
glucose (GLU) by glycolysis in the cytosol. PYR can be reversibly converted by lactate 
dehydrogenase (LDH) into lactate or imported into the mitochondrial matrix by a 
dedicated pyruvate carrier (Herzig, Raemy et al. 2012). Within the mitochondrion 
PYR is converted into acetyl coenzyme A (acetyl-CoA) that enters the tricarboxylic 
acid (TCA) cycle to yield two molecules of CO
2
, one molecule of ATP, four molecules 
of NADH and one molecule of FADH
2
. NADH and FADH
2
 serve as substrates for the 
oxidative phosphorylation (OXPHOS) system to generate ATP (Duchen 2004). The 
OXPHOS system consists of four multi-subunit complexes (CI-CIV) that form the 
electron transport chain (ETC) and the ATP-generating F
o
F
1
-ATPase (CV). Within the 
ETC electrons donated by NADH (at CI) and FADH
2
 (at CII) are transported to CIII 
and CIV by coenzyme Q
10
 (CoQ
10
) and cytochrome-c (cyt-c), respectively. At CIV, 
electrons are donated to molecular oxygen (O
2
) to form water. The energy released 
during electron transport is utilized at CI, CIII and CIV to transport H+ out of the 
mitochondrial matrix across the MIM. This process generates an inward-directed 
proton-motive force (PMF) consisting of an electrical (ΔΨ) and chemical component 
(ΔpH). At CV the energy associated with H+ re-entry into the mitochondria matrix is 
used to generate ATP from ADP and inorganic phosphate (P
i
). 
In addition to ATP generation, mitochondria also play a key role in various other 
cellular processes, including reactive oxygen species (ROS) generation, calcium 
signaling and apoptosis induction. Therefore it is not surprising that dysfunction 
of the OXPHOS system, which sustains most mitochondrial functions, is associated 
with a broad range of human disorders (Kim, Vlkolinsky et al. 2001, Orth and Schapira 
2002, DiMauro and Schon 2003, Coskun, Beal et al. 2004, Finsterer 2006, Schapira 
2006, Koopman, Willems et al. 2012). Among OXPHOS disorders, deficiency of CI 
(OMIM 252010) is the most common (Kirby, Crawford et al. 1999, Loeffen, Smeitink 
et al. 2000, Smeitink, Sengers et al. 2001, Smeitink, van den Heuvel et al. 2001, Benit, 
Steffann et al. 2003, Carroll, Fearnley et al. 2006, Kruse, Watt et al. 2008, Distelmaier, 
Koopman et al. 2009, Fassone and Rahman 2012). Human CI deficiency is associated 
with a wide range of clinical presentations including muscle weakness, heart disease, 
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liver failure, respiratory failure and congenital lactic acidosis, often leading to death 
in early childhood (Smeitink, van den Heuvel et al. 2001, Kruse, Watt et al. 2008, 
Distelmaier, Koopman et al. 2009, Fassone and Rahman 2012, Koopman, Willems 
et al. 2012, Koopman, Distelmaier et al. 2013). CI is the largest protein complex of 
the oxidative phosphorylation system and consists of 44 different proteinaceous 
subunits that are encoded by either the mitochondrial (mtDNA) or nuclear DNA 
(Koopman, Nijtmans et al. 2010, Balsa, Marco et al. 2012, Nouws, Nijtmans et al. 
2012). Regarding the cellular consequences of nDNA-encoded CI mutations, several 
studies with primary patient fibroblast have been carried out revealing aberrations in 
maximal ETC enzyme activities (V
max
) and mitochondrial morphology, increased levels 
of cellular reactive oxygen species (ROS) and disturbed calcium and ATP homeostasis 
(Visch, Rutter et al. 2004, Koopman, Visch et al. 2005, Koopman, Verkaart et al. 2007, 
Koopman, Verkaart et al. 2008, Willems, Valsecchi et al. 2008, Willems, Smeitink et al. 
2009, Koopman, Nijtmans et al. 2010). 
Recently a whole-body KO mouse model of human CI deficiency became 
available in which one of the CI accessory subunit genes (NDUFS4) is deleted (Kruse, 
Watt et al. 2008). The NDUFS4 gene encodes an 18-kDa protein (NDUFS4 or NADH 
dehydrogenase (ubiquinone) Fe-S protein 4). When NDUFS4 is absent, proper CI 
assembly is hampered and its V
max 
is reduced (van den Heuvel, Ruitenbeek et al. 
1998, Smeitink, Sengers et al. 2001, Smeitink, van den Heuvel et al. 2001, Carroll, 
Fearnley et al. 2006, Kruse, Watt et al. 2008, Fassone and Rahman 2012, Valsecchi, 
Monge et al. 2012). Importantly, several symptoms of human CI deficiency are also 
observed in NDUFS4-/- animals such as developmental delays, failure to thrive, 
lethargy, opthalmoplegia and progressive encephalomyopathy leading to early 
lethality. However, the consequences of NDUFS4 gene deletion on mitochondrial 
energy metabolism, its underlying reaction rates and reactant concentrations 
have not been investigated yet. Here we addressed this question by combining 
experimental and computational strategies to evaluate: (i) if NDUFS4 knockout 
affected the V
max
 of key ETC enzymes and citrate synthase (CS), and (ii) whether 
NDUFS4 knockout impacted on the maximal rates of PYR oxidation and ATP 
production in isolated skeletal muscle mitochondria. To this end we first adapted 
a previously validated dynamic model of mitochondrial metabolism (Wu, Yang et 
al. 2007) to our experimental conditions. Next, we used this model to predict the 
consequences of NDUFS4 knockout on the steady-state values of metabolic fluxes, 
metabolite concentrations and physiological variables including Δy. This analysis 
predicted that a reduction of ~80% in the V
max
 of CI did not affect the maximal rates 
of mitochondrial PYR oxidation and ATP production in isolated NDUFS4-/- skeletal 
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muscle mitochondria. This prediction was confirmed by experimental flux analysis 
and suggests that these mitochondria possess a substantial CI overcapacity that 
limits the impact of CI deficiency on mitochondrial metabolism.
Materials  and Methods
Animals – NDUFS4-/- knockout (KO) and wild-type (WT) mice (mixed 129/Sv: C57BL6 
background) were generated by crossing heterozygote (NDUFS4+/-) mice. The 
genotype was confirmed by polymerase chain reaction (PCR) testing. Mice had 
ad libitum access to food and water and were fed on a standard animal diet (Ssniff 
GmbH, Soest, Germany: V1534-300 R/M-H). Animals were group housed at 22°C 
and maintained on a day and night rhythm of 12 hours. The animal studies were 
approved by the Regional Animal Ethics Committee (Nijmegen, The Netherlands) 
and performed under the guidelines of the Dutch Council for Animal Care. Both male 
and female animals were used in this study yielding similar results.
Measurement of maximal pyruvate oxidation, ATP production and enzymatic 
activities in mitoplasts – Skeletal muscle tissue from the entire hind limb was 
harvested from 5 wks old WT and KO animals, homogenized and centrifuged 
at 600g. Importantly, maximal PYR oxidation rates, ATP production rates and 
enzymatic activities (V
max
) were performed using the same 600g supernatant 
using standardized protocols (Janssen, Trijbels et al. 2006, Rodenburg 2011). To 
quantify pyruvate oxidation, mitochondrial preparations were incubated with 
radiolabelled substrate ([1-14C] pyruvate). After 20 min the reaction was stopped 
and the amount of liberated radioactive CO
2
 (14CO
2
) was quantified [40]. The 
assay medium (pH 7.4) contained K+- phosphate buffer (30 mM; source of P
i
), KCl 
(75 mM), Tris (8 mM), K-EDTA (1.6 mM), P1,P5-Di (adenosine-5′) pentaphosphate 
(Ap5A; 0.2 mM), MgCl
2
 (0.5 mM), ADP (2 mM), creatine (20 mM), malate (1 mM) 
and [1-14C] pyruvate (1 mM). AP5A is a potent adenylate kinase (AK) inhibitor 
required to prevent interference of the AK reaction with the levels of produced 
ATP, as well as with the excess of ADP required for this assay. For ATP production 
measurements, the same assay medium was used but with pyruvate instead of 
[1-14C] pyruvate. After 20 min, the reaction was stopped by addition of 0.1 M 
HClO
4
. The reaction mixture was centrifuged at 14000g for 2 min at 2 °C. To the 
supernatant, 1.2 vol (V/V) of 0.333 M KHCO
3
 was added, and this mixture was 
diluted 2-fold. The amount of ATP and phosphocreatine formed during the reaction 
were measured in the supernatant using a Konelab 20XT auto-analyzer (Thermo 
Scientific). Mitochondrial ATP production rate was corrected using a parallel assay 
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in which residual glycolysis was blocked by arsenite (2 mM) (Janssen, Trijbels et al. 
2006). The maximal activities of complex I (CI), complex II (CII), complex III (CIII), 
complex IV (CIV) and citrate synthase (CS) were measured in freeze-thawed 600g 
supernatants, as described in (Rodenburg 2011).
Mathematical modeling and statistical analysis – Dynamic modeling and statistical 
analysis were performed using custom scripts written in Matlab 6.1 (Mathworks, 
Natick, Massachusetts, U.S.A.). The latter are available upon request. Unless stated 
otherwise, experimental data is presented as mean±SEM (standard error of the 
mean) and statistical significance between datasets is assessed using an independent 
2-population Student’s t-test.
Results & Discussion
Overall experimental and computational strategy – In this study we used 
mitochondria from skeletal muscle of wildtype (WT) mice and NDUFS4-/- (KO) mice 
for experimental analysis. Mitochondria were placed in an assay medium and were 
considered as a classical input-output (I/O) system (cartoon in Fig. 1), which converts 
pyruvate (PYR; input) into ATP (output) via the integrated action of transporters, the 
TCA cycle and the OXPHOS system (Fig. 2). To perform computational analysis of 
this system we adapted a mathematical model of the mitochondrial bioenergetic 
system that was previously validated by Beard and co-workers (Wu, Yang et al. 
2007). This model consists of a collection of ordinary differential equations (ODEs) 
and parameters, which allows integrated simulation of the above I/O system and 
prediction of the underlying fluxes, metabolite concentrations and physicochemical 
parameters. Our overall strategy (Fig. 1) aimed to first adapt the published model 
to the conditions under which PYR oxidation and ATP production are measured 
in our experimental assay medium (explained in more detail below). This yielded 
a mathematical model for isolated WT mitochondria (“WT model”). Next, the WT 
model was adjusted by including the measured maximum activities (V
max
) of CI, 
CII, CIII, CIV and citrate synthase (CS) in mitochondria from WT and KO mice. This 
was achieved by multiplying the V
max
 values in the WT model by a “pre-factor” (KO/
WT) corresponding to the experimental change observed in these values for KO 
mitochondria. In this way a pre-factor >1 represented an increase in V
max
 for the KO 
vs. the WT condition, whereas a pre-factor <1 represented a decrease in V
max
 for the 
KO vs. the WT condition. We also generated two alternative KO models (KO model 
B and C) to simulate the consequences of increased CS activity with respect to 
TCA cycle enzyme activity and mitochondrial volume (see below for details). The 
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KO models were used to predict the maximal PYR oxidation and ATP production 
rates (expressed as KO/WT ratios), which where compared with experimentally 
determined values for model validation, as well as other relevant reaction fluxes, 
metabolite concentrations and physiological parameters.
Figure 1 
 
 
 
 
 
 
 
Figure 1. Overall experimental and computational strategy. A mathematical model of 
mitochondrial metabolism developed by Beard and coworkers [39] was adapted to match 
our experimental conditions. This yielded a model for isolated mitochondria from skeletal 
muscle of wild-type mice (WT model). By including experimental data, the WT model was 
adapted to create various KO models (A, B and C) for simulating mitochondrial metabolism 
in isolated muscle mitochondria from NDUFS4-/- (KO) mice with isolated complex I deficiency. 
Predicted PYR oxidation and ATP consumption rates were compared with experimental flux 
measurements for model validation and predictive analysis (see main text for details). 
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Figure 2 
 
Figure 2 
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WT model – The model of Beard et al (Wu, Yang et al. 2007) consists of three 
compartments (mitochondrial matrix, inter-membrane space and buffer space) and 
incorporates 43 flux expressions including TCA cycle fluxes, OXPHOS fluxes, substrate 
and cation fluxes, passive permeation fluxes and buffer reaction fluxes (Fig. 2). This 
model also contains various TCA control pathways including regulation of pyruvate 
dehydrogenase (PDH), a-ketoglutarate dehydrogenase (a-KGDH), aconitase (ACO) 
and fumarase (FUM; for a full list see Table 2 in (Wu, Yang et al. 2007)). All reactions in 
the model are thermodynamically balanced, and its parameters are validated using 
experimental data (LaNoue, Nicklas et al. 1970, Kohn, Achs et al. 1979, Kohn, Achs 
et al. 1979, Kohn and Garfinkel 1983, Bose, French et al. 2003, Wu, Yang et al. 2007). 
To generate the WT model we first removed metabolites, reactions and constant 
state variables from the Beard model that were not relevant under our experimental 
conditions (see Supplement for full details). These include two ATP-consuming 
reactions in the buffer space (i.e. hexokinase and adenylate kinase), one reaction 
for passive AMP permeation, one adenylate kinase reaction in the inter-membrane 
Figure 2. Predicted metabolic consequences of mitochondrial complex I deficiency in 
isolated mouse skeletal muscle mitochondria. (A) Isolated mitochondria were placed 
in an assay medium (grey) for experimental analysis. This was modeled using the depicted 
metabolic network containing exchange fluxes, TCA cycle and the mitochondrial oxidative 
phosphorylation (OXPHOS) system. Numerals represent the predicted steady-state values of 
fluxes (in mmol s–1 (l mito volume)–1 or mmol s–1 (l cyto volume)–1) and metabolite concentrations 
(in mM) for the WT situation. (B) Similar to panel A, but now for mitochondria from NDUFS4-/- 
(KO) animals. Colors indicate whether a flux or concentration is increased (green), decreased 
(red) or not affected (white) in the KO model. Abbreviations: ACCOA, Acetyl-CoA; ACO, 
Aconitase; ADP, Adenosine diphosphate; AKM, α-ketoglurarate (α-KG) / malate (MAL) 
antiporter; ANT, Adenine nucleotide translocase; ATP, Adenosine triphosphate; CI, Complex I; 
CII, Complex II or Succinate dehydrogenase; CIII, Complex III; CIT, Citrate; CIV, Complex IV; CK, 
Creatine kinase; CM, Citrate (CIT) / malate (MAL) antiporter; COQ, Oxidized ubiquinol; Cox, 
Oxidized cytochrome-c; Cred, Reduced cytochrome-c; CS, Citrate synthase; CV, Complex 
V or FoF1-ATPase; EX1, ADP exchange with assay medium; EX2, α-KG exchange with assay 
medium; EX3, ATP exchange with assay medium; EX4, CIT exchange with assay medium; EX5, 
MAL exchange with assay medium; EX6, Pi exchange with assay medium; EX7, PYR exchange 
with assay medium; EX8, SUC exchange with assay medium; FUM, Fumarase; FUM, Fumarate; 
GDP, Guanosine diphosphate; GTP, Guanosine triphosphate; H+, Hydrogen; HL, H+-leak;  HP, 
H+-Pi cotransporter; ICDH, Isocitrate dehydrogenase; ICIT, Isocitrate; MAL, Malate; MDH, 
Malate dehydrogenase; NAD+, Nicotinamide adenine dinucleotide; NADH, Reduced NAD+; 
NDPK, Nucleoside diphosphokinase; OAA, Oxaloacetate; PDH, Pyruvate dehydrogenase; Pi, 
Inorganic phosphate; PYR, Pyruvate; PYRH, PYR-H+ cotransporter; QH
2
, Reduced ubiquinol; 
SCOA, Succinyl-CoA; SCS, Succinyl-CoA synthetase; SM, Succinate (SUC) / malate (MAL) 
antiporter; SUC, Succinate; α-KG, α-ketoglutarate; α-KGDH, α-ketoglurarate dehydrogenase; 
Δψ, mitochondrial membrane potential
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space, two substrate transport reactions (isocitrate and fumarate transport). Next, 
various metabolite concentrations were adapted to match the conditions of our 
experimental assay (e.g. [PYR]=1 mM, [P
i
]=30 mM, [malate] ([MAL])= 1 mM, [ATP]= 
0 mM, [ADP]= 2 mM; a full list is provided in Supplementary Table S2). The final WT 
model consisted of 46 state variables (including Δy) and 37 flux expressions. Analysis 
of this model at steady-state (i.e. compatible with the experimental conditions of the 
PYR and ATP flux assays) yielded predictions of various fluxes, reactant concentrations 
and derived variables for the WT situation (Fig. 2A). 
Experimental analysis of ETC complex and citrate synthase in isolated skeletal 
muscle mitochondria from KO mice – The V
max
 of CI was reduced by 79% in KO 
vs. WT mitochondria (Table 1; “Experimental data, V
max
 values”). This reduction in CI 
activity was paralleled by a 45-72% increase in V
max
 of the other ETC enzymes and of 
the TCA-cycle enzyme citrate synthase (CS) 
KO models – To create KO model A, the V
max
 values for CI, CII, CIII, CIV and CS in 
the WT model were multiplied by the fractional change in this parameter in KO vs. 
WT (Table 1: “Parameters in the model”). The predictions of KO model A at steady-
state are summarized in Figure 2B. Interestingly, although CI activity was reduced 
by 79% in KO muscle mitochondria the model predicted no change in the maximal 
PYR oxidation (input of the system) or ATP production (Table 1; “Predicted by the 
model, Flux values”). The latter was confirmed by experimental analysis (Table 1; 
“Experimental data, Flux values”). The lack of effect of NDUFS4-/- knockout on PYR 
and ATP fluxes might relate to the fact that mitochondria were isolated from 5 wks old 
KO mice. At this age the pathophysiological phenotype of the NDUFS4 gene deletion 
are still relatively mild (Kruse, Watt et al. 2008).
Maximal CS activity was 1.72 higher in KO than in WT mitochondria. This might 
reflect a general increase in TCA-cycle enzyme level/activity and/or an increase in 
mitochondrial volume [e.g.(Mazat, Rossignol et al. 2001)]. To explore the potential 
effect of such changes on PYR and ATP fluxes in KO mitochondria we generated two 
additional KO models (KO model B and C). KO model B was derived from KO model 
A by increasing the activity of all TCA cycle enzymes by a “CS factor” of 1.72. KO 
model C was derived from KO model A by increasing the V
max
 of all other enzymes/
transporters in the model and mitochondrial volume by the CS-factor of 1.72. KO 
model B correctly predicted the lack of change in PYR and ATP fluxes, whereas KO 
model C predicted that these fluxes should be 59-69% higher in KO than in WT 
mitochondria (Table 1). This suggests that the increase in CS maximal activity might 
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reflect a general increase in the level of TCA enzymes but cannot be considered a 
measure of mitochondrial volume. 
Metabolic changes in skeletal muscle mitochondria from KO mice – Comparing 
the predictions of the WT model (Fig. 2A) and those of KO model A (Fig. 2B) highlighted 
changes in the TCA cycle and metabolite transport system. Interestingly, the TCA 
cycle was divided into an “upper” and “lower” segment defined by its reaction 
fluxes (Fig. 2B; lower segment colored green). To the best of our knowledge such a 
bifurcation of the TCA cycle was not reported previously in CI deficiency. The upper 
segment consists of reactions of Citrate synthase (CS), Aconitase (ACO), Isocitrate 
dehydrogenase (ICDH) and Malate dehydrogenase (MDH). The lower segment 
consists of a-ketoglurarate dehydrogenase (a-KGDH), Succinyl-CoA synthetase (SCS), 
Succinate dehydrogenase (CII) and Fumarase (FUM). In the upper TCA segment, WT 
steady-state reaction fluxes were more than 3-fold higher than those within the 
lower segment (Fig. 2A). In the WT case, the flux through ICDH flux (0.89 mM/s) 
gets divided at the end of the upper half segment of the TCA cycle: 69% of the flux 
(0.61 mM/s) goes out of the mitochondrial matrix to the IMS via the a-ketoglurarate 
(a-KG) / malate (MAL) antiporter (AKM) mechanism. The latter reaction is also 
the most active among the three antiporter mechanisms that bring MAL into the 
mitochondrial matrix to participate in initial part of the upper segment of the TCA 
cycle. Utilizing this flux, the upper TCA segment, along with Pyruvate dehydrogenase 
(PDH) generates 3 NADH molecules to fuel CI (Fig. 2A). The remaining part (31%) of 
the ICDH flux goes to a-KGDH (0.27 mM/s) to enter the lower half of the TCA cycle 
to fuel CII and also produce 1 ATP and 1 NADH molecule. The two remaining antiport 
mechanisms for MAL entry into the TCA cycle are the Citrate (CIT) / malate (MAL) 
antiporter (CM) and the Succinate (SUC) / malate (MAL) antiporter (SM). Together, 
CM and SM only contribute 0.5% to the total MAL entry to the matrix (Fig. 2A). 
Figure 2A further shows that in WT mitochondria the upper and lower TCA segments 
mainly provide substrates to CI and CII, respectively. Obviously, the combined action 
of CI and CII then provides electrons to the other ETC complexes to sustain the PMF 
and fuel ATP generation by CV. Of note, a substantial part of the entering PYR does 
not contribute to ATP production. Every PYR produces 4 NADH after entering the 
TCA cycle. ATP produced per NADH oxidized, which is same as ATP produced per 
O
2
 consumed, can be calculated simply by dividing the CV flux by the CIV flux. For 
the WT mice CV/CIV = 7.09/3.20 = 2.22. According to this calculation we should have 
obtained 363 * 4 * 2.22 = 3223 nmol/h/mg protein ATP, which is 45% higher than the 
observed ATP flux (Table 1). In the KO mice, the expected ATP production rate is 391 * 
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4 * (7.03/3.19) = 3447 nmol/h/mg protein, which is 65% higher than the experimental 
value. The lower rate of observed vs. predicted ATP production may be due to the 
absence in the model of other PYR-consuming mechanisms, for instance conversion 
into lactate (LAC).  In addition to the above, analysis of the KO model suggested 
various changes in other reaction fluxes and metabolite concentrations (Fig. 2B). 
In the CI-deficient state the lower segment of the TCA cycle carried 10-11% more 
flux than the WT model. Also the ICDH flux distribution to the lower segment and 
to the antiport mechanism was altered in the KO model. Of the ICDH flux, 35% is 
diverted towards the lower segment (31% in WT) and 65% towards the AKM system 
(69% in WT) to transport MAL into the matrix. Reducing CI activity by 80% only 
marginally affected its flux. It was also predicted that the flux through the upper 
part of the TCA cycle was only slightly reduced in KO mitochondria. This reduction 
is compensated by an increase (11%) in flux through the lower part of the TCA cycle, 
explaining the absence of effect on the total mitochondrial ATP production rate. The 
KO model further predicted a change in the steady-state matrix concentration of 
intermediate metabolites (Fig. 2B). Our predictions are compatible with the results 
of Mazat et al [48], where a reduction in ETC complex activity only slightly affected 
the fluxes of these complexes but major changes occurred in the concentration 
of metabolites associated with the affected complexes. With respect to CI, the KO 
model predicts a reduction in its upstream metabolite (reduced ubiquinol; “QH
2
” 
or ubiquinol: decreased by 65%) and an increased in its downstream metabolite 
(oxidized ubiquinol; “COQ” or ubiquinone: increased by 11%). Compatible with the 
measured increase in V
max
 of CII and CIII in KO mitochondria, the KO model predicts 
a decrease in the concentration of intermediate metabolites downstream of these 
complexes (i.e. succinate and reduced cytochrome-c were down by 71% and 26%, 
respectively). Similarly, the increased V
max
 of CIII in the KO model was associated 
with an increase in its upstream metabolites oxidized ubiquinol (‘COQ’; by 11%) and 
oxidized cytochrome-c (“C
ox
”; by 13%). Mitochondrial NADH/NAD+ ratio and Δy and 
were predicted to be (slightly) increased and depolarized, respectively. The latter 
predictions are compatible with results obtained in patient fibroblasts with inherited 
CI deficiency and cells treated with the CI inhibitor rotenone (Distelmaier, Koopman 
et al. 2009, Koopman, Nijtmans et al. 2010).
Predicting the consequences of CI deficiency – Patients with isolated CI deficiency 
display a variably reduced CI activity (V
max
) in muscle homogenates and primary 
fibroblasts (Valsecchi, Monge et al. 2012). During the last years, the consequences 
of isolated CI deficiency in primary patient fibroblasts have been extensively studied 
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at the cellular level (Visch, Rutter et al. 2004, Koopman, Visch et al. 2005, Koopman, 
Verkaart et al. 2007, Koopman, Verkaart et al. 2008, Koopman, Nijtmans et al. 2010). 
Native gel electrophoresis revealed variable amounts of holo-CI in patient cells, 
where in general three patterns were observed (i) the amount of active holo-CI was 
reduced (NDUFS2, NDUFS7, NDUFS8) (ii) the amount of active holo-CI was reduced 
and a ~830-kDa CI was present (NDUFV1, NDUFS1) (iii) or only a ~830-kDa CI was 
present (NDUFS4) (Valsecchi, Koopman et al. 2010, Blanchet, Buydens et al. 2011). 
Analysis of total cell homogenates by Western blotting revealed that the level of 
the 39-kDa CI subunit was twofold reduced in patient cohorts as compared to the 
controls, however cellular expression levels of other OXPHOS complex subunits 
was not altered significantly (Koopman, Verkaart et al. 2007). To gain further 
insight into the metabolic consequences of CI activity reduction at steady-state we 
performed various simulation runs with the WT model using different V
max
 values 
for CI (i.e.  lowering it from 100% to 1% of its normal maximal activity). A complete 
overview of the numerical data generated by these simulations (i.e. steady-state 
reaction fluxes, metabolite concentrations and physiological parameters) is provided 
in Supplementary Tables S4 and S5. Of note, the WT model was not compatible with 
a CI activity of 0%, which resulted in all fluxes being zero. The relationship between 
residual CI activity and key variables in the model are summarized in Figure 3. Most 
of the fluxes of the OXPHOS complexes (Fig. 3A), TCA cycle (Fig. 3B) and trans-MIM 
exchangers (Fig. 3C) were not altered by moderate CI activity reduction. As discussed 
above, the CII flux increased with decreasing CI activity (Fig. 3A), compatible with the 
predicted activation of the lower half of the TCA cycle (Fig. 3B). 
In general, reaction fluxes became substantially affected when CI activity was 
reduced by more than 90%. Compatible with our experimental observations and KO 
model predictions (Table 1), PYR oxidation and ATP production only were substantially 
reduced when CI activity was lowered by more than 90% (Fig. 3D). The concentration 
of ATP, ADP, GTP, GDP, P
i
 (Fig. 3E), TCA intermediates (Fig. 3F), matrix ions (Fig. 4G) and 
metabolites involved in redox homeostasis (Fig. 4H) were generally not affected by 
moderate CI activity reduction. Again, these parameters changed when CI activity 
was reduced by more than 90%. This suggests that steady-state energy homeostasis 
under non substrate-limited conditions is not affected when a certain (critical) 
amount of residual CI activity remains. In other words, CI activity can be inhibited to 
a certain threshold value (in our case near to 90% inhibition) before its consequences 
become apparent. Similar observations were made in various rotenone-treated rat 
tissues, where mitochondrial O
2
 consumption substantially dropped only when CI 
was inhibited by more than 80% (Rossignol, Malgat et al. 1999, Mazat, Rossignol et 
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Figure 3 
 
 
 
 
 
 
 
 
Figure 3. Predicted consequences of CI deficiency in isolated mouse skeletal muscle 
mitochondria. The V
max
 of CI (x-axis) was gradually reduced from 100% to 1% of that in the 
WT model and the effect on various steady-state metabolic fluxes, concentrations and other 
variables was predicted. To facilitate visual inspection, values on the y-axis were expressed as 
% of their value at 100% CI activity. (A) Effect of increasing CI deficiency on the flux through the 
OXPHOS system (CI, CII, CIII=CIV, and CV). (B) Similar to panel A, but now for TCA fluxes. (C) 
Similar to panel A, but now for exchange fluxes across the mitochondrial inner membrane (MIM). 
(D) Similar to panel A, but now for pyruvate (PYR) and ATP fluxes. (E) Similar to panel A, but now 
for ADP and GTP concentration in the mitochondrial matrix. (F) Similar to panel A, but now for 
TCA cycle intermediates. (G) Similar to panel A, but now for the free concentration of H+, K+ and 
Mg2+ in the mitochondrial matrix. (H) Similar to panel A, but now for redox-related parameters. (I) 
Similar to panel A, but now for mitochondrial membrane potential Δy (See main text for details).
al. 2001). Overcapacity of OXPHOS complexes is not specific for CI (Davey and Clark 
1996, Mazat, Rossignol et al. 2001). For instance, a reduction in CIV activity by almost 
50% had virtually no effect on CIV flux and O
2
 consumption in patient cells (Kuznetsov, 
Clark et al. 1996, Mazat, Rossignol et al. 2001).
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Metabolic control analysis (MCA) of the WT model revealed that the control 
coefficient for CI equaled 0.013, which was lower than a previously reported value (Davey 
and Clark 1996). Our model also predicted control coefficients for CII, CIII, CIV and CV (see 
Supplementary Fig. S1) that were lower than previously reported values (Rossignol, Malgat 
et al. 1999). In general, lower control coefficients are associated with a higher threshold 
value (Rossignol, Letellier et al. 2000, Mazat, Rossignol et al. 2001). In this sense, the high CI 
threshold value predicted by our model might be considered too high. This might be due 
the fact that although the original model was parametrized using experimental data (Wu, 
Yang et al. 2007), it was not a skeletal muscle-specific model. Compatible with previous 
results in genetic and inhibitor-induced fibroblast models of CI deficiency (Distelmaier, 
Koopman et al. 2009, Koopman, Nijtmans et al. 2010, Balsa, Marco et al. 2012), the WT 
model predicted that a reduction in CI activity was associated with redox alterations 
(e.g. an increase in NADH/NAD+ ratio; Fig. 3H) and partial Dy depolarization (Fig. 3I). 
Summar y and conclusion
This study combines experimental and in silico strategies to gain insight into the 
consequences of isolated mitochondrial CI deficiency in isolated skeletal muscle 
mitochondria from NDUFS4-/- mice. We demonstrate that NDUFS4-/- gene deletion 
reduces maximal CI activity and is paralleled by increased activity of CII, CIII, CIV and 
CS. Surprisingly, NDUFS4 knockout did not affect the maximal rate of PYR oxidation and 
ATP production. Mathematical modeling suggests that this phenomenon might be due 
to increased activity of the lower half of the TCA cycle, including CII. It further appears 
that mouse skeletal muscle mitochondria possess a substantial CI overcapacity, which 
further minimizes the effects of partial CI deficiency on mitochondrial metabolism. 
This means that CI activity can be inhibited to a certain threshold value (in our case 
near to 90% inhibition) before its consequences become apparent. We conclude that 
the metabolic consequences of CI dysfunction in KO mitochondria are minimized 
by CII-mediated fueling of the OXPHOS system and CI overcapacity. This still leaves 
open the possibility that mitochondrial ATP generation becomes limited when energy 
substrates are scarce and/or cellular energy demands increase during cell activation. 
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1.  SUPPLEMENTARY M ATERIALS AND METHODS
Modelling the effects of NDUFS4 knockout and increasing levels of CI deficiency - 
To predict the consequences of NDUFS4 knockout or increasing levels of CI deficiency 
we used a model of the mitochondrial bioenergetic system developed previously. 
Full details regarding the rate laws, ODE, estimated parameters, initial conditions 
and experimental validation are provided in the original paper [1]. We adapted this 
model to match the conditions under which our experimental data was obtained as 
described in the next section.
Removing metabolites and reactions from the original model of Wu et al., 2007 [1] 
- The original Wu model consists of three compartments and 43 flux expressions that 
mathematically describe the TCA cycle, OXPHOS system, substrate/ion homeostasis, 
passive permeation fluxes and buffer reaction fluxes. We first deleted reactions from 
the model that were not relevant in our experimental setup. These consisted of two 
ATP-consuming reactions in the buffer space (i.e. hexokinase ‘J_HK’ and adenylate 
kinase ‘J_AKe’), one reaction for passive AMP permeation (‘J_AMP’), one adenylate 
kinase reaction in the inter-membrane space (‘J_AKi’), and two substrate transport 
reactions (isocitrate ‘J_ICITt’ and fumarate transport ‘J_FUMt’). This was achieved 
by either completely removing the reactions from the model or by setting their 
V
max
 value to zero. Similarly, several state variables were constant or absent in our 
experimental system and were either removed from the model or assumed constant 
(Table S1).
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Table S1. Metabolites removed from the original model of Wu et al., 2007 [1].
Mitochondrial matrix 
AMP Not relevant as the ODE for AMP_x in the model is zero
Oxygen (O
2
) Constant
Total CO
2
 (CO
2,tot
) Constant
Mitochondrial intermembrane space
Isocitrate (ICIT) Not relevant in the model
Fumarate (FUM) Not relevant in the model as V
max
 of FUMt is zero
AMP Reaction for passive AMP permeation and AK were removed
Hydrogen (H+) Constant
Magnesium (Mg2+) Constant
Potassium (K+) Constant
Cytoplasm/buffer space
Hydrogen (H+) Constant
Magnesium (Mg2+) Constant
Potassium (K+) Constant
Glucose (GLC) Not relevant as HK is not present in the model
Glucose 6 phosphate (G6P) Not relevant as HK is not present in the model
Isocitrate (ICIT) Not used in the model
Fumarate (FUM) Not relevant in the model as V
max
 of FUMt is zero
AMP Reaction for passive AMP permeation and AK were removed
Phosphocreatine (PCr) Creatine was used instead of Phosphocreatine 
1.1.2. Model adaptation for the wild type and NDUFS4 knockout condition – To 
mimic our experimental assay conditions, we first changed the initial concentration of 
all relevant metabolites in the model (Table S2). For all other metabolites their initial 
concentration was left unchanged ([1]. The resulting model was used to simulate 
the wildtype (WT) condition (‘WT model’). In case of the NDUFS4 knockout (KO) 
situation, we adapted the WT model in 3 different ways to yield 3 different KO models 
(KO model A, B and C). 
1.1.3. KO model A – In KO model A, the experimentally obtained V
max
 values for CI, CII, 
CIII, CIV and CS were changed in the WT model according to the experimental values in 
Table 1. For this purpose, the original V
max
 of CI in the WT model (i.e. that published in 
[1]) was multiplied by a factor of 0.21. Similarly, the V
max
 value of CII, CIII, CIV and CS was 
multiplied by 1.56, 1.45, 1.70, and 1.72 respectively (see Table S3 for numerical values). The 
V
max
 values of all other enzymes were identical to their original values published in [1]. 
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KO model B and KO model C – To investigate whether an increase in the level 
of mitochondrial TCA cycle enzymes or mitochondrial mass (as suggested by the 
1.72-fold higher V
max
 of CS) might play a role in the KO situation we also modified KO 
model A to generate KO model B, in which the Vmax of all TCA cycle enzymes was 
increased by the ‘CS-factor’ of 1.72. Finally, to study potential effects of mitochondrial 
volume on model predections KO model A was adapted to yield KO model C. In the 
latter model the mitochondrial volume and V
max
 of all other remaining enzymes was 
increased by the ‘CS-factor’of 1.72.  
Table S2. Adjusted initial metabolite concentrations in the model
Metabolite
Initial concentration (M)
(In WT and KO model)
ADP 2.00E-03
Phosphate (P
i
) 3.00E-02
Creatine (Cr) 2.00E-02
Pyruvate (PYR) 1.00E-03
Malate (MAL) 1.00E-03
Aspartate (ASP) 0
Citrate (CIT) 0
a-ketoglurarate (AKG) 0
Succeinate (SUC) 0
Glutamate (GLU) 0
Performing model simulations – After setting the initial concentration and model 
parameters according to the experimental conditions, we solved the ODE model 
using the ode15s function of MATLAB. Simulations were run until the steady-state 
condition was reached. This required running the simulations for 1200 seconds. To 
simulate various degrees of CI deficiency and its metabolic consequences under 
steady-state conditions we performed simulation runs with the WT model using 
different V
max
 values for CI (i.e. by stepwise reducing the maximal CI activity from 
100% to 1% of this value in the WT model). 
Analysis of the control coefficient for CI-CV in the WT model – Control coefficients 
of all mitochondrial complexes (CI-CV) were calculated according to Mazat et al 
2001 [2]. Figure S1A-E represent threshold curve of mitochondrial complexes CI-CV 
respectively, where flux through each enzyme (y-axis) is plotted against the % inhibition 
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of the enzyme (y-axis). The control coefficient is given by the initial slope of the 
obtained “threshold curve”. Figure S1F depicts the effect of CI-CV activity reduction 
(x-axis) on the flux through CIV, representing mitochondrial oxygen consumption. The 
latter becomes affected when CI-CIV activity is reduced by more than 80%.
Table S3. Adjusted parameters (reaction rate coefficient) in the various models
Reactions WT [1] KO Model A KO Model B KO Model C
Complex I (CI) 32364.8187 6796.612 6796.612 6796.612
Complex II (CII or SDH; also in TCA) 0.08578868 0.13383 0.13383 0.13383
Complex III (CIII) 0.79081375 1.14668 1.14668 1.14668
Complex IV (CIV) 0.00010761 0.000183 0.000183 0.000183
Complex V (CV; F
o
F
1
-ATPase) 8120.39325 8120.3932 8120.39325 13967.07639
Aconitase (ACO) 0.02766541 0.0276654 0.047584505 0.047584505
α-ketoglurarate dehydrogenase (α-KGDH) 0.08763 0.08763 0.1507236 0.1507236
Citrate synthase (CS) 9.82530751 16.89953 16.89953 16.89953
Fumarase (FUM) 0.00707728 0.0070773 0.012172922 0.012172922
Glutamate oxaloacetate transaminase (GOT) 4.55139184 4.5513918 7.828393965 7.828393965
Isocitrate dehydrogenase (ICDH) 0.49204755 0.4920476 0.846321786 0.846321786
Pyruvate dehydrogenase (PDH) 0.20509364 0.2050936 0.352761061 0.352761061
Malate dehydrogenase (MDH) 0.07706001 0.07706 0.132543217 0.132543217
Nucleoside diphosphokinase (NDPK) 0.02554352 0.0255435 0.02554352 0.043934854
Succinyl-CoA synthetase (SCS) 0.44852045 0.4485205 0.771455174 0.771455174
α-ketoglurarate (α-KG) / malate (MAL) 
antiporter (AKM)
0.28209145 0.2820915 0.28209145 0.485197294
Adenine nucleotide translocase (ANT) 0.00752212 0.0075221 0.00752212 0.012938046
Citrate (CIT) / malate (MAL) antiporter (CM) 80.4321103 80.43211 80.4321103 138.3432297
Glutamate (GLU)-H+ cotransporter (GLUH) 272511422 272511422 272511422 468719645.8
Malate (MAL) / P
i
 anti-transporter (MALP) 16.0624419 16.062442 16.0624419 27.62740007
Aspartate (ASP) / Glutamate (GLU) 
antitransporter (AG)
5.87E-05 5.87E-05 5.87E-05 0.000100964
H+-leak (HL) 4758023.13 4758023.1 4758023.13 8183799.784
H+-P
i 
cotransporter (HP) 33355685 33355685 33355685 57371778.2
PYR-H+ cotransporter (PYRH) 299677927 299677927 299677927 515446034.4
Succinate (SUC) / malate (MAL) antiporter (SM) 96.9956183 96.995618 96.9956183 166.8324635
Creatine kinase (CK) 1.00E+07 1.00E+07 1.00E+07 1.00E+07
P
i
 exchange with assay medium (EX6) 327 327 327 562.44
Permeability coefficients for TCA intermediates 85 85 85 146.2
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Figure S1: Control coefficients of CI-CV. Using the WT model, the activity of CI-CV (x-axis) was gradually lowered 
from 100% to 1%. The corresponding flux value was plotted on the y-axis. The initial slope (m) of each curve (red lines) 
was used as a measure of the control coefficient. (A) Analysis of complex I (CI). (B) Analysis of complex II (CII). (C) 
Analysis of complex III (CIII). (D) Analysis of complex IV (CIV). (E) Analysis of complex V (CV). (F) Effect of lowering the 
activity of CI-CV on the flux through CIV (i.e. oxygen consumption).  
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Figure S1. Control coefficients of CI-CV. Using the WT model, the activity of CI-CV (x-axis) was 
gradually low red from 100% to 1%. The corresponding flux value was plotted n the y-axis. 
The initial slope (m) of each curve (red lines) was used as a measure of the control coefficient. 
(A) Analysis of complex I (CI). (B) Analysis of complex II (CII). (C) Analysis of complex III (CIII). 
(D)  Analysis of complex IV (CIV). (E) Analysis of complex V (CV). (F) Effect of lowering the 
activity of CI-CV on the flux through CIV (i.e. oxygen consumption). 
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SUPPLEMENTARY RESULT S
Table S4. Predicted effect of progressive CI deficiency on steady-state reaction fluxes.
Name 100% CI 90% CI 80% CI 70% CI 60% CI 50% CI 40% CI 30% CI 20% CI 10% CI 1% CI
OXPHOS system enzymes (mmol s–1 (l mito volume)–1)
1: Complex I (CI) 2.932 2.930 2.927 2.923 2.918 2.912 2.902 2.887 2.859 2.792 2.370
2: Complex II (CII or SDH; also in TCA) 0.272 0.274 0.276 0.278 0.281 0.286 0.292 0.302 0.320 0.356 0.422
3: Complex III (CIII) 3.204 3.203 3.202 3.201 3.200 3.198 3.195 3.190 3.179 3.148 2.792
4: Complex IV (CIV) 3.204 3.203 3.202 3.201 3.200 3.198 3.195 3.190 3.179 3.148 2.792
5: Complex V (CV; FoF1-ATPase) 7.095 7.092 7.088 7.083 7.075 7.066 7.051 7.028 6.984 6.869 5.938
TCA cycle enzymes (mmol s–1 (l mito volume)–1)
6: Aconitase (ACO) 0.885 0.884 0.882 0.880 0.878 0.874 0.869 0.860 0.845 0.811 0.649
7: α-ketoglurarate dehydrogenase (α-KGDH) 0.275 0.277 0.279 0.281 0.284 0.289 0.295 0.305 0.322 0.357 0.422
8: Complex II (CII or SDH; also in OXPHOS) 0.272 0.274 0.276 0.278 0.281 0.286 0.292 0.302 0.320 0.356 0.422
9: Citrate synthase (CS) 0.886 0.885 0.883 0.881 0.878 0.875 0.869 0.861 0.846 0.812 0.650
10: Fumarase (FUM) 0.272 0.274 0.276 0.278 0.281 0.286 0.292 0.302 0.320 0.356 0.422
11: Isocitrate dehydrogenase (ICDH) 0.885 0.884 0.882 0.880 0.878 0.874 0.869 0.860 0.845 0.811 0.649
12: Pyruvate dehydrogenase (PDH) 0.886 0.885 0.883 0.881 0.878 0.875 0.869 0.861 0.846 0.812 0.650
13: Malate dehydrogenase (MDH) 0.886 0.885 0.883 0.881 0.878 0.875 0.869 0.861 0.846 0.812 0.650
14: Nucleoside diphosphokinase (NDPK) 0.275 0.277 0.279 0.281 0.284 0.289 0.295 0.305 0.322 0.357 0.422
15: Succinyl-CoA synthetase (SCS) 0.275 0.277 0.279 0.281 0.284 0.289 0.295 0.305 0.322 0.357 0.422
Trans MIM metabolite/ion exchangers (mmol s–1 (l mito volume)–1)
16: α-ketoglurarate (α-KG) / malate (MAL) antiporter (AKM) -0.610 -0.607 -0.604 -0.599 -0.593 -0.585 -0.574 -0.555 -0.524 -0.454 -0.227
17: Adenine nucleotide translocase (ANT) 7.370 7.369 7.366 7.364 7.360 7.354 7.346 7.333 7.306 7.227 6.360
18: Citrate (CIT) / malate (MAL) antiporter (CM) -5.2E-04 -5.2E-04 -5.2E-04 -5.2E-04 -5.1E-04 -5.1E-04 -5.0E-04 -4.9E-04 -4.7E-04 -4.3E-04 -3.0E-04
19: H+-leak (HL) 2.294 2.293 2.292 2.290 2.287 2.283 2.278 2.269 2.253 2.217 2.062
20: H+-P
i
 cotransporter (HP) 7.370 7.369 7.366 7.364 7.360 7.354 7.346 7.333 7.306 7.227 6.360
21: PYR-H+ cotransporter (PYRH) 0.886 0.885 0.883 0.881 0.878 0.875 0.869 0.861 0.846 0.812 0.650
22: Succinate (SUC) / malate (MAL) antiporter (SM) -0.003 -0.003 -0.003 -0.003 -0.003 -0.003 -0.003 -0.002 -0.002 -0.002 -0.001
Other (mol s–1 (l mito volume)–1), CK ( mmol s–1 (l cyto volume)–1)
23: ADP exchange with assay medium (EX1) 7.370 7.369 7.366 7.364 7.360 7.354 7.346 7.333 7.306 7.227 6.360
24: α-KG exchange with assay medium (EX2) -0.610 -0.607 -0.604 -0.599 -0.593 -0.585 -0.574 -0.555 -0.524 -0.454 -0.227
25: ATP exchange with assay medium (EX3) 7.370 7.369 7.366 7.364 7.360 7.354 7.346 7.333 7.306 7.227 6.360
26: CIT exchange with assay medium (EX4) -5.2E-04 -5.2E-04 -5.2E-04 -5.2E-04 -5.1E-04 -5.1E-04 -5.0E-04 -4.9E-04 -4.7E-04 -4.3E-04 -3.0E-04
27: Creatine kinase (CK) -0.462 -0.462 -0.461 -0.461 -0.461 -0.461 -0.460 -0.459 -0.458 -0.453 -0.398
28: MAL exchange with assay medium (EX5) 0.614 0.611 0.607 0.603 0.597 0.588 0.577 0.558 0.526 0.456 0.228
29: P
i
 exchange with assay medium (EX6) 7.370 7.369 7.366 7.364 7.360 7.354 7.346 7.333 7.306 7.227 6.360
30: PYR exchange with assay medium (EX7) 0.886 0.885 0.883 0.881 0.878 0.875 0.869 0.861 0.846 0.812 0.650
31: SUC exchange with assay medium (EX8) -0.003 -0.003 -0.003 -0.003 -0.003 -0.003 -0.003 -0.002 -0.002 -0.002 -0.001
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SUPPLEMENTARY RESULT S
Table S4. Predicted effect of progressive CI deficiency on steady-state reaction fluxes.
Name 100% CI 90% CI 80% CI 70% CI 60% CI 50% CI 40% CI 30% CI 20% CI 10% CI 1% CI
OXPHOS system enzymes (mmol s–1 (l mito volume)–1)
1: Complex I (CI) 2.932 2.930 2.927 2.923 2.918 2.912 2.902 2.887 2.859 2.792 2.370
2: Complex II (CII or SDH; also in TCA) 0.272 0.274 0.276 0.278 0.281 0.286 0.292 0.302 0.320 0.356 0.422
3: Complex III (CIII) 3.204 3.203 3.202 3.201 3.200 3.198 3.195 3.190 3.179 3.148 2.792
4: Complex IV (CIV) 3.204 3.203 3.202 3.201 3.200 3.198 3.195 3.190 3.179 3.148 2.792
5: Complex V (CV; FoF1-ATPase) 7.095 7.092 7.088 7.083 7.075 7.066 7.051 7.028 6.984 6.869 5.938
TCA cycle enzymes (mmol s–1 (l mito volume)–1)
6: Aconitase (ACO) 0.885 0.884 0.882 0.880 0.878 0.874 0.869 0.860 0.845 0.811 0.649
7: α-ketoglurarate dehydrogenase (α-KGDH) 0.275 0.277 0.279 0.281 0.284 0.289 0.295 0.305 0.322 0.357 0.422
8: Complex II (CII or SDH; also in OXPHOS) 0.272 0.274 0.276 0.278 0.281 0.286 0.292 0.302 0.320 0.356 0.422
9: Citrate synthase (CS) 0.886 0.885 0.883 0.881 0.878 0.875 0.869 0.861 0.846 0.812 0.650
10: Fumarase (FUM) 0.272 0.274 0.276 0.278 0.281 0.286 0.292 0.302 0.320 0.356 0.422
11: Isocitrate dehydrogenase (ICDH) 0.885 0.884 0.882 0.880 0.878 0.874 0.869 0.860 0.845 0.811 0.649
12: Pyruvate dehydrogenase (PDH) 0.886 0.885 0.883 0.881 0.878 0.875 0.869 0.861 0.846 0.812 0.650
13: Malate dehydrogenase (MDH) 0.886 0.885 0.883 0.881 0.878 0.875 0.869 0.861 0.846 0.812 0.650
14: Nucleoside diphosphokinase (NDPK) 0.275 0.277 0.279 0.281 0.284 0.289 0.295 0.305 0.322 0.357 0.422
15: Succinyl-CoA synthetase (SCS) 0.275 0.277 0.279 0.281 0.284 0.289 0.295 0.305 0.322 0.357 0.422
Trans MIM metabolite/ion exchangers (mmol s–1 (l mito volume)–1)
16: α-ketoglurarate (α-KG) / malate (MAL) antiporter (AKM) -0.610 -0.607 -0.604 -0.599 -0.593 -0.585 -0.574 -0.555 -0.524 -0.454 -0.227
17: Adenine nucleotide translocase (ANT) 7.370 7.369 7.366 7.364 7.360 7.354 7.346 7.333 7.306 7.227 6.360
18: Citrate (CIT) / malate (MAL) antiporter (CM) -5.2E-04 -5.2E-04 -5.2E-04 -5.2E-04 -5.1E-04 -5.1E-04 -5.0E-04 -4.9E-04 -4.7E-04 -4.3E-04 -3.0E-04
19: H+-leak (HL) 2.294 2.293 2.292 2.290 2.287 2.283 2.278 2.269 2.253 2.217 2.062
20: H+-P
i
 cotransporter (HP) 7.370 7.369 7.366 7.364 7.360 7.354 7.346 7.333 7.306 7.227 6.360
21: PYR-H+ cotransporter (PYRH) 0.886 0.885 0.883 0.881 0.878 0.875 0.869 0.861 0.846 0.812 0.650
22: Succinate (SUC) / malate (MAL) antiporter (SM) -0.003 -0.003 -0.003 -0.003 -0.003 -0.003 -0.003 -0.002 -0.002 -0.002 -0.001
Other (mol s–1 (l mito volume)–1), CK ( mmol s–1 (l cyto volume)–1)
23: ADP exchange with assay medium (EX1) 7.370 7.369 7.366 7.364 7.360 7.354 7.346 7.333 7.306 7.227 6.360
24: α-KG exchange with assay medium (EX2) -0.610 -0.607 -0.604 -0.599 -0.593 -0.585 -0.574 -0.555 -0.524 -0.454 -0.227
25: ATP exchange with assay medium (EX3) 7.370 7.369 7.366 7.364 7.360 7.354 7.346 7.333 7.306 7.227 6.360
26: CIT exchange with assay medium (EX4) -5.2E-04 -5.2E-04 -5.2E-04 -5.2E-04 -5.1E-04 -5.1E-04 -5.0E-04 -4.9E-04 -4.7E-04 -4.3E-04 -3.0E-04
27: Creatine kinase (CK) -0.462 -0.462 -0.461 -0.461 -0.461 -0.461 -0.460 -0.459 -0.458 -0.453 -0.398
28: MAL exchange with assay medium (EX5) 0.614 0.611 0.607 0.603 0.597 0.588 0.577 0.558 0.526 0.456 0.228
29: P
i
 exchange with assay medium (EX6) 7.370 7.369 7.366 7.364 7.360 7.354 7.346 7.333 7.306 7.227 6.360
30: PYR exchange with assay medium (EX7) 0.886 0.885 0.883 0.881 0.878 0.875 0.869 0.861 0.846 0.812 0.650
31: SUC exchange with assay medium (EX8) -0.003 -0.003 -0.003 -0.003 -0.003 -0.003 -0.003 -0.002 -0.002 -0.002 -0.001
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Table S5. Predicted effect of progressive CI deficiency on steady-state metabolite concentration and 
physiological parameters
Variables 100% CI 90% CI 80% CI 70% CI 60% CI 50% CI 40% CI 30% CI 20% CI 10% CI 1% CI
Concentration in mitochondrial matrix (M)
1: ACCOA (Acetyl-CoA) 3.010 3.010 3.010 3.010 3.010 3.010 3.010 3.010 3.010 3.010 3.010
2: ADP (Adenosine diphosphate) 0.685 0.694 0.707 0.719 0.734 0.757 0.792 0.848 0.957 1.241 3.303
3: α-KG (α-ketoglutarate) 0.002 0.002 0.002 0.002 0.002 0.002 0.002 0.002 0.002 0.002 0.001
4: ATP (Adenosine triphosphate) 9.315 9.306 9.293 9.281 9.266 9.243 9.208 9.152 9.043 8.759 6.697
5: CIT (Citrate) 1.502 1.496 1.487 1.481 1.473 1.462 1.446 1.424 1.384 1.312 1.152
6: COASH (Coenzyme A) 0.004 0.004 0.004 0.004 0.004 0.004 0.004 0.003 0.003 0.003 0.003
7: COQ (Oxidized ubiquinol) 1.16 1.16 1.16 1.17 1.17 1.18 1.19 1.20 1.22 1.25 1.33
8: FUM (Fumarate) 0.196 0.196 0.196 0.197 0.198 0.199 0.200 0.202 0.205 0.212 0.212
9: GTP (Guanosine triphosphate) 4.667 4.663 4.657 4.651 4.644 4.633 4.616 4.590 4.538 4.403 3.407
10: GDP (Guanosine diphosphate) 0.330 0.334 0.340 0.346 0.353 0.364 0.381 0.407 0.459 0.594 1.590
11: H+ 5.2E-05 5.2E-05 5.21E-05 5.21E-05 5.21E-05 5.20E-05 5.21E-05 5.20E-05 5.20E-05 5.17E-05 5.10E-05
12: ICIT (Isocitrate) 0.033 0.033 0.033 0.033 0.032 0.032 0.032 0.031 0.030 0.028 0.022
13: K+ 137.066 137.159 137.401 137.371 137.284 137.243 137.353 137.266 137.221 136.452 134.543
14: PYR (Pyruvate) 0.714 0.714 0.713 0.713 0.714 0.714 0.714 0.715 0.717 0.723 0.749
15: MAL (Malate) 0.603 0.602 0.600 0.600 0.601 0.601 0.601 0.602 0.603 0.611 0.639
16: Mg2+ 1.416 1.415 1.409 1.413 1.419 1.425 1.433 1.449 1.474 1.548 2.044
17: NAD+ (Nicotinamide adenine 
dinucleotide) 
1.308 1.308 1.308 1.306 1.303 1.299 1.295 1.287 1.274 1.237 1.059
18: NADH (Reduced NAD+) 1.662 1.662 1.662 1.664 1.667 1.671 1.675 1.683 1.696 1.733 1.911
19: OAA (Oxaloacetate) 4.37E-07 4.36E-07 4.35E-07 4.34E-07 4.32E-07 4.29E-07 4.25E-07 4.20E-07 4.10E-07 3.88E-07 2.97E-07
20: P
i
 (Inorganic phosphate) 18.980 18.957 18.897 18.906 18.931 18.945 18.925 18.956 18.984 19.219 20.072
21: QH
2
 (Reduced ubiquinol) 0.192 0.190 0.187 0.183 0.179 0.173 0.165 0.153 0.133 0.097 0.022
22: SCOA (Succinyl-CoA) 3.21E-04 3.18E-04 3.15E-04 3.12E-04 3.08E-04 3.03E-04 2.95E-04 2.85E-04 2.66E-04 2.29E-04 1.15E-04
23: SUC (Succinate) 0.046 0.045 0.045 0.044 0.043 0.042 0.040 0.037 0.033 0.026 0.008
Physiochemical and derived parameters
24: C
ox
 (Oxidized cytochrome-c) 1.793 1.795 1.799 1.802 1.805 1.811 1.819 1.831 1.853 1.900 2.099
25: C
red
 (Reduced cytochrome-c) 0.907 0.905 0.901 0.898 0.895 0.889 0.881 0.869 0.847 0.800 0.601
26: Mitochondrial membrane potential (Δψ) 190.7969 190.7028 190.613 190.4295 190.1798 189.8552 189.4232 188.6933 187.419 184.3922 171.5277
27: NADH/NAD+ ratio 1.270 1.271 1.271 1.274 1.279 1.286 1.293 1.307 1.332 1.401 1.806
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Table S5. Predicted effect of progressive CI deficiency on steady-state metabolite concentration and 
physiological parameters
Variables 100% CI 90% CI 80% CI 70% CI 60% CI 50% CI 40% CI 30% CI 20% CI 10% CI 1% CI
Concentration in mitochondrial matrix (M)
1: ACCOA (Acetyl-CoA) 3.010 3.010 3.010 3.010 3.010 3.010 3.010 3.010 3.010 3.010 3.010
2: ADP (Adenosine diphosphate) 0.685 0.694 0.707 0.719 0.734 0.757 0.792 0.848 0.957 1.241 3.303
3: α-KG (α-ketoglutarate) 0.002 0.002 0.002 0.002 0.002 0.002 0.002 0.002 0.002 0.002 0.001
4: ATP (Adenosine triphosphate) 9.315 9.306 9.293 9.281 9.266 9.243 9.208 9.152 9.043 8.759 6.697
5: CIT (Citrate) 1.502 1.496 1.487 1.481 1.473 1.462 1.446 1.424 1.384 1.312 1.152
6: COASH (Coenzyme A) 0.004 0.004 0.004 0.004 0.004 0.004 0.004 0.003 0.003 0.003 0.003
7: COQ (Oxidized ubiquinol) 1.16 1.16 1.16 1.17 1.17 1.18 1.19 1.20 1.22 1.25 1.33
8: FUM (Fumarate) 0.196 0.196 0.196 0.197 0.198 0.199 0.200 0.202 0.205 0.212 0.212
9: GTP (Guanosine triphosphate) 4.667 4.663 4.657 4.651 4.644 4.633 4.616 4.590 4.538 4.403 3.407
10: GDP (Guanosine diphosphate) 0.330 0.334 0.340 0.346 0.353 0.364 0.381 0.407 0.459 0.594 1.590
11: H+ 5.2E-05 5.2E-05 5.21E-05 5.21E-05 5.21E-05 5.20E-05 5.21E-05 5.20E-05 5.20E-05 5.17E-05 5.10E-05
12: ICIT (Isocitrate) 0.033 0.033 0.033 0.033 0.032 0.032 0.032 0.031 0.030 0.028 0.022
13: K+ 137.066 137.159 137.401 137.371 137.284 137.243 137.353 137.266 137.221 136.452 134.543
14: PYR (Pyruvate) 0.714 0.714 0.713 0.713 0.714 0.714 0.714 0.715 0.717 0.723 0.749
15: MAL (Malate) 0.603 0.602 0.600 0.600 0.601 0.601 0.601 0.602 0.603 0.611 0.639
16: Mg2+ 1.416 1.415 1.409 1.413 1.419 1.425 1.433 1.449 1.474 1.548 2.044
17: NAD+ (Nicotinamide adenine 
dinucleotide) 
1.308 1.308 1.308 1.306 1.303 1.299 1.295 1.287 1.274 1.237 1.059
18: NADH (Reduced NAD+) 1.662 1.662 1.662 1.664 1.667 1.671 1.675 1.683 1.696 1.733 1.911
19: OAA (Oxaloacetate) 4.37E-07 4.36E-07 4.35E-07 4.34E-07 4.32E-07 4.29E-07 4.25E-07 4.20E-07 4.10E-07 3.88E-07 2.97E-07
20: P
i
 (Inorganic phosphate) 18.980 18.957 18.897 18.906 18.931 18.945 18.925 18.956 18.984 19.219 20.072
21: QH
2
 (Reduced ubiquinol) 0.192 0.190 0.187 0.183 0.179 0.173 0.165 0.153 0.133 0.097 0.022
22: SCOA (Succinyl-CoA) 3.21E-04 3.18E-04 3.15E-04 3.12E-04 3.08E-04 3.03E-04 2.95E-04 2.85E-04 2.66E-04 2.29E-04 1.15E-04
23: SUC (Succinate) 0.046 0.045 0.045 0.044 0.043 0.042 0.040 0.037 0.033 0.026 0.008
Physiochemical and derived parameters
24: C
ox
 (Oxidized cytochrome-c) 1.793 1.795 1.799 1.802 1.805 1.811 1.819 1.831 1.853 1.900 2.099
25: C
red
 (Reduced cytochrome-c) 0.907 0.905 0.901 0.898 0.895 0.889 0.881 0.869 0.847 0.800 0.601
26: Mitochondrial membrane potential (Δψ) 190.7969 190.7028 190.613 190.4295 190.1798 189.8552 189.4232 188.6933 187.419 184.3922 171.5277
27: NADH/NAD+ ratio 1.270 1.271 1.271 1.274 1.279 1.286 1.293 1.307 1.332 1.401 1.806
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Abstract
Background. Children with mitochondrial disorders are frequently anesthetized 
for a wide range of operations. These disorders may interfere with the response 
to surgery and anesthesia. We examined anesthetic sensitivity to and respiratory 
effects of isoflurane in the Ndufs4 knockout (KO) mouse model. These mice exhibit 
an isolated mitochondrial complex I (CI) deficiency of the respiratory chain, and 
they also display clinical signs and symptoms resembling those of patients with 
mitochondrial CI disease.
Methods. We investigated seven Ndufs4-/- knockout (KO), five Ndufs4+/- heterozygous 
(HZ) and five Ndufs4+/+ wild type (WT) mice between 22-25 days and again between 
31-34 days post-natal. Animals were placed inside an airtight box, breathing 
spontaneously while isoflurane was administered in increasing concentrations. 
Minimum alveolar concentration (MAC) was determined with the bracketing study 
design, using the response to electrical stimulation to the hind paw. 
Results. MAC for isoflurane was significantly lower in KO mice than in  HZ and WT 
mice: 0.81% ± 0.01  vs. 1.55% ± 0.05 and 1.55% ± 0.13, respectively, at 22-25 days,  and 
0.65% ± 0.05, 1.65% ± 0.08 and 1.68% ± 0.08 at 31-34 days. The KO mice showed severe 
respiratory depression at lower isoflurane concentrations than the WT and HZ mice. 
Conclusion. We observed an increased isoflurane anesthetic sensitivity and severe 
respiratory depression in the KO mice. Both paradigms were progressive with age. 
Since the pathophysiological consequences from complex I deficiency are mainly 
reflected in the central nervous system and our mouse model involves progressive 
encephalopathy, further investigation of isoflurane effects on brain mitochondrial 
function is warranted.
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Introduction
Mitochondria produce the energy requirements of cells, adenosine triphosphate 
(ATP), mainly through the reduction and oxidation reactions of the electron transfer 
chain (ETC) and oxidative phosphorylation (OXPHOS). The OXPHOS pathway consists 
of five multi-subunit enzyme complexes (complexes I-V) and two electron carriers 
(cytochrome C and coenzyme Q).
Mitochondrial disorders are most frequently due to defects in OXPHOS, and 
are genetically and phenotypically a heterogeneous group of disorders having an 
incidence of 1 in 10,000 live births (Smeitink, van den Heuvel et al. 2001). The onset 
of symptoms may vary from birth to late adulthood. Organs that are highly energy-
dependent such as the brain, heart and skeletal muscle are most vulnerable to 
mitochondrial defects. Since a treatment to correct this is not yet available, therapy 
is purely empirical and is still not very successful (Distelmaier, Koopman et al. 2009).
Children with mitochondrial disease are frequently anaesthetized for diagnostic 
muscle biopsy, but also for a wide range of other procedures. These children often 
have several signs and symptoms (encephalomyopathy, respiratory and cardiac 
compromise, difficulty in swallowing and regurgitation), which may increase the risk 
associated with anesthesia and surgery (Driessen 2008). Patients with mitochondrial 
disease resulting from a variety defects in the respiratory chain and oxidative 
phosphorylation vary in their response to anesthetics and possibly in their peri-
operative risk (Morgan, Hoppel et al. 2002, Driessen 2008).
The most frequently occurring defect in the OXPHOS system in humans is an 
isolated complex I (NADH:ubiquinone oxidoreductase) deficiency (Loeffen, Smeitink 
et al. 2000). Most children suffering from complex I deficiency develop symptoms 
during their first year of life, and show rapid deterioration (Distelmaier, Koopman et al. 
2009). The majority of children with complex I deficiency present with Leigh or Leigh-
like syndrome, which involves psychomotor retardation, brainstem dysfunction, 
seizures, failure to thrive, muscular hypotonia, abnormal eye movements and lactic 
acidosis (Koene, Willems et al. 2011).
The volatile anesthetic isoflurane inhibits complex I enzymatic rates (Kayser, 
Suthammarak et al. 2011). In the nematode C. elegans, animals with a complex I 
deficiency, are hypersensitive to volatile anesthetics (Kayser, Suthammarak et 
al. 2011). In a clinical study, Morgan et al. (Morgan, Hoppel et al. 2002) observed 
profound hypersensitivity to volatile anesthetics in a subset of children with 
defects in complex I function, requiring very low doses of sevoflurane to reach a 
bispectral index (BIS) value of 60. However, BIS monitoring, used in that study, is not 
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a reliable index of anesthetic sensitivity in children who have central nervous system 
dysfunction  (Allen 2003).
The Ndufs4 subunit plays an important role in the assembly or stability of complex I 
and mutations in the Ndufs4 gene, located on chromosome 5, cause a reduced complex 
I content as detected by blue native gel electrophoresis (BN-PAGE) and enzymatic 
activity measurements (Kruse, Watt et al. 2008). Patients harboring mutations in this 
gene show Leigh or Leigh-like syndrome with death occurring at a very young age 
(Budde, van den Heuvel et al. 2003, Koene, Willems et al. 2011). The clinical signs and 
symptoms of Ndufs4 KO mice show extensive similarities to those of patients with 
mitochondrial complex I disease (Kruse, Watt et al. 2008, Koene and Smeitink 2011).The 
aim of this study was to investigate the anesthetic sensitivity and respiratory response 
to exposure of a volatile anesthetic agent, isoflurane, in the Ndufs4 KO mouse model 
at two stages, before and after the onset of severe symptoms.
Methods 
All experiments were approved by the Regional Animal Ethics Committee (Nijmegen, 
The Netherlands) and performed under the guidelines of the Dutch Council for 
Animal Care. All efforts were made to reduce animal suffering and number of animals 
used in this study.
Animals
To determine isoflurane sensitivity in our experimental model, studies were conducted 
using Ndufs4 -/- knockout (KO) and Ndufs4 +/- heterozygous (HZ) mice, and their wild 
type (WT) Ndufs4 +/+ littermates (mixed 129/Sv: C57BL6 background), n=7, n=5, and n=5 
respectively.(Kruse, Watt et al. 2008) Mice were bred locally from heterozygous parent 
mice. Genotype was confirmed by polymerase chain reaction testing. Both male and 
female mice were included. Mice had ad libitum access to food and water and were fed 
on a standard animal diet (Ssniff GmbH, Soest, 76. Germany. V1534-300 R/M-H). Animals 
were group housed at 22°C and were maintained on a day and night rhythm of 12 hours.
Experimental Design
Measurements took place when the mice were between postnatal (PN) 22-25 days 
(experiment I) before the pathophysiological symptoms appeared in the KO mice, 
and again between PN days 31-34 (experiment II) when Ndufs4 KO mice started to 
develop pathophysiological symptoms but before major inconvenience, as described 
by Kruse et al (Kruse, Watt et al. 2008). Weights and symptoms were recorded daily.
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Each mouse was individually placed inside an airtight Plexiglas chamber (0.20 l), 
breathing spontaneously. Isoflurane (TEVA Pharmachemie, Haarlem, The Netherlands) 
was administered using an IsoTec-5 Isoflurane Anesthesia Vaporizer (Datex-Ohmeda, GE 
healthcare) with 33 % oxygen in air at a total flow rate of 0.5 l/min. The concentrations 
of isoflurane and CO
2
 were measured continuously at the exhaust port of the chamber 
using a Capnomac-Ultima monitor (Datex, Helsinki). CO
2
 levels in the chamber remained 
unmeasurably low throughout all experiments proving lack of rebreathing.
Anesthetic endpoints mostly used in mice are the loss of righting reflex (LORR), 
which is used as a marker of unconsciousness/hypnosis and the withdrawal reflex to 
tail clamping or electrical pedal stimulation, as a measure of immobilization (Drexler, 
Antkowiak et al. 2011).
We used the withdrawal reflex to determine the MAC (Eger, Raines et al. 2008). 
We used the withdrawal reflex to hind paw electrical stimulation, not tail clamping, to 
determine immobilization, because, in pilot experiments, it gave more reliable and 
reproducible responses without any local noxious effects. In rats it gave comparable 
MAC values when compared to tail clamping (Laster, Liu et al. 1993). Concentrations of 
isoflurane measured in the chamber, after equilibration during 6 minutes, were used 
as substitute for alveolar concentrations in determining MAC. 
The first experiment was performed when the mice were between PN 22-25 days. 
Based on pilot experiments isoflurane was administered at 1.5% in WT and HZ mice 
and 1.0% in KO mice. The time to loss of mobility (LOM) and time to loss of righting 
reflex (LORR) were measured. LOM was reached when a mouse remained immobile 
for 60 seconds. LORR was defined as the lack of the ability to return to recumbency 
within 60 seconds after tilting the box 90 degrees. Concentrations of isoflurane in 
the box at these time points were recorded. When anesthetized a rectal temperature 
probe, ECG electrodes, and stimulation electrodes to the hind paw were applied. The 
eyes were lubricated. Animal breathing was clinically assessed by monitoring thoracic 
movement and by recording respiratory rate. Two experienced anesthesiologists 
counted the respirations during 15 sec epochs. Temperature was maintained at 
36-38 °C, using a heating lamp and warming pad.
Isoflurane was increased stepwise at regular intervals with equilibration time of 
6 min. After equilibration the response to electrical stimulation (pulse intensity 4 mA, 
pulse duration 4 milliseconds, train duration 500 milliseconds, frequency 100 Hertz 
(interval 10 milliseconds) of the hind paw was recorded. Purposeful movement of the 
head and/or legs was considered a response.(Irifune, Katayama et al. 2007) When a 
response was noticed the anesthetic concentration was increased stepwise with 0.2% 
increments until the response was lost. When this point was reached the anesthetic 
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concentration was decreased until there was a return of response.(Quasha, Eger et 
al. 1980, Sonner 2002) The MAC was determined as the average concentration of 
isoflurane at loss and return of response to pedal electrical stimulation. 
After the MAC was determined and after removal of electrodes, isoflurane was 
reset to 1% in KO, and 1.5 % in WT and HZ mice. After equilibration, isoflurane was 
discontinued and the time till the return of righting reflex (RORR) and return of 
ambulation (ROA) were recorded. Total anesthesia duration (TAD) was also recorded. 
After the first anesthetic depth determinations were performed between 
PN 22-25 days, the animals were allowed to fully awaken, and were returned to their 
housing. A similar experiment was performed when the mice were between PN 31-34 days. 
After the end of the second experiment the animals were anesthetized again with 
a lower isoflurane concentration than the MAC to obtain an arterial blood gas sample, 
taken directly from the abdominal aorta. In some cases puncture of the abdominal 
aorta caused a hemorrhage that was aspirated for lactate determination. Arterial 
blood gas analysis was performed using i-STAT® System (Abbott Point of Care Inc., 
Princeton, USA). Subsequently the animals were sacrificed by cervical dislocation.
Statistical Analysis
Statistical analysis was performed using Prism 5 (GraphPad Software Inc., La Jolla, 
Ca, USA). Comparisons between the three groups were performed using the non-
parametric Kruskal-Wallis test as a Gaussian distribution was not observed. Comparisons 
between groups were performed using the non-parametric Mann-Whitney test. The 
Pearson test was used to assess the correlation between the MAC values and the 
decrease in respiratory rate at the MAC in KO vs WT mice. All data are presented as 
Mean ± Standard Error of the Mean (SEM). Significance was defined as P < 0.05.
Results
There were no statistical significant differences in age in both the first and second 
experiment between all groups. There were no differences in weight between HZ 
and WT mice. KO mice weighed significantly less (12.3 ± 0.71 grams), in the second 
experiment, than WT (15.3 ± 0.60 grams) and HZ mice (17.1 ± 1.30 grams), P<0.02 (table 1). 
Despite being of the same age the KO mice were clinically clearly distinguishable by 
their smaller size and hair loss.
During the first experiment the maximum (baseline) respiratory rate of KO 
mice (130 ± 7.5 breaths/min), did not differ from WT (130 ± 6.3 breaths/min) and HZ 
(135 ± 10.7 breaths/min) mice. At the more advanced age the KO mice showed a lower 
maximum (baseline) respiratory rate (83 ± 10.5 breaths/min) (P< 0.001), than WT and 
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HZ mice (139 ± 2.3 breaths/min, and 157 ± 3.4 breaths/min) respectively (table 2). During 
increasing isoflurane concentration there was progressive slowing of the respiratory 
rate. The maximal decrease in respiratory rate at MAC concentrations was greater in 
KO mice. Also signs of airway obstruction were more frequent at higher isoflurane 
concentrations. Both the baseline and the minimal respiratory rates at reaching the 
MAC were significantly lower at experiment II than I. During the second experiment 
one KO mouse died of apnea. Respiratory depression caused by isoflurane exposure 
was quickly reversible by lowering the isoflurane concentration. Although we started 
at lower isoflurane concentrations in KO mice, they had a significantly shorter onset 
time of anaesthesia, measured by time until LOM (P < 0.02) and LORR (P< 0.02), and 
at lower isoflurane concentrations (P< 0.01) when compared to WT and HZ mice in 
both the first and second experiment (table 3). There were no significant differences 
between WT and HZ mice. Mean heart rate while being anesthetized with isoflurane 
Table 1. Age and Weight
WT HZ KO
Age I 23.6 ± 0.51 23.2 ± 0.58 23.3 ± 0.18
  II 32.8 ± 0.58 32.6 ± 0.51 32.7 ± 0.52
Weight I   9.6 ± 0.77   9.5 ± 0.41   7.8 ± 0.48
  II 15.3 ± 0.60 17.1 ± 1.30  12.3 ± 0.71*
WT = Ndufs4 +/+ mice, HZ= Ndufs4 +/- mice, KO = Ndufs4 -/- mice.  Age in days, Weight in grams.   I = experiment I, 
II = experiment II. All data in Mean ± SEM. * = Statistical significance
Table 2. Clinical Features during Isoflurane Anesthesia
WT HZ
Temp I  37.2 ± 0.21    36.6 ± 0.12
  II  37.3 ± 0.17    36.5 ± 0.24
HR I   273 ± 12.4     268 ± 10.9
  II   286 ± 11.3   297 ± 8.9
Baseline RR I 130 ± 6.3     135 ± 10.7
  II 139 ± 2.3   157 ± 3.4
Δ RR I   44 ± 5.5       52 ± 13.4
  II   70 ± 5.6      83 ± 8.9
WT = Ndufs4 +/+ mice, HZ= Ndufs4 +/mice, KO = Ndufs4 -/- mice.  Temp = mean temperature in °C, HR= mean 
heart rate in beats/minute, Max RR = maximum or baseline respiratory rate in breaths /minute, Δ RR = maximal 
decrease in respiratory rate in breaths/minute. I = experiment I, II = experiment II.  All data represent Mean ± 
SEM. * = Statistical significance
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was similar in all groups, in both experiment I and II (table 2). The same was true for 
mean temperature during the experiment (table 2).
The MAC in KO mice (0.81% ± 0.01) was significantly lower than in both HZ (1.55% 
± 0.05) and WT (1.55% ± 0.13) mice, (P<0.003), in the first experiment (table 4). In the 
second experiment MAC could not be determined in three mice because of severe 
respiratory depression, before a loss of response to the stimulus was reached at 
isoflurane concentrations of 0.70%. One of these mice died as a consequence of 
respiratory depression. The mean MAC in experiment II for KO mice was 0.65% ± 
0.05, HZ 1.65% ± 0.08 and WT 1.68% ± 0.08, (P<0.02) (table 4). There was no difference 
in MAC between HZ and WT mice in both experiments (figure 1).The correlation 
between the MAC and decrease of respiratory rate from baseline is shown in figure 2. 
There was a significant correlation between MAC of isoflurane and the decrease in 
respiratory rate in the KO mice, but not in the WT mice.
Only in the first round of experiments KO mice demonstrated a faster return 
of righting reflex (RORR) than WT and HZ mice, P<0.003 (table 5). In the second 
experiment we had to lower isoflurane concentrations rapidly in 6 out of 7 KO 
mice, because of severe respiratory depression. This could be a factor in the lack of 
Table 3. Loss of Mobility and Righting Reflex 
   
 
 
LOM LORR
Time (sec) Isoflurane (%) Time (sec) Isoflurane %
Experiment I WT  85.2 ± 11.5 1.18 ± 0.05 160.2 ± 15.1 1.34 ± 0.03
HZ  95.8 ± 15.6 1.27 ± 0.07 146.8 ± 17.7 1.38 ± 0.03
    KO  57.3 ± 3.0*  0.74 ± 0.06*   99.0 ± 7.8*  0.84 ± 0.05*
Experiment II WT 121.6 ± 18.9  1.32 ± 0.003  179.8 ± 23.7 1.37 ± 0.01
HZ 106.0 ± 14.3  1.22 ± 0.007  165.2 ± 14.4 1.34 ± 0.03
    KO  51.6 ± 5.6*  0.76 ± 0.03*   86.1 ± 8.0*  0.87 ± 0.02*
LOM = Loss of mobility, LORR = Loss of righting reflex. WT = Ndufs4 +/+ mice (n=5), HZ= Ndufs4 +/- mice (n=5), KO 
= Ndufs4 -/- mice (n=5). All data in Mean ± SEM.* = Statistical significance.
Table 4. Minimum Alveolar Concentration of Isoflurane
WT HZ KO
MAC (%) I 1.55 ± 0.13 1.55 ± 0.05 0.81 ± 0.01*
  II 1.70 ± 0.08 1.68 ± 0.08 0.68 ± 0.05*
WT = Ndufs4 +/+ mice (n=5), HZ= Ndufs4 +/- mice (n=5) KO = Ndufs4 -/- mice (n=7), MAC = minimum alveolar 
concentration of Isoflurane. I= experiment I, II= experiment II. All data are Mean (SEM). * = statistical significance.
105
4
Iso
flu
r
a
n
e a
n
esth
e
tIc
 h
y
per
sen
sItIv
It
y
 a
n
d
 pr
o
g
r
essIv
e r
espIr
a
to
ry
 d
epr
essIo
n
 In
 a
 m
o
u
se m
o
d
el... 
 
Figure 1 
WT HZ KO
0.0
0.5
1.0
1.5
2.0 EXP I
EXP II
*
*
GENOTYPE
M
AC
 Is
of
lu
ra
ne
 
 
 
Figure 2 
 
0 20 40 60 80 100 120
0.0
0.5
1.0
1.5
2.0
 WT
 KO
Δ RR
 Is
of
lur
an
e (
MA
C)
 
 
 
 
 
 
Figure 1. MAC of Isoflurane: Minimum alveolar concentration (MAC) of Isoflurane for 
WT=Ndufs4 +/+ (n=5); HZ = Ndufs4 +/- (n=5); KO = Ndufs4 -/- (n=7). EXP I = Experiment I, EXP 
II = Experiment II. Bars represent mean MAC for WT, HZ, and KO mice. Error bars show the 
standard error of the mean. The values for the KO mice were significantly different from those 
for WT and HZ mice, in both experiment I and II. *p<0.005
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Figure 2. Decrease in respiratory rate vs MAC. Cumulative correlation plot between 
decrease in respiratory rate (DRR) vs minimum alveolar concentration (MAC) in Exp I and Exp II: 
Correlation was determined for Ndufs4 +/+ (WT) n=5, Ndufs4-/- (KO) n=7 mice. Solid black circles 
indicate the WT mice and solid black squares indicate the KO mice. There was no significant 
correlation between (DRR) vs MAC in the WT mice (ns)*, however a significant correlation was 
observed for the KO mice (p=0.019), (ns = not significant)*.
difference in RORR in this experiment. There was no difference in time till return of 
ambulation (ROA) between groups (table 5). In KO mice total anesthesia duration 
(TAD) was significantly shorter than in WT and HZ mice in both experiments (table 5) 
due to the fact that in KO mice the MAC was achieved at lower concentrations, 
achieved in a shorter period of time.
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There were no statistically significant differences in KO mice between experiment 
I and II in onset and recovery times.  
The results of blood gas analysis are presented in table 6. There were no signs 
of hypoxemia or hypercarbia observed in either group. In two KO mice lactate, 
determined in the blood aspirated from the hemorrhage that occurred with puncture 
of the abdominal aorta, was 15.6 and 15.6 mmol/l. These results clearly point to a 
metabolic acidosis due to lactic acidemia.
Table 5. Recovery from Anaesthesia
    WT HZ KO
RORR (sec) I    567 ± 130.2  463 ± 52.5 105 ± 6.8*
  II  238 ± 50.8  239 ± 46.9 202 ± 42.3
ROA (sec) I 1092 ± 95.2 1233 ± 64.4   681 ± 225.0
  II     712 ± 159.7  702 ± 85.0 420 ± 30.4
TAD (min) I 120 ± 9.6 110 ± 8.5   69 ± 4.1*
  II   118 ± 10.7   90 ± 5.8   42 ± 3.3*
WT = Ndufs4 +/+ mice (n=5), HZ= Ndufs4 +/- mice (n=5), KO = Ndufs4 -/- mice (n=5). RORR= Return of righting reflex, 
ROA = Return of ambulation, TAD= Total anaesthesia duration. All data in Mean ± SEM. *= Statistical significance
Table 6. Arterial Blood Gas analysis at the end of experiments
 
  pH 
PaO
2
PaCO
2
BE 
HCO
3
- SaO
2
Lactate
(mmHg) (mmHg) (mmol/L) (%) (mmol/L)
KO 7.02 192 37.4 -21.0 9.6 99 13.30
KO 7.00 x 28.7 -24.0 7.1 x x
KO 7.09 178 30.2 -21.0 9.2 99 11.29
KO* -27.0 4.1 98 15.58
KO* -26.0 2.6 100 15.57
HZ 7.34 206 36.8 -5.0 20.2 100 3.35
HZ 7.38 215 27.8 -9.0 16.5 100 6.01
HZ 7.35 206 34.8 -6.0 19.3 100 4.16
HZ 7.44 302 26.1 -6.0 17.8 100 5.95
WT 7.34 191 37.9 -5.0 20.6 100 3.99
WT 7.42 215 33.2 -2.0 22.0 100 4.49
WT 7.40 213 26.3 -8.0 16.4 100 4.60
WT* 16.4 100 4.19
KO = Ndufs4 -/- mice, WT = Ndufs4 +/+ mice, HZ= Ndufs4 +/- mice. * = analysis after direct aspiration of hemorrhage 
from abdominal aorta. x= no result. 
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Discussion
The main result of our study was increased isoflurane sensitivity in Ndufs4 knockout 
mice, compared to their wild type and heterozygous littermates. This involved both 
the righting reflex, considered as a marker of unconsciousness, and the withdrawal 
reflex to electrical hind paw stimulation, as a marker of immobilization, used to 
determine MAC. The MAC was slightly lower at the more advanced age (31-34 days) 
compared to the younger age (22-25 days). All our KO mice, except one that died 
from respiratory depression during the experiment, showed a fast and complete 
recovery from anaesthesia when isoflurane exposure was terminated. Quintana 
et al. (Quintana, Morgan et al. 2012) recently reported almost identical data with 
a 2.5 - 3-fold higher sensitivity in a tail clamp response to isoflurane and halothane 
at 23-27 days in Ndufs4 KO mice compared to WT.  The higher sensitivity in their 
study could be explained by a different stimulation method, but also by shorter 
equilibration times used in our study. Furthermore a limitation of our study was that 
it was impossible to administer equal isoflurane concentrations to KO mice since 
they got severe respiratory depression much faster. Anyway, this effect in complex I 
deficient mice cannot yet be extrapolated to children with complex I deficiency 
since a human study did not directly point to a specific hypersensitivity to volatile 
anesthetics(Driessen, Willems et al. 2007). Furthermore, in our KO mice there is a 
complete inactivation of the Ndufs4 gene while in children with Ndufs4 mutations 
some residual activity of complex I is still present.
No mention was made about respiratory effects during anesthesia in the report of 
Quintana et al (Quintana, Morgan et al. 2012) We observed a strong, progressive, near 
fatal, but completely reversible, respiratory depression during isoflurane exposure 
in Ndufs4 KO mice. This already occurred at concentrations well below the MAC 
for immobilization.  Ndufs4 KO mice are known to develop progressive respiratory 
dysfunction i.e. bradypnea and apnea, leading to premature death (Quintana, Zanella 
et al. 2012). Central rather than peripheral mechanisms are involved. Older awake KO 
mice in that study had lower breathing rates than controls, which was also observed 
in our study. There were no signs of hypoxemia or hypercarbia in all groups in the 
arterial blood gas analysis at the end, although this can be partly explained by the 
fact that all mice were allowed to recover from anesthesia before (briefly) being 
anesthetized again to obtain the arterial blood sample. However, it is likely that 
KO mice did develop hypercarbia, and possibly hypoxemia, caused by the severe 
respiratory depression at reaching MAC concentrations.  Future investigations of 
anesthesia-induced respiratory depression in complex I deficient mice is warranted. 
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Awaiting such data, it may be presumed  that children with complex I deficiency are 
also at an increased risk of respiratory depression during anesthesia, even before 
a deep anesthetic phase is reached, and one should monitor ventilation carefully 
during and after administration of (volatile) anesthesia in case of (suspected) 
mitochondrial disease.
We did not observe significant differences in heart rate, using electrocardiographic 
monitoring, during isoflurane anesthesia between all groups. A previous study 
reported a lower heart rate for KO mice than for control mice, especially in late stages 
of the disease (Quintana, Zanella et al. 2012). The heart rates in unanaesthetized mice 
in that study were much higher than heart rates of both KO and control mice in our 
study during anesthesia.
Despite being used in millions of patients, the mechanism by which volatile 
anesthetics produce their effects is still scarcely known. The many endpoints 
associated with the general anesthetic state are probably the result of effects at 
different sites of action (Humphrey, Sedensky et al. 2002). It was long assumed that 
they interact non-specifically with neuronal membranes based on their lipophilicity 
(Eger, Raines et al. 2008). However, at present general anesthetics are believed to 
exert their effects by binding to specific protein targets, including ligand-gated ion 
channels, such as GABA
A
 receptors, NMDA receptors and a range of two-pore domain 
potassium channels (Eger, Raines et al. 2008, Franks 2008). Since different classes of 
general anesthetics act on different spectra of receptors and channels it is unlikely 
that there is one common mechanism for all general anesthetics. 
It has long been known that volatile anesthetics cause depression of mitochondrial 
function (Cohen 1973). Halothane, isoflurane and sevoflurane inhibit oxidation 
of substrate at complex I in a dose-dependent fashion (Hanley, Ray et al. 2002). 
Inhalational anesthetics are also known to uncouple mitochondrial respiration from 
ATP generation (Rottenberg 1983). They induce mitochondrial flavoprotein oxidation 
through the opening of adenosine triphosphate-dependent mitochondrial potassium 
(mitoK-ATP) channel (Kohro, Hogan et al. 2001). 
Complex I malfunction causes several mitochondrial effects including reduced 
ATP-production, changes in membrane depolarization, increased NADH levels, 
increased production of ROS and lipid peroxidation, alterations in redox state, cellular 
calcium homeostasis, and changes in mitochondrial morphology (Koene, Willems 
et al. 2011, Roestenberg, Manjeri et al. 2012). In C.elegans with defective function 
of complex I, there is hypersensitivity to volatile anesthetics causing reversible 
immobility (Kayser, Suthammarak et al. 2011). Our study confirms these results are 
also true in a mammalian animal model. Although there is a clear correlation between 
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complex I-dependent oxidative phosphorylation capacity and anesthetic sensitivity, 
it is not the absolute rate of complex I enzymatic activity which predicts the threshold 
for immobilization to volatile anesthetics (Kayser, Suthammarak et al. 2011). At present 
it  remains difficult to explain the exact link between complex I dysfunction and 
volatile anesthetic hypersensitivity (Quintana, Morgan et al. 2012).
Children with complex I deficiency have early onset neurological deterioration. 
Optimal complex I function and mitochondrial ROS production are necessary to 
maintain neuronal activity and synaptic transmission. Cellular ROS production is 
inversely correlated with CI activity and altered reactive oxygen species levels, as 
seen in human fibroblasts, and might have a central regulatory role in the pathology 
of CI deficiency (Distelmaier, Koopman et al. 2009). ROS are routinely generated 
as by-products of the interaction between free electrons and oxygen and are an 
unavoidable consequence of aerobic metabolism. Mitochondria are also necessary 
for the generation of substances that eliminate free radicals formed during aerobic 
metabolism. If the production of ROS becomes too great to be counterbalanced by its 
antioxidant system, damage to proteins, lipids and DNA occur. Sensitivity to volatile 
anesthetics may be related to both complex I mediated impairment of OXPHOS 
and to oxidative damage to specific molecules (Kayser, Sedensky et al. 2004). It may 
be that certain specific proteins are damaged due to complex I deficiency and that 
the accumulation of these damaged molecules is responsible for the increase in 
anesthetic sensitivity (Kayser, Sedensky et al. 2004, Kayser, Suthammarak et al. 2011).
Volatile anaesthetics also have a well-known protective effect on mitochondria, 
which is responsible for cardioprotection against ischemia and reperfusion via 
anesthetic preconditioning (Hirata, Shim et al. 2011). Volatile anesthetics have also 
been shown to have both neuroprotective and neurotoxic effects in animal models 
(Zhang, Zhou et al. 2011). Neurotoxic effects of volatile anesthetics occur especially in 
the developing brain and mitochondrial damage seem to be an important target of 
anesthesia induced developmental neurodegeneration (Sanchez, Feinstein et al. 2011). 
Volatile anesthetics may also cause neuroprotection by mild inhibition of respiratory 
chain complexes I-V and subsequent mitochondrial membrane depolarization (Bains, 
Moe et al. 2006). It has already been known in 1992 that isoflurane reduces excitatory 
synaptic transmission in the rat hippocampus (Berg-Johnsen and Langmoen 1992). 
In conclusion, there is obviously a broad range of complex biochemical and 
physiological aspects of complex I dysfunction. Since the pathology from complex 
I deficiency occurs mainly in the central nervous system  (Distelmaier, Koopman et 
al. 2009), we stress the necessity of specific investigation of the effects of general 
anesthetics on brain mitochondrial function.
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Abstract
We reported before that the minimal alveolar concentration (MAC) of isoflurane is 
decreased in complex I-deficient mice lacking the NDUFS4 subunit of the respiratory 
chain (RC) (1.55 and 0.81% at postnatal (PN) 22-25 days and 1.68 and 0.65% at PN 31-34 
days for wildtype (WT) and CI-deficient KO, respectively). 1.0 MAC isoflurane caused 
a more severe respiratory depression in KO mice (respiratory rate values of 86 and 
45 at PN 22-25 days and 69 and 29 at PN 31-34 days for anesthetized WT and KO, 
respectively). Here, we address the idea that isoflurane anesthesia causes a much 
larger decrease in brain mitochondrial ATP production in KO mice thus explaining 
their increased sensitivity to this anesthetic. Brains from WT and KO mice of the above 
study were removed immediately after MAC determination at PN 31-34 days and a 
mitochondria-enriched fraction was prepared. Aliquots were used for measurement 
of maximal ATP production in the presence of pyruvate, malate, ADP and creatine 
and, after freeze-thawing, the maximal activity of the individual RC complexes in the 
presence of complex-specific substrates. CI activity was dramatically decreased in KO, 
whereas ATP production was decreased by only 26% (p<0.05). The activities of CII, CIII 
and CIV were the same for WT and KO. Isoflurane anesthesia decreased the activity 
of CI by 30% (p<0.001) in WT. In sharp contrast, it increased the activity of CII by 37% 
(p<0.001) and 50% (p<0.001) and that of CIII by 37% (p<0.001) and 40% (p<0.001) in 
WT and KO, respectively, whereas it tended to increase that of CIV in both WT and KO. 
Isoflurane anesthesia increased ATP production by 52% and 69% in WT (p<0.05) and 
KO (p<0.01), respectively. Together these findings indicate that isoflurane anesthesia 
interferes positively rather than negatively with the ability of CI-deficient mice brain 
mitochondria to convert their main substrate pyruvate into ATP. 
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Introduction
Inhaled anesthetics such as isoflurane and sevoflurane are extensively used in clinical 
practice but much concern remains regarding their possible detrimental effects, 
particularly on the developing brain (Loepke and Soriano 2008; Hays and Deshpande 
2011; Chiao and Zuo 2014). Recent work shows that these anesthetics can induce 
mitochondrial fission in the developing brain, suggesting a mitochondrial component 
in the process of anesthesia-induced brain damage (Boscolo, Milanovic et al. 2013).
Further evidence for a putative role of mitochondria in the process of anesthesia-
induced brain damage comes from the observation that children with a deficiency 
of complex I (CI), but not complex III (CIII), of the respiratory chain (RC), are 
hypersensitive to volatile anesthetics (Morgan, Hoppel et al. 2002; Driessen, Willems 
et al. 2007). However, it is still debated whether these anesthetics put CI-deficient 
children at increased risk of neurological complications (Niezgoda and Morgan 2013). 
Recent studies with mice genetically engineered to lack the NDUFS4 subunit of CI of 
the RC (referred to herein as “CI-deficient KO mice”) corroborate the finding that the 
sensitivity to volatile anesthetics is increased in CI deficiency (Quintana, Morgan et 
al. 2012; Roelofs, Manjeri et al. 2014). 
Regarding a putative role of CI in the mechanism of action of volatile anesthetics, 
studies investigating the effects of direct application of these anesthetics to intact 
and broken mitochondria conclude that low concentrations reversibly inhibit the 
oxidation of CI-, but not CII-, linked substrates (Miller and Hunter 1970; Harris, 
Munroe et al. 1971). Another line of evidence supporting a direct action of volatile 
anesthetics on CI comes from studies with C. elegans. This organism does not 
possess specialized respiratory systems and complex circulatory organs and relies 
entirely on the diffusion of gases across the gut lumen and the cuticle (Van Voorhies 
and Ward 2000). Loss-of-function mutations in CI, but not CII, genes, render these 
worms hypersensitive to volatile anesthetics in terms of immobility induction 
(Kayser, Morgan et al. 1999; Falk, Kayser et al. 2006). Analysis of several CI-deficient 
worm strains with different oxidation rates of CI-linked substrates revealed that the 
anesthetic sensitivity increased with decreasing oxidation rate (Falk, Kayser et al. 
2006). In agreement with these observations, isoflurane was demonstrated to bind 
to a site distal to the flavoprotein subcomplex of CI (Kayser, Suthammarak et al. 2011). 
Taken together, these studies indicate that volatile anesthetics bind to CI to reduce its 
activity and that this inhibitory effect is increased by loss-of-function mutations in CI.
The RC generates the proton motive force used by CV (F0F1-ATP synthase) to 
produce ATP and with the activity of CI being reduced in CI-deficient KO mice and 
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CI being a direct target of volatile anesthetics, it is speculated that these anesthetics 
reduce brain mitochondrial ATP production to a much larger extent in these KO 
mice than in WT mice. As a consequence, brain ATP levels would be much more 
decreased in anesthetized KO mice thus explaining their increased sensitivity to 
volatile anesthetics (Kayser, Sedensky et al. 2004). To test this idea, we determined 
the maximal rate of ATP production and the maximal activity of the individual RC 
complexes in a whole brain mitochondria-enriched fraction from the WT and CI-
deficient KO mice described in the previous study (Roelofs, Manjeri et al. 2014). 
We show that in vivo treatment of WT mice with isoflurane decreased the maximal 
activity of CI, while it increased maximal ATP production. Isoflurane anesthesia also 
increased maximal ATP production in CI-deficient KO mice. In both WT and KO mice, 
the effect of isoflurane on brain mitochondrial ATP production was accompanied by 
an increase in CII and CIII maximal activity and a tendency to increase for CIV. Our data 
show that isoflurane anesthesia improves rather than worsens the ATP generating 
ability of brain mitochondria in both WT and CI-deficient KO mice.
Materials  and Methods
All experiments were approved by the Regional Animal Ethics Committee (Nijmegen, 
The Netherlands) and performed under the guidelines of the Dutch Council for 
Animal Care. All efforts were made to reduce animal suffering and number of animals 
used in this study.
Animals
This study uses the brains from the WT (ndufs4+/+) and KO (ndufs4-/-) mice included in 
our previous study on the anesthetic and respiratory depressant effects of isoflurane 
(Roelofs, Manjeri et al. 2014). The genotype of the mice was confirmed by polymerase 
chain reaction and both male and female mice were included. Mice were group-
housed at the central animal facility (CDL) of the Radboud University at 22°C on a 
day and night rhythm of 12 hours. The animals had ad libitum access to food and 
water and were fed on a standard animal diet (Ssniff GmbH, Soest, 76. Germany. 
V1534-300 R/M-H).
Isoflurane administration 
WT (n=5) and KO (n=7) mice were subjected twice, i.e. at PN 22-25 and PN 31-34 days, to a 
well-established anesthesia protocol to determine the minimal alveolar concentration 
(MAC) of isoflurane (Roelofs, Manjeri et al. 2014). Briefly, the isoflurane concentration 
was increased with steps of 0.2% until the response to electrical stimulation of the 
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hind paw was lost. When this point was reached the isoflurane concentration was 
decreased until return of the response. After the first MAC determination at PN 
22-25 days, the animals were returned to their housing and determination of the 
MAC was repeated at PN 31-34 days.
Tissue harvesting for biochemical analyses 
Animals were sacrificed at PN 31-34 days by cervical dislocation. Isoflurane-treated 
mice were sacrificed immediately after determination of the MAC at PN 31-34 days. 
Whole brains were transferred to ice-cold SEF buffer (0.25 mol/L sucrose, 2mmol/L 
EDTA, 10 mmol/L Potassium phosphate, pH 7.4), minced with a Sorvall TC2 tissue 
chopper and homogenized with a glass/Teflon Potter Elvehjem homogenizer 
within 1 h of harvest. The homogenate was centrifuged at 600g and a portion 
of the supernatant was used for measurement of the maximal rates of pyruvate 
oxidation and ATP production. The remainder of the 600g supernatant was frozen 
in 10 µl aliquots in liquid nitrogen and kept at -80º C for maximal enzymatic activity 
measurements. The protein concentration was measured according to Rodenburg 
(Rodenburg 2011).  
Pyruvate oxidation and ATP production measurements
To determine the maximal rate of pyruvate oxidation, the freshly prepared 600g 
supernatant was incubated with radiolabeled substrate ([1-14C] pyruvate). After 
20 min the reaction was stopped and the amount of liberated radioactive CO
2
 (14CO
2
) 
was quantified (Janssen, Trijbels et al. 2006). The assay medium (pH 7.4) contained 
K+- phosphate buffer (30 mM; source of Pi), KCl (75 mM), Tris (8 mM), K-EDTA 
(1.6 mM), P1,P5-Di (adenosine-5′) pentaphosphate (Ap5A; 0.2 mM), MgCl
2
 (0.5 mM), 
ADP (2 mM), creatine (20 mM), malate (1 mM) and [1-14C] pyruvate (1 mM). AP5A is a 
potent adenylate kinase inhibitor required to prevent interference of the adenylate 
kinase reaction with the levels of produced ATP, as well as with the excess of ADP 
required for this assay. For measurement of the maximal rate of ATP production, the 
same assay medium was used but with pyruvate instead of [1-14C] pyruvate. After 
20 min, the reaction was stopped by addition of 0.1 M HClO
4
. The reaction mixture 
was centrifuged at 14000g for 2 min at 2 °C. To the supernatant, 1.2 vol (V/V) of 0.333 
M KHCO
3
 was added, and this mixture was diluted 2-fold. The amount of ATP and 
phosphocreatine formed during the reaction were measured in the supernatant using 
a Konelab 20XT auto-analyzer (Thermo Scientific). Mitochondrial ATP production 
rate was corrected using a parallel assay in which residual glycolysis was blocked by 
arsenite (2 mM) (Janssen, Trijbels et al. 2006). 
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Respiratory chain enzyme assays
The liquid nitrogen frozen portion of the 600g supernatant was thawed and used for 
measurement of the maximal activity of the complexes I (CI), II (CII), III (CIII) and IV 
(CIV) and citrate synthase (CS), as described by Rodenburg (Rodenburg 2011).  
Statistical Analysis
Statistical analysis was performed using Prism 5 (GraphPad Software Inc., La Jolla, 
Ca). Normal distribution of the datasets was confirmed using Lilliefors test. Results 
were expressed as mean ± SD and comparisons between groups were performed 
using a two way analysis of variance (ANOVA) and Bonferroni’s post-test. Statistical 
significance was set at (p<0.05).
Results
In mitochondrial enzyme diagnostics, the activity of CS, which is an indicator of 
mitochondrial mass, is used for normalization between mitochondria-enriched 
preparations (Rodenburg 2011). The CS activity per mg protein was the same for 
WT and KO mice and did not change upon isoflurane anesthesia (Figure 1). In the 
remainder of this paper all values are expressed per mg protein.
The maximal rate of ATP production was significantly decreased by 26% in untreated 
KO as compared to untreated WT (Figure 2a). Unexpectedly, isoflurane anesthesia 
Figure 1. Effect of isoflurane on citrate synthase activity. Untreated and isoflurane-treated 
WT and KO mice were sacrificed at PD 31-34 and a mitochondria-enriched fraction was prepared 
from total brain. Citrate synthase activity was measured and expressed per mg protein. The data 
presented show the absence of any difference in between the four experimental conditions. The 
data presented are the mean ± SD of 5 WT and 5 KO untreated and 5 WT and 7 KO isoflurane-treated.
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significantly increased this rate in both WT and KO by 52% and 69%, respectively. 
The maximal rate of pyruvate oxidation revealed a tendency to be lower in untreated 
KO as compared to untreated WT and isoflurane anesthesia tended to increase this 
rate in both WT and KO by 26% and 50%, respectively (Figure 2b). To evaluate the 
efficiency by which the oxidation of pyruvate was coupled to the production of ATP, 
we calculated the ratio of ATP production to pyruvate oxidation. The ratios obtained 
showed similar values for untreated and treated WT and KO mice (Figure 2c).  
Analysis of the maximal activity of CI, revealed a significant decrease by 30% in 
isoflurane-treated WT as compared to untreated WT (Figure 3a). As expected, this 
activity was virtually absent in untreated KO and isoflurane treatment did not lead 
to any alteration. The maximal activity of CII, was similar between untreated WT and 
untreated KO (Figure 3b). Isoflurane anesthesia significantly increased this activity 
by 37% and 50% in WT and KO, respectively. The same results were obtained for 
CIII (Figure 3c). Isoflurane anesthesia significantly increased the maximal activity of 
this complex by 37% and 40% in WT and KO, respectively. For CIV, no difference in 
maximal activity was observed between untreated WT and untreated KO (Figure 3d). 
Although isoflurane anesthesia tended to increase this activity in both WT (17%) and 
KO (16%), no statistical significance was reached.
Discussion
Previous work with the NDUFS4 KO mouse model of human CI deficiency showed a 
decrease in respiratory rate (Quintana, Morgan et al. 2012; Roelofs, Manjeri et al. 2014) and 
heart rate (Quintana, Zanella et al. 2012) in the later stages of the disease. The respiratory 
rate of the KO mice used in this study decreased from 130 at PN 22-25 days to 83 at PN 
31-34 days (Roelofs, Manjeri et al. 2014). This decrease in respiratory rate was paralleled by 
neurological complications that progressed with age (Quintana, Kruse et al. 2010). Although 
a decrease in respiratory rate suggests ATP shortage, other disease mechanisms remain to 
be considered, including increased production of reactive oxygen species (Koopman, 
Distelmaier et al. 2013) and triggering of innate immune responses (Yu, Song et al. 2015).
Here, we show that maximal ATP production from pyruvate and malate is 25% 
decreased in a mitochondria-enriched fraction from KO mice brain at PN 31-34 days. 
The same observation was reached in another NDUFS4 KO mouse model (Leong, 
Komen et al. 2012). At first glance, this relatively moderate decrease seems difficult to 
reconcile with the virtually complete absence of active CI in a freeze-thawed aliquot of 
this mitochondria-enriched fraction, see also (Kruse, Watt et al. 2008 and Calvaruso, 
Willems et al. 2012). However, there is evidence that CIII stabilizes NDUFS4-lacking CI 
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Figure 2. Effect of isoflurane on ATP production. Untreated and isoflurane-treated WT and 
KO mice were sacrificed at PD 31-34 and a mitochondria-enriched fraction was prepared from 
total brain. The rates of ATP production and pyruvate oxidation were measured at non-rate-
limiting concentrations of pyruvate, malate, ADP and creatine and expressed per mg protein. 
(a) The ATP production rate measured under these conditions was significantly decreased in 
untreated KO as compared to untreated WT (indicated with a* as compared with a). Isoflurane 
anesthesia significantly increased this rate in both WT and KO. (b) The maximal pyruvate 
oxidation rate tended to be decreased in untreated KO and increased in isoflurane-treated WT 
and KO. However, none of these differences reached statistical significance. (c) The ratio of 
the rate of ATP production to that of pyruvate oxidation, reflecting the coupling efficiency, was 
not significantly different between the different experimental conditions. The data presented 
are the mean ± SD of the number of animals indicated in the caption to figure 1. Statistical 
significance is displayed as * (p<0.5) and ** (p<0.01).
b
c
0
5000
10000
15000
n/
h.
m
g 
pr
ot
ei
n
a
a*
**
Maximal pyruvate oxidation rate 
0
1000
2000
3000 Untreated
Treated
Untreated
Treated
n/
h.
m
g 
pr
ot
ei
n
 A
TP
 p
ro
du
ct
io
n
ra
te
 / 
P
yr
uv
at
e 
ox
id
at
io
n
ra
te
2
4
6
8
10
*
a Maximal ATP production rate
20000 Untreated
Treated
W
T
W
T
W
T
KO
KO
KO
0
Manjeri et al., Fig. 2
             
123
5
In
c
r
e
a
sed
 m
Ito
c
h
o
n
d
r
Ia
l a
tP Pr
o
d
u
c
tIo
n
 c
a
Pa
c
It
y
 In
 b
r
a
In
 o
f h
e
a
lth
y
 m
Ic
e...
Figure 3. Effect of isoflurane on the enzymatic activities of the mitochondrial respiratory 
chain complexes. Untreated and isoflurane-treated WT and KO mice were sacrificed at PD 31-34 
and a mitochondria-enriched fraction was prepared from total brain. The activities of the four 
respiratory chain complexes were measured under non-rate-limiting substrate conditions and 
expressed per mg protein. The values obtained reflect the maximum catalytic capacities of 
the complexes. (a) As expected, KO brain was virtually devoid of CI activity (indicated with a** 
as compared with a). Isoflurane anesthesia significantly decreased this activity in WT. (b) The 
activity of CII did not differ between WT and KO. Isoflurane anesthesia significantly increased 
this activity to the same extent in both WT and KO. (c) The activity of CIII was the same for WT 
and KO and also in this case isoflurane anesthesia increased this activity to the same extent in 
both WT and KO. (d) Also the activity of CIV was the same for WT and KO. Isoflurane anesthesia 
tended to increase this activity in both cases but this effect did not reach statistical significance. 
The data presented are the mean ± SD of the number of animals indicated in the caption to 
figure 1. Statistical significance is displayed as ** (p<0.01) and *** (p<0.001).
to provide partial activity (Calvaruso, Willems et al. 2012). This stabilization may be lost 
upon freeze-thawing of the mitochondria-enriched fraction. Intriguingly, isoflurane 
anesthesia of KO mice restored brain mitochondrial ATP production to WT levels. This 
result indicates that the underlying process does not involve irreversible damage, 
as is thought to occur at increased levels of reactive oxygen species. It is tempting 
to speculate that isoflurane improves the stabilization of NDUFS4-lacking CI by CIII. 
Manjeri et al., Fig. 3
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The most intriguing observation of the present study is that isoflurane anesthesia 
increased rather than decreased brain mitochondrial ATP production in both WT and 
CI-deficient KO mice. To our best knowledge, this is the first report that describes such 
an effect of a volatile anesthetic, see also (Miro, Barrientos et al. 1999). A recent in vivo 
study showed that isoflurane anesthesia decreased ATP levels in mouse brain (Wang, 
Xu et al. 2015). Together, these data lead us to postulate that isoflurane acts outside 
the mitochondrion to reduce the supply of pyruvate, which is the main mitochondrial 
substrate in brain. 
The increase in brain mitochondrial ATP production observed in anesthetized 
WT and KO mice was paralleled by a tendency to increase for the pyruvate oxidation 
rate, whereas the CS activity remained unaltered. This may suggest that pyruvate 
dehydrogenase is not the rate-limiting enzyme in the untreated condition. Isoflurane 
anesthesia significantly increased the activities of CII and CIII and tended to increase 
the activity of CIV. This may suggest that the activity of the RC is rate-limiting in the 
untreated condition and that isoflurane can simultaneously increase their activity by a 
hitherto unknown mechanism, which may, however, be triggered by ATP shortage (see 
above). In sharp contrast, the activity of CI was significantly decreased in anesthetized 
WT mice, indicating that this enzyme is not rate-limiting in the untreated condition. 
Analysis of the ratio of ATP production to pyruvate oxidation revealed similar values 
for WT and CI-deficient KO mice regardless whether they were anesthetized or not. 
This result indicates, firstly, that the absence of the NDUFS4 subunit does not alter the 
coupling of pyruvate oxidation to ATP production and, secondly, that in vivo exposure to 
isoflurane does not alter this efficiency. Pyruvate oxidation is measured in the presence 
of an excess of pyruvate and malate, which is converted into oxaloacetate to trap acetyl-
CoA, and an excess of ADP, which is converted into ATP. Under these conditions, a 
decreased efficiency of the coupling of pyruvate oxidation to ATP production would be 
indicative of an increased proton leak across the inner mitochondrial membrane. The 
present finding that in vivo exposure to isoflurane does not alter the coupling efficiency 
is of relevance since in vitro studies showed that direct addition of halothane to isolated 
mitochondria caused a limited uncoupling at concentrations between 0.5 and 2% used 
clinically to achieve anesthesia (Miller and Hunter 1970).
Thus far, only inhibitory effects of volatile anesthetics on mitochondrial ATP 
production have been reported (Miller and Hunter 1970; Harris, Munroe et al. 1971). 
Available evidence indicates that volatile anesthetics act directly on CI (Kayser, 
Suthammarak et al. 2011) to decrease its activity (Miller and Hunter 1970; Harris, Munroe 
et al. 1971). Crucially, these studies employ direct application of the anesthetic to isolated 
mitochondria. For example, halothane, was shown to dose-dependently inhibit the 
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rate of ADP-stimulated oxygen consumption in the presence of CI-, but not CII-linked 
substrates (Miller and Hunter 1970). Direct application of halothane to deoxycholate-
treated mitochondria confirmed that CI, and not CII, was the primary target of the 
anesthetic (Harris, Munroe et al. 1971). The present study shows that the in vitro activity 
of CI was also decreased after in vivo exposure. The inhibitory effect in direct application 
studies was reversed in less than 5 min (Miller and Hunter 1970; Harris, Munroe et al. 
1971), indicating that the mechanism of inhibition must be different from that in the 
present study. Our finding of a sustained effect of volatile anesthetics is corroborated 
by a recent study showing that 4 hours of anesthesia at the larval stage of C. elegans 
caused a marked reduction of the chemotactic response at day 4 of life (Gentry, Steele et 
al. 2013). Also in this study, it was observed that the degree of reduction was significantly 
more in worms with a loss-of-function mutation in a CI gene than in wild type worms. 
Unfortunately, our anesthesia protocol does not allow drawing conclusions on 
whether the effects of isoflurane anesthesia at PN 31-34 days are acute or whether, 
and, if so, to which extent, they are a consequence of processes triggered during the 
first period of isoflurane anesthesia at PN 22-25 days. Long-term effects of volatile 
anesthetics have been reported in the literature and can be neuroprotective, as 
observed in a variety of animal stroke models, reviewed in (Burchell, Dixon et al. 2013) 
or neurotoxic, as evidenced by animal studies showing that volatile anesthesia can 
trigger widespread cell death in the neonatal developing brain (Jevtovic-Todorovic, 
Hartman et al. 2003; Yon, Daniel-Johnson et al. 2005; Istaphanous, Howard et al. 2011; 
Istaphanous, Ward et al. 2013; Xiong, Zhou et al. 2013)
A limitation of our study is that we used a mitochondria-enriched fraction from 
whole brain homogenate. Since regional susceptibilities to mitochondrial dysfunction 
have been reported within the CNS (Leong, Komen et al. 2012; Pinto, Pickrell et al. 
2012; Quintana, Zanella et al. 2012), a further detailed investigation should involve 
specific regions of the brain. Thus, from the results presented in this study, we 
conclude that isoflurane exposure might preserve the ATP production capacity in 
brain mitochondria of CI-deficient KO mice and that the isoflurane hypersensitivity 
in these mice is not a consequence of ATP deficits in the brain. 
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Abstract
Oxygen radical formation in mitochondria is an incompletely understood attribute 
of eukaryotic cells. Recently, a kinetic model (Speijer 2011) was proposed, in which 
the ratio between electrons entering the respiratory chain via FADH
2
 or NADH 
determines radical formation. During glucose breakdown the ratio is low; during 
fatty acid breakdown, the ratio is high (the ratio increasing –asymptotically- with 
fatty acid length to 0.5, as compared to 0.2 for glucose) (Speijer 2011). Thus, fatty acid 
oxidation would generate higher levels of radical formation. As a result, breakdown of 
fatty acids, performed without generation of extra FADH
2
 in mitochondria, could be 
beneficial for the cell, especially in the case of long and very long chained ones. This 
possibly has been a major factor in the evolution of peroxisomes. Increased radical 
formation, as proposed by the model, can also shed light on the lack of neuronal 
fatty acid oxidation and tells us about hurdles during early eukaryotic evolution. 
We will specifically focus on extending and discussing the model in light of recent 
publications and findings.
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Introduction
Mitochondria, derived from endosymbionts of alpha-proteobacterial origin(Yang, 
Oyaizu et al. 1985, Thrash, Boyd et al. 2011), underwent complex evolutionary 
rearrangements influencing the metabolic potential of their archeal host (Yutin, 
Makarova et al. 2008). During this process, the endosymbiont gene content was 
severely reduced from at least hundreds of genes (Huynen et al. 2013), to present day 
mitochondrial genomes encoding only up to 64 proteins in Reclinomonas americana 
(Lang, Burger et al. 1997) and merely 13 in humans. Thus, almost all genes encoding 
the endosymbiont’s original metabolic pathways have been relegated to the nuclear 
genome, while leaving many, but not all, the endosymbiotic metabolic pathways 
in the organelle(Gabaldon and Huynen 2005). The proteins originally encoded by 
the endosymbiotic genome had to be retargeted to mitochondria. Interestingly, 
this losing of genes from the organelle to the nucleus and accompanying protein 
rerouting started immediately, in evolutionary terms, after the endosymbiosis 
event (Huynen, Duarte et al. 2013). Recent analyses show a few endosymbiont 
systems retained entirely by mitochondria, despite their genes’ relocalization to the 
nucleus. These are large protein complexes such as the respiratory chain complexes 
and the mitochondrial ribosome (Szklarczyk and Huynen 2010). Some of the 
endosymbiont pathways are now found in other cellular compartments, and many 
mitochondrial pathways not using large protein complexes bear bacterial -not always 
proteobacterial- evolutionary footprints. Mitochondria also gained new functions 
including membrane proteins at the interface with the rest of the cell (Szklarczyk 
and Huynen 2010) with entirely new roles in for instance cellular apoptosis. The 
severely reduced genome should thus not be seen to indicate a lack of importance 
of the organelle.
The mitochondrion is the essential powerhouse of the cell, with more than 90% of 
all energy (in the form of ATP) generated by the breakdown of glucose coming from 
oxidative mitochondrial processes in which the electron flow through respiratory 
chain complexes is coupled to the establishment of a proton motive force used 
for ATP generation: oxidative phosphorylation, the OXPHOS system (Mitchell 1961, 
Smeitink, van den Heuvel et al. 2001). Most biochemists would agree that highly 
complex (multi) cellular organisms seem unlikely to evolve in the absence of the 
highly efficient ATP generation occurring in mitochondria. However, whether the 
role of oxygen as the final electron acceptor was crucial and is still debated. In any 
case, many instances of present-day anaerobic uni- or multicellular eukaryotes are 
known (Muller, Mentel et al. 2012). For a discussion considering which aspects of 
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the development of mitochondria from the endosymbiont were crucial in allowing 
major increases in (genome) complexity see e.g. (Lane and Martin 2010). Regardless, 
the OXPHOS system is extremely efficient. Oxygen might also have played a more 
indirect role in enabling further organismal complexity, as it seems indispensable for 
full-fledged epigenetic signaling (via a.o. the marking of DNA and histone proteins, 
using methylation of cytosines and lysines, respectively). Getting rid of methylation 
in these cases seems to depend on oxygenases, and thus on oxygen (Jeltsch 2013).
There is a price to pay however (Harman 1981), the use of molecular oxygen (O
2
) 
as the final electron acceptor of the respiratory chain, with the formation of H
2
O, 
inevitably leads to the formation of very toxic by-products. They are found in the 
form of reactive oxygen species (Turrens 2003, Murphy 2009, Brand 2010), such as the 
highly reactive free radicals (superoxide anions, .O
2
-, and hydroxyl radicals, HO.) and 
peroxides (e.g. H
2
O
2
). It is estimated that of all molecular oxygen consumed 0.1 to 2.0 
% ends up in the form .O
2
-, depending on the respiratory state of the mitochondrion 
(Murphy 2009). These form large pools of toxic molecules that the cell has to cope 
with. During the evolution of the two ancestors of the first eukaryotes and later on, 
several mechanisms evolved to deal with reactive oxygen species (ROS), such as 
mitochondrial manganese-containing superoxide dismutase (MnSOD), cytoplasmic 
copper-zinc-containing superoxide dismutase (CuZnSOD), glutathione-based 
systems and thioredoxins. For an overview of general and mitochondrion-specific 
anti-oxidant measures, see (Andreyev, Kushnareva et al. 2005).
Most of the present day eukaryotes and animals in particular, use O
2
 as the 
final electron acceptor of the respiratory chain, with exception of organisms using 
mitosomes, retaining only the role the mitochondrion has in Fe-S cluster assembly, 
or hydrogenosomes, producing molecular hydrogen instead of water (Lindmark and 
Muller 1973, Hackstein, Tjaden et al. 2006). Even metazoans have now been found to 
live under conditions of continuous anoxia (Danovaro, Dell’Anno et al. 2010, Muller, 
Mentel et al. 2012). Still, most eukaryotes build up the proton motive force for ATP 
generation using the oxidative OXPHOS system. This means that high amounts of 
ATP for eukaryotes are intrinsically linked to ROS formation inside the cell: internal 
radicals are inevitable in complex cellular life. Eukaryotes seem to have responded in 
two ways: as described above, they have harnessed older mechanisms to cope with 
the toxic by-products of using oxygen and evolved new mechanisms (Szklarczyk, 
Nooteboom et al. 2014). Additionally, eukaryotes made a virtue of necessity, by 
using mitochondria and their oxygen radical generating ability as an important part 
of the apoptotic process used in (multicellular) eukaryotes (Korsmeyer, Yin et al. 
1995, Wang and Youle 2009). 
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Challenges during early eukaryotic evolution
During the first stage of metabolic reintegration upon the uptake of the 
precursor of the mitochondrion the (pre)eukaryote must have been confronted 
with multiple hurdles during its transition to the full eukaryotic state. We 
will concentrate on the hurdles presumably involved in catabolic oxidative 
processes using the alpha-proteobacterial respiratory chain as the final route 
that the energy rich electrons from different food sources have to take to end 
up reducing molecular oxygen, allowing optimal ATP generation. Two problems 
seem logical at the onset of symbiosis. First of all, toxic ROS formed in the 
respiratory chain becomes a bigger problem for the composite cell, than it was 
for its constituent alpha-proteobacterium. Radical formation on the outskirts 
of the bacterium (which could even have played a role in cellular defence) now 
occurs in the middle of the new cellular entity. Additionally, over time, the new 
composite organism was likely confronted with other ROS related problems 
as well, as separate catabolic routes of both endosymbiont and host had to be 
integrated to form a functioning eukaryotic cell. The host (as reflected by the 
current location of glycolysis in the cytoplasm) had sugar breakdown pathways, 
while the proto-mitochondrion was equipped with aerobic catabolic pathways 
for lipids, amino acids and glycerol, including a complete respiratory chain, beta 
oxidation and at least part of the citric acid cycle (Gabaldon and Huynen 2003, 
Gabaldon and Huynen 2004, Hackstein, Tjaden et al. 2006).  Though the ability 
to use alternating sources of energy such as glucose or fatty acids over time is of 
course an enormous source of versatility, greatly extending possible ecological 
niches of the eukaryotes [as illustrated by yeast, (Landry, Townsend et al. 2006)], 
we can think of intrinsic problems here as well.
One of the problems arising has to do with the fact that the relative amounts 
of FADH
2
 and NADH (as reflected in FADH
2
/NADH ratios) generated during 
the breakdown of glucose differ from that of the breakdown of fatty acids. A 
respiratory chain functioning in glucose breakdown might encounter problems 
upon switching to fatty acid catabolism due to competition for fully oxidized 
ubiquinone, as ubiquinone is also used as an acceptor by the electron transfer 
flavoprotein: ubiquinone oxidoreductase (ETF:QO) oxidizing FADH
2
 (Watmough 
and Frerman 2010, Speijer 2011). This FADH
2 
is generated from FAD by reduction 
during the first recurring step of beta oxidation for every Acetyl-CoA generated 
during fatty acid breakdown (a step catalysed by Acyl-CoA Dehydrogenase). This 
implies that especially during the breakdown of longer fatty acids the competition 
for ubiquinone becomes more difficult for complex I, which is known to be the 
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major source of oxygen radicals (Brand 2010). As described before (Speijer 2011), 
large electron fluxes via both complex I on the one hand and complex II, as well as 
ETF, on the other, would probably lead to a significant increase in radical formation, 
see also (Brand, Buckingham et al. 2004, Murphy 2009). We will further focus on the 
implications of these ‘catabolic’ difficulties with regard to radical formation in (pre)
eukaryotic cells for eukaryotic evolution, and for metabolic reprogramming at the 
cellular and multicellular (tissue) level. A schematic overview of possible solutions 
to the problem of increased radical formation due to catabolism of substrates 
associated with high FADH
2
/NADH ratios is given in figure 1.
Figure 1 
 
 
 
 
 
 
  
 
 
 HIGH FADH2/NADH ratios 
   
  
 
 
 
 
Uncoupling 
Complex adjustments 
Peroxisomes Mitophagy 
Supercomplexes 
Figure 1. Schematic representation of possible adaptations to interior radical formation 
by respiratory chain complexes (especially complex I) upon catabolizing substrates with 
high FADH
2
/NADH ratios. Clockwise: 1. Development of mechanisms to induce (regulated) 
mild uncoupling (e.g. UCPs). 2. Segregation of fatty acid oxidation (completely in neurons, 
plants and some yeasts, limited to VLCFA’s only in most mammalian cells). 3. Evolving specific 
mitophagy pathways. Apart from mitophagy, a MAD pathway (resembling the ERAD pathway, 
see text) appeared. 4. Stimulating supercomplex formation, allowing e.g. complex I ‘direct’ 
access to its ‘own’ ubiquinone pool. 5. Adjusting complexes (especially I) and their synthesis to 
lessen both radical formation and its impact.
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Did (proto) mitochondria create circumstances favouring the rise 
of peroxisomes?
A number of predictions can be derived from the hypothesis that high FADH
2
/NADH 
flux ratios lead to increased mitochondrial radical formation, especially in cells with 
high energy needs. First of all, eukaryotic cells would have an advantage if they 
evolved mechanisms to lower FADH
2
/NADH flux ratios during fatty acid breakdown 
at a minimal ATP loss. Second, all cells that are difficult to replace or very sensitive 
to oxidative damage should, as far as possible, forego mitochondrial catabolism in 
general and beta oxidation specifically. We will consider the possible evolutionary 
solutions reflecting the first prediction next.
As already stated before (Speijer 2011) the previous considerations give a 
surprisingly good explanation for the eukaryotic invention of peroxisomes. The 
hypothesis explaining their origin can be described as follows. Peroxisomes are 
known to be derived from, or coevolved with, the ER (Gabaldon, Snel et al. 2006, 
Tabak, Hoepfner et al. 2006, Tabak, van der Zand et al. 2008, Tabak, Braakman et al. 
2013). According to the model, the forces giving rise to the evolution of peroxisomes 
stem from fatty acid catabolism, because of the fact that advantage accrues from 
mechanisms to lower the FADH
2
/NADH ratio during fatty acid breakdown. This is 
exactly what happened in the emerging peroxisome, the oldest pathway of which is 
beta oxidation (Gabaldon, Snel et al. 2006), without the generation of FADH
2
 which 
has to be taken care of by the mitochondrial respiratory chain. Beta oxidation occurs 
in 4 steps: 1, dehydrogenation (mitochondria) or direct oxidation (peroxisomes), 2, 
hydration, 3, oxidation by NAD+, and 4, thiolysis, i.e. cleavage by the thiol group of 
Coenzyme A. The eponymous H
2
O
2 
formed in the first reaction is dealt with by a 
specific peroxisomal enzyme, catalase. For more specific details see (Reddy and 
Hashimoto 2001). The ways in which the (partial) redistribution occurred are telling as 
well. In mammalian peroxisomes, such as our own, the trade-off between minimal ATP 
loss (the ‘ATP content’ of FADH
2 
generated in peroxisomes is lost because of direct 
oxidation, forming H
2
O
2
) and overall reduction of the FADH
2
/NADH ratio led to the 
specific breakdown of very long chain fatty acids (VLCFA’s) in the peroxisomes only. 
The VLCFA’s have the highest FADH
2
/NADH ratios, consistent with our expectations.
In plants and most yeasts, evolution led to the migration of all beta oxidation 
from mitochondria to peroxisomes. This further reduces mitochondrial radical 
formation by lowering competition between complex I and FADH
2
 containing 
complexes, but at some energetic cost (see above). So why complete migration in 
plants and yeasts? Plants are able to be slightly less efficient with energy because 
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they became autotrophs, synthesizing their own food. Plants gained this ability 
upon the secondary endosymbiotic event, the uptake of a cyanobacterium, which 
gave rise to the chloroplast. Many yeasts species seem to use sugars, alcohol or 
organic acids as major sources of energy and in many cases have retained efficient 
fermentation pathways. All of this makes a complete relocation of fatty acid oxidation 
to the peroxisomes possible, while reducing oxygen radical generation. Reduction 
of radical formation by the respiratory chain can go even further, again at some 
energetic cost in the form of reduced proton pumping. Interestingly, mitochondria 
of Saccharomyces cerevisiae lack complex I, instead having a rotenone-insensitive 
NADH dehydrogenase (Ndi1). Ndi1 is formed by a single polypeptide which lacks all 
proton pumping function (Iwata, Lee et al. 2012). This points to a specific oxygen 
radical generating vulnerability associated with complex I even in the absence of beta 
oxidation (see also below). However, it should be mentioned that Saccharomyces 
cerevisiae is not an ideal model is this context, as in its case, respiration seems a 
condition which it just tries to survive, while thriving during fermentation.
Recently, an evolutionary force associated with fatty acid metabolism playing a role in 
the evolution of peroxisomes (providing a possible advantage by sequestering toxic by-
products of such metabolism), has again been postulated (Gabaldon 2014, Speijer 2014). 
However, in this case the cellular site at which oxygen radical formation during fatty acid 
metabolism leads to the selective force favouring peroxisome formation, is thought to 
be the endoplasmic reticulum, instead of the (proto)mitochondrion (Gabaldon 2014). 
Also, possible radical formation during fatty acid synthesis, instead of breakdown, is 
considered a driving force for peroxisomal sequestering of such reactions. There are, 
however, some issues that need to be resolved (Speijer 2014). As mentioned, the most 
ancestral peroxisomal pathway is beta oxidation, the 4 steps of which are catalysed by 
only three enzymes, as step 2 and 3 are catalysed by only one protein: Pox2p (yeast 
nomenclature), an enzyme stemming from the alpha-proteobacterial heritage. This 
suggests a crucial contribution of mitochondrial metabolic enzymes to the evolution 
of peroxisome. Such a mitochondrial ‘input’ with regard to peroxisomal evolution is 
further strengthened by the following observations. Mammalian mitochondria and 
peroxisomes have been shown to communicate and cooperate intensively (Schrader and 
Yoon 2007). Quite recently, even a direct relationship between both organelles has been 
found in HeLa cells, taking the form of cargo-selected transport from mitochondria to 
peroxisomes (Neuspiel, Schauss et al. 2008). We also practically always find peroxisomes 
and mitochondria together. Amitochondriate, but hydrogenosome containing species 
such as Giardia Lamblia do not contain peroxisomes. Loss of peroxisomes goes together 
with extremely reduced mitochondrial function, such as lack of beta oxidation, in 
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apicomplexans. Therefore it appears that a likely candidate for the driving force behind 
peroxisome evolution is indeed reduction of mitochondrial radical formation inherent 
in beta oxidation of fatty acids due to the high FADH
2
/NADH ratio involved. We know 
present-day peroxisomes are derived from the ER (see above). We also know that the 
peroxisomal protein import machinery is homologous to, and possibly derived from, 
the ER-associated degradation (ERAD) system (Gabaldon, Snel et al. 2006). Interestingly, 
a related mitochondrial system (MAD) has been discovered to operate (Margineantu, 
Emerson et al. 2007, Heo, Livnat-Levanon et al. 2010, Taylor and Rutter 2011). This 
makes the reconstruction of the strict evolutionary order of events even more difficult. 
Although purely hypothetical, one could envisage all new endomembrane structures, 
such as peroxisomes, the nucleus, and the ER evolving in reaction to evolutionary 
pressures resulting from endosymbiont entry. Both ER and Golgi formation took place 
over a relatively short time span, early on in eukaryotic evolution (Dacks and Field 2007). 
Indeed, a large number of important evolutionary events occurred rapidly between 
endosymbiont acquisition and subsequent eukaryotic radiation, which is consistent with 
early acquisition of, and adjustment to, mitochondria in eukaryotic evolution (Huynen, 
Duarte et al. 2013). Using an adaptation to the endosymbiont to explain a general 
characteristic (here the peroxisome) of the eukaryotic lineage is also found in other 
models. One can think of Martin and Koonin’s explanation for the development of a 
nucleus (and by extension of the ER) in response to alphaproteobacterial group II introns 
migrating to the host genome (Martin and Koonin 2006).
Further adaptations to internal radical formation upon 
competition for ubiquinone
What other kind of eukaryotic adaptations are possibly related to suppressing radical 
formation during breakdown of substrates with high FADH
2
/NADH ratios? First of 
all the widespread tendency of respiratory chain complexes to form quaternary 
structures called supercomplexes is in line with such a function. For instance, it was 
observed that all the standard respiratory chain complexes except the FADH containing 
complex II can associate in such supercomplexes (Moreno-Lastres, Fontanesi et al. 
2012, Barrientos and Ugalde 2013, Lapuente-Brun, Moreno-Loshuertos et al. 2013). 
Such supercomplex formation could restrict a (dedicated) ubiquinone pool to use by 
complex I only, reducing the chance of radical formation by reverse electron transfer 
(RET) from a general pool reduced by complex II. There are many indications that 
supercomplexes are involved in reducing radical formation (Winge 2012) and that 
loss of supercomplex formation leads to increased superoxide formation and the 
mitochondrial aging phenotype, most severely in post-mitotic tissues (Gomez and 
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Hagen 2012). Supercomplex formation represents a dynamic mechanism allowing 
cells to organize the respiratory chain optimally in dealing with varying carbon 
sources (and in specific cell-types (Lapuente-Brun, Moreno-Loshuertos et al. 2013).
Apart from supercomplex formation, the appearance of so-called uncoupling 
proteins could be linked to the dangers of radical formation by the mitochondrial 
respiratory chain inside the cell. Extensive radical formation via RET at complex 
I is found to be more pronounced when electrons are supplied to ubiquinone 
from succinate, alpha-glycerophosphate or fatty acid oxidation (Murphy 2009). 
This radical production comes from electrons entering complex I through the 
ubiquinone-binding site(s), but is only observed if Dp is high (e.g. during extensive 
oxidation of both NADH and FADH
2
). All the observations above are consistent 
with the kinetic model of radical formation due to competition for ubiquinone. 
The precise molecular mechanisms playing a role are unclear. However, a high 
Dp and large electron flows via FADH containing enzymes seem to be essential. 
In isolated mitochondria, RET induced radical formation is abolished upon slight 
decreases of Dp (Murphy 2009). This could mean that lowering Dp by the expression 
of uncoupling proteins (UCPs) would efficiently reduce radical formation in the cell. 
The UCPs form a family of proton transporters in the mitochondrial inner membrane 
which have been implicated in thermo regulation and protection against oxidative 
damage by their ability to induce uncoupling (Nicholls, Bernson et al. 1978, Azzu 
and Brand 2010, Jastroch, Divakaruni et al. 2010). UCPs belong to the mitochondrial 
carriers family, an inner membrane protein family involved in transporting keto acids, 
amino acids, nucleotides, inorganic ions and co-factors across the mitochondrial 
inner membrane (Kunji and Robinson 2010). Mitochondrial carriers are part of the 
organellar interface - and as such arose with the early eukaryote (Szklarczyk and 
Huynen 2010). More recent evolution of UCPs indicate multiple duplications in 
vertebrates (Hughes and Criscuolo 2008). Five different UCPs have been identified 
(Ricquier and Bouillaud 2000). They are found in highly variable amounts in various 
tissues in all modern mammals (Jastroch, Divakaruni et al. 2010), as well as in plants 
and unicellular eukaryotes. UCP1-3 have been studied in some detail, but UCP 
4 and 5 (interestingly, both mainly expressed in the brain, see below) have only 
been characterized more recently. UCP1 in mammalian brown adipose tissue has a 
clear role in heat production, whereas UCP1, UCP2 and UCP3, in other species are 
implicated in ROS reduction, though their precise roles are still heavily debated. 
Interestingly, when mammalian UCP1 was expressed in yeast mitochondria, proton 
transport was increased significantly in the presence of the (saturated C-16) fatty 
acid palmitate or an oxidized fatty acid (4-hydroxy-2-nonenal) only. Together they 
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showed a clear synergistic effect (Esteves, Parker et al. 2006). 4-hydroxy-2-nonenal 
can be formed by the activity of superoxide, a well-known ROS species, which can 
also activate UCPs on its own. So it seems that, as high ROS formation due to RET in 
complex I driven by oxidation of fatty acids is acutely sensitive to Dp, it could thus be 
controlled via slight uncoupling of oxidative phosphorylation. This is accomplished 
by fatty acids via activation of UCPs. That activation would be even stronger in 
the simultaneous presence of oxidized fatty acids. See also (Brand, Affourtit et al. 
2004) and (Brand, Buckingham et al. 2004). In conclusion, the data regarding most 
members of the UCP protein family seem to support a role in dealing with specific 
problems of internal radical formation during fatty acid oxidation.
The ‘special’ position of neurons
Above we predicted that all cells which are ‘irreplaceable’ or extraordinarily sensitive 
to oxidative damage should have reduced levels of mitochondrial fatty acid oxidation. 
A prime example of such cells is neurons. Neurons have very high energy demands. 
It has been calculated that the brain only accounts for ~ 2% of body mass, while it 
consumes 20% of total oxygen taken up by the entire body. In the brain, neurons have 
the maximum energy consumption, whereas astrocytes are only responsible for ~5 – 
15% of its energy requirements (Attwell and Laughlin 2001). This immense metabolic 
demand of neurons results from the fact that they are highly differentiated cells needing 
large amounts of ATP for maintenance of ionic gradients across cell membranes for 
neurotransmission (Kann and Kovacs 2007). We should also point out that neurons are 
completely dependent on the OXPHOS system for their ATP needs, as they are not 
able to switch to glycolysis when OXPHOS becomes limited (Knott, Perkins et al. 2008). 
In an apparent conflict with these high energy demands, it is beneficial for organisms 
if neurons are long lived, because they carry essential information for the organism. 
This poses a dilemma, as oxidative catabolism generates toxic oxygen radicals. Our 
considerations regarding FADH
2
/NADH ratios explain why neurons do not use beta 
oxidation (Yang, He et al. 1987, Speijer 2011, Schonfeld and Reiser 2013), instead relying 
on glucose (and ketone bodies) for their energy supply, even though fatty acids have 
about twice the energy content of sugars. Despite of the banishment of fatty acids 
from the menu, neurons of course still need complete oxidative catabolism of glucose, 
with full mitochondrial involvement. This still results in radical damage, albeit reduced, 
that neurons accumulate due to their high energy needs.
Mitochondrial diseases have extremely inconsistent clinical presentations, 
affecting any organ in isolation or combination at any age with variable severity. 
The genetic basis of these diseases is complex. Mutations in more than a 100 genes 
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encoded by the nucleus, inherited in a Mendelian manner, or on the mitochondrial 
genome, inherited maternally, have been found so far (Tucker, Compton et al. 
2010, Schapira 2012). Organs with high energy demand are especially afflicted, 
most prominently the brain (Kirby and Thorburn 2008, Tucker, Compton et al. 
2010, Schapira 2012). Neurodegeneration, in which neurons are specifically steadily 
destroyed, leads to a progressive loss of nervous system structure and function 
(Przedborski, Vila et al. 2003, Deuschl and Elble 2009). Again, the pathological 
picture in neurodegenerative disorders is heterogeneous, affecting unique areas 
of the nervous system. In the brain, Purkinje cells and neurons of the dentate nuclei 
of the cerebellum as well as neurons of the inferior olivary nuclei of the medulla are 
considered to be most energy demanding, and thus most susceptible to damage 
(Breuer, Koopman et al. 2013). Symptoms range from acute and rapid in progression 
to subtle and chronic (Koopman, Distelmaier et al. 2013). The critical function of  the 
neuronal OXPHOS system in maintaining bioenergetic needs is illustrated by the 
fact that OXPHOS dysfunction leads to defects in growth and trafficking, as well as 
to apoptosis and neuronal death (Fukui and Moraes 2008). This in turn can lead to 
microglial activation, a pathophysiological consequence that can trigger catastrophic 
events such as further oxidative and nitrosative stress, ultimately leading to further 
neuronal damage and death (DiFilippo, Chiasserini et al.2010). OXPHOS dysfunction 
seems also involved in the occurrence of non-functional synapses and axonal 
degeneration; see e.g. (Dutta, McDonough et al. 2006).
The possible role of mitochondrial ROS production 
in neurodegenerative disorders
Despite not using beta oxidation, neuronal radical formation by complex I is still 
involved in pathogenesis. Increasing evidence shows that disrupted mitochondrial 
function, especially at complexes I and III, enhances ROS production in 
neurodegenerative disorders. Here we briefly review the role of ROS in Parkinson’s 
disease (PD), amyotrophic lateral sclerosis (ALS), and Alzheimer’s disease (AD) (Lin 
and Beal 2006, de Moura, dos Santos et al. 2010, Scaglia 2010).
In PD, neurons in the motor centers such as the cerebellum and the striatum are 
decreased. Substantial decreases in dopaminergic neurons, containing proteinaceous 
Lewy bodies, of the substantia nigra pars compacta are observed (Tansey and 
Goldberg 2010). PD patients not only show depletion of dopaminergic neurons, but 
also decrease in Purkinje cell numbers in the cerebellar cortex, explaining motor 
skill losses. It is still mostly unknown what causes PD, however genetic mutations 
in Parkin (Mortiboys, Thomas et al. 2008) and PINK1 (Heeman, Van den Haute et 
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al. 2011), both implicated in the removal of damaged mitochondria via autophagy 
have been observed. Defects in mitochondrial respiration, particularly at complex I 
(Mortiboys, Thomas et al. 2008, Mounsey and Teismann 2010) also result in elevated 
ROS production which further leads to increased oxidative stress and dopaminergic 
neuronal degeneration, all strongly correlating with development of PD (de Moura, 
dos Santos et al. 2010). Interestingly, in the context of our model regarding high FADH
2
/
NADH ratios leading to ROS production because of competition for the acceptor 
ubiquinone, reduced complex I activity can be compensated by increased complex 
II activity in PD fibroblasts. Indeed, the contribution of complex II to ATP generation 
is hardly diminished as compared to control fibroblasts (Mortiboys, Thomas et al. 
2008). Moreover, 50 % of late onset sporadic PD patient derived fibroblasts even 
were able to restore complex I activity upon incubation with ubiquinone (Winkler-
Stuck et al. 2004). These findings are paralleled in Drosophila mitochondria: Parkin 
and PINK1 mutant phenotypes were found to be enhanced by mutations in the 
UBIAD1/Heix gene, involved in making the alternative electron acceptor vitamin K2. 
Overexpressing wt Heix or supplying vitamin K2 ‘rescued’ Drosophila from PD-like 
symptoms (Vos, Esposito et al. 2012).
The motor neuron disease ALS shows loss of motor neurons in cortex, brain 
stem and spinal cord with aggregated neurofilaments in proximal axons of motor 
neurons. ALS presents Bunina bodies, eosinophilic aggregates found in anterior 
horn cells (Goodall & Morrison 2006). Apart from rare predisposing mutations in the 
mitochondrial superoxide dismutase gene (MnSOD; see above), ALS has no known 
causes. Surprisingly, in MnSOD mutant rats binding of the misfolded mutant protein 
to VDAC1 was shown, resulting in reduced VDAC1 activity and loss of motor neurons 
(Israelson, Arbel et al. 2010). This could imply that loss of MnSOD function in ROS 
protection is not important in the development of ALS.
AD is characterized by significant decreases in intellectual ability and memory, as 
well as  personality changes (Perry and Hodges 1999). AD gives rise to neurofibrillary 
tangles, constituting of hyper phosphorylated tau proteins. Extracellular senile 
plaques of β-amyloid (Aβ) are most prominently found on cholinergic neurons 
supplying the hippocampus (Kar, Slowikowski et al. 2004). Increasing evidence points 
to a role of OXPHOS dysfunction in the development of AD.  In a transgenic mouse 
model study, decreased mitochondrial membrane potential and decreased ATP levels 
in neurons could be observed and degree of cognitive impairment correlated with 
the amount of synaptic mitochondrial dysfunction (Dragicevic, Mamcarz et al. 2010). 
Interestingly, Aβ seems to inhibit several key mitochondrial enzymes in the brain, 
complex IV looking most relevant (Reddy and Beal 2008). This last observation nicely 
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illustrates one of the key problems in describing a neurodegenerative disease such 
as AD from a perspective of mitochondrial dysfunction and concomitant radical 
formation: is it cause or effect (Morais and De Strooper 2010)?
Complex I as the most important site of radical formation
As seen from the description of the clearest example of the involvement of ROS 
generation and a dysfunctional OXPHOS in the aetiology of neurodegenerative 
disease, PD, complex I plays a crucial role. It is known to be the major source of 
oxygen radicals (Brand 2010). Complex I has grown considerably in size during 
evolution, gathering so-called supernumerary subunits. It grew from its 14 bacterial 
subunits, to encompass 30 in algae and plants, 37 in fungi and at least 44 in human 
beings (Balsa, Marco et al. 2012). The process of complexification was most likely 
already (almost) complete in the very last eukaryotic common ancestor (LECA) 
(Gabaldon and Huynen 2005, Huynen, de Hollander et al. 2009, Cardol 2011). It is 
tempting to think, that apart from performing chaperone functions during assembly 
and membrane insertion, as well as giving stability to this huge protein complex, 
some supernumerary subunits are specifically involved in minimizing the occurrence 
of, and combating, radical formation. This however has to await further research into 
the specific roles of ‘extra’ subunits.
Interestingly, at the origin of the vertebrate lineage, Acyl-CoA dehydrogenase 9 
(ACAD9), closely resembling very long-chain acyl-CoA dehydrogenase (VLCAD), lost 
its function in mitochondrial oxidation of fatty acids. Instead it became a required 
factor for complex I assembly (Nouws, Nijtmans et al. 2010). This could be another 
indication for a functional link between expressing enzymes involved in fatty acid 
oxidation and stress for complex I  (Speijer 2011). Very recently, pluripotent stem 
cells from patients carrying a common mutation in mitochondrial DNA, m.3243A>G, 
mutating the tRNA LEU gene, were generated. The most pronounced problems were 
associated with complex I. Upon differentiation to neurons, complex I seemed to 
be actively and specifically (!) degraded via mitophagy (involving PINK1 and Parkin-
positive autophagosomes). After  the concentration of complex I is thus diminished, 
complex IV becomes slightly impaired, possibly due to extensive radical formation, 
and complex II is up regulated, presumably to compensate for the loss in ATP 
generation, as previously observed in patients carrying this mitochondrial DNA 
mutation (Hamalainen et al. 2013). Although it is known that oxidative stress can 
induce autophagy (Korsmeyer, Yin et al. 1995, Gurusamy and Das 2009), such specific 
targeting of malfunctioning complex I points to its crucial position in the balancing 
act between ATP generation and radical formation.
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Conclusions
Aerobic eukaryotic life has to perform a balancing act between efficient ATP 
generation and oxygen radical formation. If the cell is easily replaceable in a 
multicellular organism and it has high energy needs, it will use mitochondrial beta 
oxidation of fatty acids, with the exception of one class, as explained by the model 
presented here. Such cells will only relegate VLFCAs to the peroxisomes, giving high 
ATP yields, while only somewhat reducing radical formation via complex I. Neurons 
have a different position along the line of mammalian cells as characterized by the 
trade-off between efficient ATP generation and amount of ROS generated. Neurons 
will not oxidize any fatty acids, but consume only less energy-rich glucose. However 
breakdown has to be performed efficiently, with full mitochondrial involvement. Stem 
cells and some cancer cells (consider the Warburg effect) also only consume glucose, 
but can rely on permanent glycolysis with resulting lactate being recycled to glucose 
by other cells in the body (such as the hepatocytes), even further reducing their 
mitochondrial contribution and amount of ROS generated, especially by complex I. 
An impressive array of cellular mechanisms evolved partially to cope with the arrival of 
an internal oxygen radical generator in the form of the (pre)mitochondrion, amongst 
others: uncoupling mechanisms, partial or total segregation of fatty acid oxidation, 
mitophagy, the mitochondrion associated decay (MAD) pathway, supercomplex 
formation, adjustment of the respiratory chain complexes themselves, and even 
apoptosis when possible. The results described here are fully consistent with the 
model we focussed on, one in which FADH
2
/NADH ratios, as encountered during 
breakdown of different metabolites, are crucial to ROS formation. However, in light 
of all the cellular adaptations just mentioned, proof will not be easy to come by. We 
have to await future experiments.
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Abstract
Complex I (CI) dysfunction leads to a myriad of cell biological aberrations thought to 
be due to excess ROS levels. Here, we investigate the potential of the water soluble 
Vitamin E analog, Trolox, as an antioxidant strategy to alleviate the pathophysiological 
abnormalities observed in an Ndufs4-/- mouse model of human CI deficiency. 
Ndufs4-/- mice showed a progressive decline in rope grip performance, which was 
delayed (p<0.05) at week 6 of life following twice-daily intraperitoneal injections of 
400 mg/kg body weight starting at week 3 of life. Mice were sacrificed at week 6 
and biochemical characterization of a mitochondria-enriched preparation from hind 
limb skeletal muscle revealed no trend toward normalization of the maximal rate of 
CI-linked ATP production in Trolox-treated Ndufs4-/- mice. Similarly, measurements 
of the maximal activities of the individual respiratory chain complexes failed to show 
any change as compared to vehicle-treated Ndufs4-/- mice. The area of the granular 
layer of the cerebral cortex occupied by GFAP positive cells did not differ between 
vehicle-treated Ndufs4-/- and wildtype (WT) mice and was not influenced by Trolox-
treatment. The same observation was reached for the number of Purkinje cells in 
the cerebellum. Regarding the retina, layer thickness tended to be decreased for 
RGC (p=0.06), IPL (p=0.06) and INL (p=0.06) in vehicle-treated Ndufs4-/- mice. The 
same layers showed no tendency for decreased thickness between Trolox-treated 
Ndufs4-/- and WT mice. Trolox-treated Ndufs4-/- showed a significant increase in 
EPL thickness as compared to Trolox-treated WT mice. GFAP staining was increased 
in RGC+IPL of Ndufs4-/- mice and remained increased following Trolox treatment. 
Finally, Trolox-treatment fully restored the decrease in the number of NeuN positive 
cells observed in the RGC of vehicle-treated Ndufs4-/- mice. Taking into account the 
rapidly progressive, lethal phenotype of the Ndufs4-/- mice, the present finding that 
Trolox has some beneficial effect on neuro-motor function and retinal integrity might 
warrant translation to the human situation. 
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Introduction
The mitochondrial oxidative phosphorylation (OXPHOS) system is the final biochemical 
pathway engaged in the generation of ATP and is estimated to generate 90% of cellular 
ATP (Smeitink, van den Heuvel et al. 2001, Rich 2003). The OXPHOS system is embedded 
in the lipid bilayer of the mitochondrial inner membrane (MIM) and is made up of five 
multi-subunit enzyme complexes and two mobile electron carriers i.e. ubiquinone (Q) and 
cytochrome c (cyt c). Electrons liberated from NADH at complex I (CI) or FADH
2
 at complex II 
(CII) flow downhill via coenzyme Q, complex II (CII), cyt c and complex IV (CIV) to oxygen 
releasing free energy that is used by CI, CIII and CIV to pump protons across the MIM to 
the intermembrane space. Due to this translocation of protons an electrochemical proton 
gradient arises, referred to as proton motive force (PMF), that is used by complex V (CV) to 
drive the condensation of ADP and P
i 
into ATP (Smeitink, van den Heuvel et al. 2001).
Inherent to the above process of oxidative phosphorylation (OXPHOS), 
mitochondria produce significant amounts of incompletely reduced derivatives of 
molecular oxygen (O
2
) (Brown and Borutaite 2012). These reactive oxygen species 
(ROS) include superoxide (O
2
●-), hydrogen peroxide (H
2
O
2
) and the hydroxyl radical 
(●OH). About, 0.1 to 0.5% of the oxygen consumed by the mitochondria is converted 
to O
2
●- (Murphy 2012). This occurs mainly at CI and CIII (Murphy 2009). Under 
normal conditions, O
2
●- is detoxified by superoxide dismutases (SODs) resulting in 
the production of H
2
O
2
. H
2
O
2
 is subsequently removed by catalases, glutathione 
peroxidases and peroxiredoxins (Koopman, Nijtmans et al. 2010). Physiological ROS 
levels play an important role in various signaling pathways (Finkel 2011, Gough and 
Cotter 2011). Excess ROS levels as observed in certain OXPHOS diseases lead to 
cellular dysfunction and, eventually, cell death (Balaban, Nemoto et al. 2005). 
Tissues of high energy demand such as skeletal muscle, heart and brain are at 
increased risk of ROS-induced damage during mitochondrial dysfunction (Quintana, 
Kruse et al. 2010, Chouchani, Methner et al. 2014, Shi, Ivannikov et al. 2014). Brain is a 
unique organ; although it represents 2% of total body mass, it consumes 20% of the 
total oxygen and 25% of the total glucose consumed by the human body (Belanger, 
Allaman et al. 2011). The brain is especially susceptible to oxidative damage as observed 
in several neuropathological conditions including Parkinson’s disease, Alzheimer’s 
disease, Huntington’s disease and amyotrophic lateral sclerosis (ALS) (Wilson 
1997, Dringen 2000). There are several factors that contribute to the heightened 
susceptibility of the brain to oxidative damage. These include a high rate of oxidative 
energy metabolism, a high content of unsaturated fatty acids that are prone to lipid 
peroxidation and a low intrinsic antioxidant capacity (Dringen 2000). Any impediment 
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in electron transfer through the mitochondrial respiratory chain will significantly 
increase superoxide O
2
●-  generation by all single electron donor sites of dysfunctional 
mitochondria, provided that there is sufficient supply of oxygen (Kudin, Bimpong-Buta 
et al. 2004, Malinska, Kulawiak et al. 2010, Napankangas, Liimatta et al. 2012).
Analysis of the cell biological consequences of CI dysfunction in primary neuronal 
cells derived from the Ndufs4fky/fky mouse, generated by insertion of a transposable 
element into the Ndufs4 gene, suggest an impairment in ATP generation without any 
changes in mitochondrial membrane potential (Bird, Wijeyeratne et al. 2014). Analysis 
of the maximal rate of CI-linked ATP production in a mitochondrial preparation 
from several tissues of the Ndufs4-/- mouse, generated by deletion of exon 2 of 
the Ndufs4 gene, showed no difference compared to wildtype for skeletal muscle 
and heart (Alam, Manjeri et al. 2015) but a significant decrease for brain (Manjeri, 
Rodenburg et al. 2016) (Chapter 2 of this thesis). Recently, a key consequence of 
neuronal mitochondrial dysfunction, namely the accumulation of lipid droplets 
(LD) in glial cells, was uncovered in pre-symptomatic Ndufs4-/- mouse (Liu, Zhang 
et al. 2015). This phenomenon was shown to occur prior to the development of 
neurodegenerative lesions (Quintana, Kruse et al. 2010, Quintana, Zanella et al. 2012). 
Evidence suggested that increased ROS levels caused activation of c-Jun-N-terminal 
Kinase (JNK) and Sterol Regulatory Element Binding Protein (SREBP) in CI-deficient 
neurons, resulting in increased lipid synthesis in neurons and LD accumulation in glial 
cells and subsequent neurodegeneration by elevated levels of lipid peroxidation. The 
onset of neurodegeneration could be delayed by N-acetyl cysteine amide (AD4), a 
blood-brain-barrier penetrating antioxidant, following intraperitoneal injection of 
150 mg/kg of body weight prior to the onset of the symptomatic phase between 
PD21 to PD28 (Liu, Zhang et al. 2015). They proposed that LD accumulation could 
be potentially used as a biomarker in neurodegeneration. The author’s reported a 
similar mechanism in several drosophila models of CI dysfunction and concluded 
that ROS-induced formation of LD during neuronal mitochondrial dysfunction is 
an evolutionarily conserved process. Mitochondrial dysfunction leads to optic 
dystrophies as observed in children with CI dysfunction. Kruse and co-workers 
reported that KO mice go blind around PD32 (Kruse, Watt et al. 2008). Yu and co-
workers, recently investigated the functional, neuroanatomical and transcriptional 
consequences of blindness in the Ndufs4-/- mice (Yu, Song et al. 2015). Recently, 
it was demonstrated that Ndufs4-/- mice subjected to chronic hypoxia showed a 
marked improvement in survival, body weight, body temperature, behavior and 
neuropathology (Jain, Zazzeron et al. 2016). Here, the authors hypothesized that 
lowering oxygen demand might limit ROS production during impaired electron 
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transport. Ndufs4-/- mice become lethargic around PD30 and severely ataxic around 
PD35 (de Haas, Russel et al. 2016) when they exhibit splayed legs, are unresponsive 
to firm nudge, right themselves slowly and occasionally lose balance and fall over. 
Between PD35 to PD50, they ceased grooming and died (Kruse, Watt et al. 2008). 
Similar observations have been reported in children with CI deficiency (Fassone and 
Rahman 2012).
Our previous work has shown that the water-soluble vitamin E analog Trolox 
can counterbalance many of the aberrations observed in primary fibroblasts 
from patients with isolated CI deficiency including increased cellular ROS levels, 
a less negative mitochondrial membrane potential, hampered Ca2+-stimulated 
mitochondrial ATP production (Koopman, Verkaart et al. 2006, Koopman, Verkaart 
et al. 2008, Distelmaier, Visch et al. 2009, Distelmaier, Valsecchi et al. 2012, Blanchet, 
Smeitink et al. 2015, Willems, Rossignol et al. 2015). This chapter investigates the 
effects of chronic Trolox treatment of Ndufs4-/- mice on behavioral paradigms 
associated with muscle function and motor coordination. The rationale of this 
approach is that brain areas associated with neuro-motor function are increasingly 
affected during mitochondrial dysfunction (Carter, Lione et al. 1999, Karl, Pabst et 
al. 2003, Kruse, Watt et al. 2008, Quintana, Kruse et al. 2010, Breuer, Willems et 
al. 2012). In addition, this chapter examines the effect of chronic Trolox treatment 
of Ndufs4-/- mice on the biochemical characteristics of the OXPHOS system in a 
mitochondria-enriched preparation from hind limb skeletal muscle. Finally, this 
chapter investigates the effect of chronic Trolox treatment on the brain neuro-
inflammatory phenotype of Ndufs4-/- mice. 
Materials  and Methods
Injections and behavioral tests
Injections – All experiments were approved by the Regional Animal Ethics Committee 
(Nijmegen, The Netherlands) and performed under the guidelines of the Dutch Council 
for Animal Care. All efforts were made to reduce animal suffering and number of animals 
used in this study. Wild type (WT) and Ndufs4-/- mice were fed on a standard animal diet 
(V1534-300 R/M-H, Ssniff GmbH, Soest, Germany) and water available ad libitum in standard 
vivarium conditions with 12 h light dark cycle. Animals were housed in groups at 22° C and 
only males were used in the experiment. Intraperitoneal injections (2 ml/kg per injection) 
were performed twice a day the first one between 8:00-9:00 h and the second one between 
14:00-15:00 h. Injections began during week 3 of life and continued until sacrifice in week 6. 
Two behavioral tests, the rope grip (day 1) and the rotarod test (day 2), were carried out at 
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30 minutes after the morning injection at 3, 5 and 6 weeks of life. After testing, the animals 
were returned to the colony room. The study included 5 WT and 4 Ndufs4-/- mice treated 
with vehicle (1 M NaHCO
3
, S3817 Sigma-Aldrich, The Netherlands, freshly prepared weekly 
and kept at 4° C) and 6 WT and 5 Ndufs4-/- mice treated with Trolox (238813-5G Sigma-Aldrich, 
400 mg/kg body weight dissolved in 1 M NaHCO
3
). Trolox was dissolved by warming the 
solution at 37°C and gentle vortexing.
Rope grip – Animals were allowed to grasp the middle of a rope (100 cm) suspended 
above the floor (30 cm) with their fore paws only. Healthy animals will grip the rope with 
all 4 limbs and successfully crawl to the end. Animals with muscular dysfunction will 
be unable to do so and fall to the padded apparatus floor. The test was automatically 
concluded when the animal fell from the rope. The test was repeated three times 
with a resting interval of 3 min and the average number of successful escapes and the 
average time on the rope were quantified.  
Rotarod – The rotarod test consisted of a 3 min training period during which the 
animals were exposed to the rotating rod set at 10 rotations per minute (RPM). Next, 
the animals were tested three times on the accelerating rod, with a 3 min resting 
period in between two consecutive trials. A trial was ended when the animal fell from 
the rod or when the maximum RPM was reached at 5 min. The average time on the 
rod was quantified. 
Biochemical analyses
Tissue harvest – Immediately after sacrifice by cervical dislocation, entire skeletal 
muscle from both hind limbs was removed, put in ice-cold SETH buffer (0.25 M 
sucrose, 2 mM EDTA, 10 mM Tris, 5x104 U heparin/L, pH 7.4), minced with a Sorvall TC2 
tissue chopper and homogenized with a glass/Teflon Potter Elvehjem homogenizer. 
The homogenate was centrifuged at 600g and a portion of the supernatant, referred 
to as mitochondria-enriched fraction, was used for measurement of the maximal 
rates of pyruvate oxidation and ATP production. The remainder was frozen in 10 µl 
aliquots in liquid nitrogen and kept at -80º C for measurement of the maximal activity 
of the individual OXPHOS complexes. Protein concentration was determined by the 
Lowry method as described before (Janssen, Trijbels et al. 2006). 
Maximal rates of pyruvate oxidation and ATP production – To determine the 
maximal pyruvate oxidation rate, a freshly prepared 600g supernatant was incubated 
with radiolabeled substrate ([1-14C] pyruvate). After 20 min, the reaction was stopped 
and the amount of liberated 14CO
2
 was quantified (Janssen, Trijbels et al. 2006). The 
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assay medium (pH 7.4) contained K+- phosphate buffer (30 mM; source of Pi), KCl 
(75 mM), Tris (8 mM), K-EDTA (1.6 mM), P1,P5-Di (adenosine-5′) pentaphosphate 
(Ap5A; 0.2 mM), MgCl
2
 (0.5 mM), ADP (2 mM), creatine (20 mM), malate (1 mM) and 
[1-14C] pyruvate (1 mM). AP5A is a potent adenylate kinase (AK) inhibitor required to 
prevent interference of the AK reaction with the ATP produced and excess of ADP 
required for this assay. The rate of ATP-linked pyruvate oxidation was obtained after 
subtraction of 14CO
2
 liberated in the absence of ADP. For measurement of the maximal 
ATP production rate, the same assay medium was used but with pyruvate instead of 
[1-14C] pyruvate. After 20 min, the reaction was stopped by addition of 0.1 M HClO
4
. 
The reaction mixture was centrifuged at 14000g for 2 min at 2° C. To the supernatant, 
1.2 vol (V/V) of 0.333 M KHCO
3
 was added and this mixture was diluted 2-fold. The 
amount of ATP and phosphocreatine formed were measured using a Konelab 20XT 
auto-analyzer (Thermo Scientific). Mitochondrial ATP production rate was corrected 
using a parallel assay in which residual glycolysis was blocked by arsenite (2 mM) 
(Janssen, Trijbels et al. 2006). 
Maximal activity of individual OXPHOS complexes – The liquid nitrogen frozen 
portion of the 600g supernatant was thawed and used for measurement of the 
Vmax of the complexes I (CI), II (CII), III (CIII) and IV (CIV) and citrate synthase (CS), as 
described previously (Rodenburg 2011). 
(Immuno)histological procedures 
Tissue harvest – Immediately after sacrifice by cervical dislocation, brains and eyes 
were removed, fixed in 4% buffered formalin and embedded in paraffin according to 
standard histological procedures. Tissue sections of 4 µm thickness were made for 
histological analyses. Brain and retinal sections were stained with Hematoxylin and 
Eosin (H&E). 
GFAP Staining – Tissue sections were preincubated for 10 min with 20% FCS (Vector, 
Burlingame, CA) in PBS. Next, sections were incubated overnight at 4° C with rabbit 
polyclonal anti-cow Glial Fibrillary Acidic Protein (DAKO), diluted with 1% BSA in PBS. 
Detection was carried out with the avidin-biotin-peroxidase complex technique using 
aminoethylcarbazole (AEC) as a substrate (Scytek, Utah, USA). 
NeuN Staining – Tissue sections were preincubated for 10 min with 20% FCS (Vector 
labs) in PBS. Next, sections were incubated overnight at 4° C with mouse monoclonal 
anti-NeuN (clone A60, Millipore), diluted with 1% BSA in PBS. Detection was performed 
as described above.  
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Quantitative analysis 
Brain GFAP staining – Images (magnification x 40) were acquired on a Zeiss 
Axioskop II microscope and GFAP intensity was quantified in the granular layer of 
the cerebellar cortex using KS 400 V3.0 software (Carl Zeiss AG, Germany) with 
a custom-written macro as described before (Navis, Bourgonje et al. 2013). The 
values presented are the mean of 10 non-overlapping microscopic fields of view 
per animal.
Purkinje cell quantification – Images (magnification x 40) were acquired as 
described above and Purkinje cell number was quantified in the Purkinje cell layer 
bordering the granular layer in the cerebellar cortex using the above software and 
macro. The values presented are the mean of 10 non-overlapping microscopic fields 
of view per animal.
Retinal thickness – Images (magnification x 40) were acquired as described 
above and thickness of the indicated retinal layers was quantified using the above 
software and macro. The values presented are the mean of 3 unique non-overlapping 
microscopic fields of view per animal. 
Retinal GFAP staining – GFAP intensity was quantified for the indicated retinal layers 
as described above. The values presented are the mean of 3 unique non-overlapping 
microscopic fields of view per animal.
Retinal NeuN stains – Images (magnification x 40) were acquired on a Zeiss Axioskop 
II microscope and NeuN positive cells were quantified in the RGC layer of the retina 
using AxioVision software (Carl Zeiss AG, Germany) with a custom-written macro. 
The data presented are the mean of 10 non-overlapping microscopic fields of view 
per animal.
Statistical Analyses
Statistical analyses were performed using unpaired Student’s t test and results 
expressed as mean ± SD. Statistical significance is indicated by (*P<0.05, **P<0.01, 
***P<0.001). 
Results
Effect of Trolox on rope grip and rotarod performance – The in vivo therapeutic 
potential of Trolox was tested in mice with a systemic knockout of the NDUFS4 
subunit of complex I (Ndufs4-/- mice). Vehicle-treated Ndufs4-/- mice (KO Veh) of 
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3, 5 and 6 weeks of life showed a progressive decline in rope grip and rotarod 
performance (Figs. 1a and 1b), suggesting that muscle endurance and motor 
coordination decrease with age (Breuer, Willems et al. 2012). In both paradigms, 
vehicle-treated WT mice (WT Veh) behaved similarly at all ages tested. Ndufs4-/- 
mice treated with Trolox (KO Trolox) showed improved rope grip and rotarod 
performance, reaching statistical significance (p<0.05) and close to statistical 
significance (p=0.07), respectively, at week 6 of life. Trolox did not affect the 
rope grip and rotarod performance of WT mice (WT Trolox). The decrease in 
rotarod performance observed with WT Trolox at week 3 of life did not reach 
statistical significance. 
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Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Behavioural analysis during chronic Trolox treatment. Starting at week 3 of life, 
mice were intraperitoneally injected twice daily (at 8:00-9:00 am and 14:00-15:00 pm) with 
400 mg / 2 ml / kg Trolox or 2 ml / kg vehicle (1 M NaHCO
3
). In total, 15 WT (14 in week 5 
and 6; WT Veh) and 12 Ndufs4-/- (9 in week 5 and 6; KO Veh) mice were treated with vehicle 
and 6 WT (WT Trolox) and 10 Ndufs4-/- (7 in week 5 and 6; KO Trolox) mice with Trolox. (A) 
Rope grip analysis: KO Veh showed a progressive decrease in rope grip performance when 
tested at weeks 3, 5 and 6 of life. Trolox did not affect rope grip performance in WT mice as 
compared to corresponding WT Veh. KO Trolox still showed a progressive decrease in rope 
grip performance at weeks 3 and 5. However, the value of week 6 was not different from that 
of week 5 and significantly higher than that of corresponding KO Veh (indicated with d*). (b) 
Rotarod analysis: KO Veh showed a progressive decrease in rotarod performance. Trolox 
did not affect rotarod performance in WT mice (WT Trolox) as compared to corresponding 
WT Veh. KO Trolox still showed a progressive decrease in rotarod performance at weeks 3 
and 5. This decrease seemed to be slowed down at week 6. However, the value obtained was 
not significantly different from that of WT Trolox at week 6 (p=0.07). Statistical analysis was 
performed with the unpaired independent student’s t-test.
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Effect of Trolox on the maximal rate of pyruvate oxidation in intact skeletal 
muscle mitochondria – At 6 weeks of life, mice were sacrificed and hind limb muscle 
was removed, homogenized and centrifuged at 600 g. The mitochondria-enriched 
600 g supernatant was used for further analysis. The maximal rate of pyruvate 
oxidation, measured in the presence of pyruvate, malate, ADP, PO
4
3- and creatine 
and corrected for the value obtained in the absence of ADP, was significantly (p<0.05) 
decreased in vehicle-treated Ndufs4-/- mice (Fig. 2a, open bars). In neither WT nor 
Ndufs4-/- mice, Trolox (closed bars) altered the maximal rate of pyruvate oxidation.
Effect of Trolox on the maximal rate of ATP production in intact skeletal muscle 
mitochondria – The maximal rate of ATP production, measured in the presence of pyruvate, 
malate, ADP, PO
4
3- and creatine, was significantly (p<0.05) decreased in vehicle-treated 
Ndufs4-/- mice (Fig. 2b, open bars). Trolox treatment (closed bars) did not significantly alter 
the maximal rate of ATP production in neither WT (p=0.052) nor Ndufs4-/- mice.
Effect of Trolox on the maximal activity of CI in broken skeletal muscle 
mitochondria – The maximal activity of the individual OXPHOS complexes was 
measured after freeze-thawing the 600 g supernatant to disrupt the mitochondrial 
membranes. This procedure allows the use of complex-specific substrates. The data 
obtained show that CI activity was virtually absent in vehicle-treated Ndufs4-/- mice 
(Fig. 2c, open bars) and that Trolox treatment (closed bars) had no effect on CI activity 
in WT mice. However, Trolox tended (p=0.054) to increase the maximal activity of this 
complex in Ndufs4-/- mice.
Effect of Trolox on the maximal activity of CII, CIII and CIV in broken skeletal 
muscle mitochondria – The maximal activity of the complexes II (Fig. 2d, open 
bars), III (Fig. 2e, open bars) and IV (Fig. 2f, open bars) was not significantly altered in 
vehicle-treated Ndufs4-/- mice and none of these activities was changed upon Trolox 
treatment (closed bars) in neither WT nor Ndufs4-/- mice.
Effect of Trolox on maximal citrate synthase activity in skeletal muscle 
mitochondria – Citrate synthase (CS) is widely used as an index for mitochondrial 
mass (Rodenburg 2011). Vehicle-treated Ndufs4-/- mice did not show any change in CS 
activity (Fig. 2g, open bars) and neither did Trolox treatment (closed bars).
Effect of Trolox on brain astrocyte activity – The decreased performance of 
Ndufs4-/- mice in the rope grip and rotarod test point to a loss of motor control. 
The cerebellum is the section of the brain that is essential for motor coordination 
and balance. Nerve injury leads to astrocyte activation and the expression of Glial 
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Fig. 2. Biochemical characterization of the effect of chronic Trolox treatment on the 
mitochondrial energy generating system of skeletal muscle. Vehicle-treated WT (n=5) 
and Ndufs4-/- (n=4) mice and Trolox-treated WT (n=6) and Ndufs4-/- (n=5) mice used in the 
behavioural experiments described in figure 1 were sacrificed between days 42 and 45 of 
life and a mitochondria-enriched 600g supernatant of a homogenate of hind limb muscle 
was prepared. Protein concentration was determined by the Lowry method as described 
before (Janssen, Trijbels et al. 2006). All values presented are expressed per mg of protein. 
(a) Pyruvate oxidation was measured in the presence of excess pyruvate, malate, PO
4
3- and 
creatine and in the absence or presence of ADP. (b) ATP production was measured in the 
presence of excess pyruvate, malate, ADP, PO
4
3- and creatine. (c-g) The maximal activity of 
individual RC complexes and citrate synthase was determined in the presence of an excess of 
complex-specific substrate after freeze-thawing of the 600 g supernatant. Statistical analysis 
was performed with the unpaired independent student’s t-test. *P<0.05, **P<0.01.
Page | 23 
 
 
 
Figure 2 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
ADP - stimulated pyruvate oxidation
WT KO
0
200
400
600
800
1000 Vehicle
Trolox
a
nm
ol/
h.m
g p
ro
t *
*
           ADP - stimulated ATP Production
WT KO
0
1000
2000
3000
4000 Vehicle
Trolox
b *
*
nm
ol/
h.m
g p
ro
t
CI activity
WT KO
0
20
40
60
80 Vehicle
Trolox
c *
**
p=0.054
mU
/ m
g p
ro
t
CII activity
WT KO
0
20
40
60
80 Vehicle
Trolox
d
mU
/ m
g p
ro
t
CIII activity
WT KO
0
100
200
300
400
500 Vehicle
Trolox
e
mU
/ m
g p
ro
t
CIV activity
WT KO
0
100
200
300
400
500 Vehicle
Trolox
f
mU
/ m
g p
ro
t
Citrate synthase
WT KO
0
100
200
300
400 Vehicle
Trolox
g
mU
/ m
g p
ro
t
164
7
E
v
a
lu
a
tio
n
 o
f th
E th
Er
a
pEu
tic
 po
tEn
tia
l o
f th
E a
n
tio
x
id
a
n
t tr
o
lo
x
 in
 a
 m
o
u
sE m
o
d
El...
Page | 24 
 
 
 
Figure 3 
a 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                
 
 
 
 
 
 
 
WT Veh 
M 
G 
W 
KO Veh 
M 
G 
W M 
G 
W 
KO Tro 
WT Tro 
M 
G 
W 
Fig. 3. Immunohistochemical evaluation of the effect of chronic Trolox treatment on brain 
astrocyte activity. Brains of the Trolox- and vehicle-treated mice used in the behavioural 
experiments described in figure 1 and sacrificed between days 42 and 45 of life as indicated in 
the legend to figure 2, were used for immunohistochemical evaluation of Glial Fibrillary Acidic 
Protein (GFAP) expression. (a) Sections of vehicle- and Trolox-treated WT and Ndufs4-/- mice 
showing GFAP positive cells in the granular layer (G) of the cerebellar cortex. (b) Area occupied 
by GFAP positive cells normalized to the total area of the granular layer analyzed. G, granular 
layer. W, white matter. M, molecular layer.
a
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Fibrillary Acidic Protein (GFAP) is widely regarded as a sensitive and reliable for marker 
for reactive astrocytes (Sofroniew and Vinters 2010). Immunostaining showed the 
presence of GFAP positive cells in the granular layer (G) of the cerebellar cortex 
(Fig. 3a). However, the area of the granular layer occupied by GFAP positive cells was 
not significantly altered in vehicle-treated Ndufs4-/- mice (Fig. 3b, open bars). Trolox 
treatment did not have any effect on the level of GFAP staining (closed bars).
Effect of Trolox on Purkinje cell number – In patients with neurodegenerative 
diseases, a loss of motor control has been correlated with a decrease in Purkinje cell 
numbers in the cerebellum (Mounsey and Teismann 2010). This urged us to quantify 
the number of Purkinje cells in the ganglionic layer of the cerebellar cortex. However, 
no differences were observed between the four experimental conditions (Fig. 4).
Effect of Trolox on retinal thickness – Neonatal Ndufs4 -/- mice were 
demonstrated to be blind (Kruse, Watt et al. 2008). Mouse eyes injected with 
rotenone showed a significant thinning of the retinal ganglion cell layer (Zhang, 
Jones et al. 2002). The retina consists of several layers (depicted in Fig. 5a). Layer 
thickness tended to be decreased for RGC (Fig. 5b; p=0.06), IPL (Fig. 5c; p=0.06) 
and INL (Fig. 5d; p=0.06) in vehicle-treated Ndufs4-/- mice as compared to vehicle-
treated WT mice (open bars). On the other hand, no change in layer thickness was 
observed for EPL (Fig. 5e, open bars) and ENL (Fig. 5f, open bars). The tendency for 
decreased thickness of RGC, IPL and INL was absent after chronic Trolox treatment 
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Fig. 4. Quantification of the effect of chronic Trolox treatment on Purkinje cell density. 
Brains of the Trolox- and vehicle-treated mice used in the behavioural experiments described 
in figure 1 and sacrificed between days 42 and 45 of life as indicated in the legend to figure 2, 
were used for evaluation of the Purkinje cell density in the Purkinje cell layer bordering the 
granular layer of the cerebellar cortex (see, Fig. 3a). The number of Purkinje cells is expressed 
per µm of Purkinje cell layer. 
166
7
E
v
a
lu
a
tio
n
 o
f th
E th
Er
a
pEu
tic
 po
tEn
tia
l o
f th
E a
n
tio
x
id
a
n
t tr
o
lo
x
 in
 a
 m
o
u
sE m
o
d
El...
(Figs. 5b-d, closed bars). This effect of Trolox appeared to be due to a decrease 
in WT mice rather than an increase in Ndufs4-/- mice (p values of 0.12, 0.052 and 
0.082 versus 0.76, 0.17 and 0.35 for its effect on WT and Ndufs4-/- RGC, IPL and 
INL, respectively). A significant difference in layer thickness was observed for EPL 
after chronic Trolox treatment (Fig. 5e, closed bars; p=0.002). Again, this effect of 
Trolox was mostly contributed by a decrease in WT mice (p=0.12) rather than an 
increase in Ndufs4-/- mice (p=0.61). Trolox treatment did not significantly alter the 
thickness of ENL (Fig. 5f, closed bars). 
Effect of Trolox on retinal astrocyte and Müller glia cell activity – Immunostaining 
revealed the presence of Glial Fibrillary Acidic Protein (GFAP)-positive cells and their 
processes in the retina (Fig. 6a). The area stained for GFAP was significantly increased 
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Fig. 5. Histochemical analysis of the effect of Trolox on the thickness of individual retinal 
cell layers. Eyes of the Trolox- and vehicle-treated mice used in the behavioural experiments 
described in figure 1 and sacrificed between days 42 and 45 of life as indicated in the legend to 
figure 2, were used for quantification of the thickness of the retinal layers after Hematoxylin 
and Eosin staining. (a) Representative images of the four experimental conditions showing 
the Retinal Ganglion Cell (RGC) layer, Internal Plexiform Layer IPL), Internal Nuclear Layer 
(INL), External Plexiform Layer (EPL) and External Nuclear Layer (ENL). (b-f) Thickness of 
the indicated layer in µm. Statistical analysis was performed with the unpaired independent 
student’s t-test. **P<0.01.
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d
in RGC+IPL (Fig. 6b; p=0.015) but not in INL (Fig. 6c), EPL (Fig. 6d) and ENL (Fig. 6e) of 
vehicle-treated Ndufs4-/- mice as compared to vehicle-treated WT mice (open bars). 
In neither WT nor Ndufs4-/- mice Trolox treatment had a significant effect on the area 
stained for GFAP in any of these layers.   
Effect of Trolox on the number of neuronal nuclei (NeuN) positive cells in the 
Retinal Ganglion Cell layer – Quantitative analysis of the thickness of the RGC 
revealed a tendency to decrease in Ndufs4-/- mice (fig. 5b, open bars; p=0.06). 
Immunostaining for NeuN is widely used to quantify the number of neuronal cells 
(Mullen, Buck et al. 1992, Xu, Huang et al. 2014). Figure 7a shows the distribution of 
NeuN positive cells in the retina of vehicle- and Trolox-treated WT and Ndufs4-/- mice. 
Quantitative analysis showed that the number of NeuN positive cells was significantly 
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Fig. 6. Immunohistochemical evaluation of the effect of Trolox on retinal astrocyte and 
Müller glia cell activity. Eyes of the Trolox- and vehicle-treated mice used in the behavioural 
experiments described in figure 1 and sacrificed between days 42 and 45 of life as indicated in 
the legend to figure 2, were used for immunohistochemical evaluation of Glial Fibrillary Acidic 
Protein (GFAP) expression. (a) Representative images of the four experimental conditions 
showing GFAP staining in the various retinal layers. (b-e) Area stained with GFAP normalized 
to the total area of the respective layer. Abbreviations are given in the legend to figure 5. 
Statistical analysis was performed with the unpaired independent student’s t-test. *P<0.05.
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Fig. 7. Immunohistochemical evaluation of the effect of Trolox on the number of neuronal 
cells in the Retinal Ganglion Cell layer. Eyes of the Trolox- and vehicle-treated mice used 
in the behavioural experiments described in figure 1 and sacrificed between days 42 and 45 
of life as indicated in the legend to figure 2, were used for immunohistochemical evaluation 
of NeuN expression. (a) Representative images of the four experimental conditions showing 
NeuN staining in the various retinal layers. (b) Number of NeuN positive cells in the RGC layer. 
Statistical analysis was performed with the unpaired independent student’s t-test. *P<0.05.
decreased in the RGC of vehicle-treated Ndufs4-/- mice (Fig. 7b, open bars; p=0.049). 
This decrease was not observed in Trolox-treated in Ndufs4-/- mice (closed bars). 
Trolox-treatment did not affect the number of NeuN positive cells in WT mice and 
significantly increased this number in Ndufs4-/- mice (p=0.036).
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Discussion
The present study was designed to investigate a potential beneficial effect of Trolox 
in a mouse model of human isolated complex I deficiency. Trolox is a water-soluble 
derivative of vitamin E with potent reactive oxygen species (ROS) scavenger activity 
(Koopman, Nijtmans et al. 2010). Trolox readily permeates the cell membrane and 
when added to primary skin fibroblasts derived from patients with isolated complex I 
deficiency, which typically show elevated intracellular ROS levels (Verkaart, Koopman 
et al. 2007), it was demonstrated to dramatically reduce these levels in an acute fashion 
(Koopman, Verkaart et al. 2008). Extensive studies have shown that Trolox can (partly) 
normalize a vast number of aberrant cellular processes in these complex I deficient 
patient fibroblasts, including the less negative mitochondrial membrane potential, 
the reduced endoplasmic reticulum Ca2+ content, and the reduced hormone-
stimulated increases in cytosolic and mitochondrial matrix Ca2+ concentration and 
mitochondrial ATP production (Willems, Valsecchi et al. 2008, Distelmaier, Visch et al. 
2009). Patient-derived skin fibroblasts express a reduced amount of fully assembled, 
catalytically active complex I and the ability of Trolox to increase this amount was 
demonstrated (Koopman, Verkaart et al. 2008). Trolox can also reduce the degree of 
lipid peroxidation, induce a less oxidized mitochondrial thiol redox state and increase 
glutathione- and mitofusin-dependent mitochondrial filamentation (Distelmaier, 
Valsecchi et al. 2012). Most importantly, the latter study showed that Trolox evoked an 
increase in cellular oxygen consumption which indicates an increased performance 
of the mitochondrial oxidative phosphorylation system.
The systemic Ndufs4-/- mouse shows many of the characteristics of human isolated 
complex I deficiency (Kruse, Watt et al. 2008). Analysis of the progression of the clinical 
phenotype revealed a first lower body weight as compared to the lightest WT littermate 
at day 8 of life, a first smaller body length as compared to the shortest WT littermate 
at day 15 of life, a first sign of hair loss (alopecia) at day 19 of life, a first sign of (partially) 
closed eyes at day 25 of life, a first sign of hypoactivity at day 29 of life, a first sign of 
ataxia at day 34 of life, a first loss of body weight at day 35 of life and severe ataxia at 
day 38 of life. Here, it should be noted that mice engineered to lack Ndufs4 selectively 
in neurons and glia display the same clinical phenotype, indicating a crucial role of the 
brain in the pathogenesis of isolated complex I deficiency (Quintana, Kruse et al. 2010). 
Skeletal muscle - To investigate a potential beneficial effect of Trolox, male WT 
and Ndufs4-/- mice were injected intraperitoneally twice per day with Trolox 
(400 mg/2 ml/kg body weight) or vehicle (1 M NaHCO
3
; 2 ml/kg body weight) starting 
at week 3 of life. Rope grip and rotarod performance were tested at weeks 3, 5 and 
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6 of life to evaluate the effect of Trolox on muscle endurance and motor coordination 
(Breuer, Willems et al. 2012). A first important observation in the present study is 
that chronic Trolox treatment starting at week 3 of life slowed down the progressive 
decline in rope grip and rotarod performance in Ndufs4-/- mice. However, Trolox 
did not improve the decrease in the maximal rate of ATP production, measured in 
a mitochondria-enriched preparation from hind limb muscle of Ndufs4-/- mice at 
week 6 (between days 42 and 45) of life, shown to parallel the decline in rope grip and 
rotarod performance. In a previous study, we demonstrated that the maximal rate 
of mitochondrial ATP production was not yet decreased in Ndufs4-/- mice sacrificed 
between 31 and 34 days of life (Chapter 2). This effect was found to be accompanied by 
an increase in maximal activity of components of the mitochondrial ATP generating 
system, including the enzyme citrate synthase and the OXPHOS complexes II, III 
and IV. Although caution must be exerted when interpreting changes in OXPHOS 
protein expression (Tronstad, Nooteboom et al. 2014), the idea that OXPHOS 
dysfunction triggers an adaptive increase in mitochondrial mass is supported by the 
observation that at 30 days of life, Ndufs4-/- mice displayed increased mitochondrial 
numbers in the sub sarcolemma of the soleus, normal rates of phosphocreatine 
recovery in the ischemic hind limb reperfusion paradigm and unaltered total muscle 
ATP and phosphocreatine levels (Kruse, Watt et al. 2008). The present study shows 
that the maximal activity of the above-mentioned enzymes is no longer increased 
at days 42-45 of life. Together, these results suggest that initially a compensatory 
mechanism is able to maintain the maximal rate of mitochondrial ATP production 
but that after 31-34 days of life this mechanism starts to fail. Importantly, our previous 
work indicates that this putative compensatory mechanism is absent in brain.
The present finding that in vivo application of Trolox does not improve the maximal 
rate of mitochondrial ATP production in a mitochondria-enriched preparation from 
hind limb muscle of WT and Ndufs4-/- mice is at variance with previous results obtained 
with primary skin fibroblasts derived from healthy volunteers (Distelmaier, Valsecchi 
et al. 2012) and patients with isolated complex I deficiency (Koopman, Verkaart et al. 
2008, Distelmaier, Visch et al. 2009). The latter studies show a wide range of beneficial 
effects of Trolox, including the upregulation of components of the OXPHOS system 
and a consequent increase in the rate of cellular oxygen consumption. Given the 
significant effect of Trolox on rope grip performance, we conclude that the protocol 
of in vivo application of Trolox was adequate but that the translation of experimental 
results from single cells to living animals is far from trivial.       
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Cerebellum - Impairment of motor coordination points to the cerebellum. Although 
GFAP positive cells were present in the granular layer (G) of the cerebellar cortex, 
their number was not significantly altered in Ndufs4-/- mice. Measurements in skin 
fibroblasts from complex I deficient patients invariably show increased rates of 
ROS production (Verkaart, Koopman et al. 2007, Koopman, Verkaart et al. 2008). 
Depending on the type of ROS, the levels reached and the cellular compartment in 
which these levels are reached, a wide range of cellular processes can be influenced 
either by favorable or unfavorable redox modifications (Koopman, Nijtmans et al. 
2010). A first indication of the existence of redox modifications in the brain of Ndufs4-/- 
mice came from a study showing increased protein carbonylation in the olfactory 
bulb (OB) (Quintana, Kruse et al. 2010). It was suggested that the increase in carbonyl 
groups, which is a consequence of protein oxidation, was due to glial activation. 
Recent experiments, performed with Drosophila mitochondrial mutants, provide 
evidence that neurodegeneration is caused by a sequence of events starting with 
increased neuronal ROS levels and ROS-induced inhibition of c-Jun-N-terminal Kinase 
(JNK) phosphatase increasing the activity of the JNK/Sterol Regulatory Element 
Binding Protein (SREBP) to stimulate the acetyl-CoA carboxylase (ACC)-catalyzed 
synthesis of neuronal lipids synthesis and followed by glial lipid accumulation and, 
finally, enhanced glial lipid peroxidation (Liu, Zhang et al. 2015). The process of glial 
lipid droplet accumulation was inhibited by overexpression of human copper-zinc 
superoxide dismutase and administration of the antioxidant N-acetyl cysteine amide 
(AD4), stressing the prerequisite role of ROS. Lipid droplet accumulation was also 
reported in astroglia and microglia of Ndufs4-/- mice (Liu, Zhang et al. 2015). Maximal 
accumulation occurred at day 23 of life, when spongiform lesions (Quintana, Kruse et 
al. 2010, Quintana, Zanella et al. 2012) were not yet observed. Lipid droplet abundance 
was high in the OB and vestibular nuclei (VN) and mild in other brain sections, 
including the cerebellum. At day 35 of life, lipid droplet accumulation was dramatically 
decreased in VN, but not OB, whereas spongiform lesions were clearly visible in 
both brain sections. An increase in reactive astrocytes in the granular layer (G) of the 
cerebellum is widely regarded as an evident pathological sign in neurodegeneration. 
Indeed, evidence was provided that reactive glia causes initial activation of apoptotic 
pathways followed by a switch to necrosis (Quintana, Kruse et al. 2010). This switch is 
compatible with our finding that the maximal rate of mitochondrial ATP production 
is significantly decreased in a mitochondria-enriched fraction from whole brain of 
Ndufs4-/- mice sacrificed at days 31-34 of life (Manjeri, Rodenburg et al. 2016). This, in 
turn, is compatible with the observed aberrant morphology of neuronal mitochondria 
in these brain regions (Quintana, Kruse et al. 2010). Here we show, however, that 
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chronic Trolox treatment did not influence the number of reactive astrocytes in the 
granular layer (G) of the cerebellum. In agreement with the lack of effect of Trolox 
on glial activation, visual inspection revealed that Trolox treatment did not prevent 
the formation of spongiform lesions in Ndufs4-/- mice (data not shown). Similar to 
Trolox, N-acetyl cysteine amide, a blood-brain-barrier penetrating antioxidant, 
improved rotarod performance when injected intraperitoneally (Liu, Zhang et al. 
2015). In this case, however, the antioxidant (150 mg/kg) was applied daily starting 
from day 21 of life until day 28 of life and a significant increase in rotarod performance 
was observed at day 30 of life followed by a progressive decline. The application of 
Trolox (400 mg/kg) also started in week 3 of life but was performed twice per day. 
The first rotarod test was performed at day 35 of life and only a slight tendency for 
improvement was observed. However, a stronger tendency for improvement was 
observed at week 6 of life (p=0.07), whereas a significant effect was observed in the 
rope grip test. Together, these data indicate that antioxidant treatment can improve 
muscle endurance and motor coordination in a mouse model of human isolated 
complex I deficiency. Although the present study shows the presence of reactive 
astrocytes in the granular layer (G) of the cerebellum of WT mice, their number was 
neither increased in Ndufs4-/- mice nor reduced by Trolox treatment. 
Retina - A second important observation in this study is that the density of NeuN 
positive cells was significantly decreased in the Retinal Ganglion Cell (RGC) layer of 
Ndufs4-/- mice and that chronic Trolox treatment fully normalized this density. The 
loss of NeuN positive cells was paralleled by an increase in GFAP staining in the RGC 
+ Internal Plexiform Layer (IPL). Retinal ganglion cells relay information from the 
photoreceptor cells to the brain and their dysfunction has been implicated in Leber 
hereditary optic neuropathy (LHON), a maternally inherited mitochondrial disease 
characterized by severe visual loss (Guy, Feuer et al. 2014). Recent experiments with 
Ndufs4-/- mice revealed a significant decrease in retinal ganglion cell function at day 
32 of life and a substantial loss of these cells at day 42 of life (Yu, Song et al. 2015). The 
same study reported a marked increase in retinal transcript levels of genes of the 
innate immune system and inflammatory response pathway between days 22 and 
33 of life. The underlying mechanism was proposed to be a ‘non-self’ response to 
misfolded complex I. Alternatively, recent work provides evidence that the liver of 
systemic Ndufs4-/- mice oxidizes glucose rather than fatty acids resulting in increased 
circulatory levels of fatty acids and lactate and that these metabolites interact with 
toll-like receptors 2 and 4 on macrophages to further increase intracellular ROS levels 
finally resulting in a state of systemic inflammation (Jin, Wei et al. 2014). Another study 
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showed that inhibition of the mechanistic target of rapamycin (mTOR) pathway by 
rapamycin reduced neuroinflammation and prevented spongiform brain lesions, 
suggesting that this pathway is activated in systemic Ndufs4-/- mice (Johnson, Yanos 
et al. 2013). In this case, it was proposed that rapamycin induced a shift from glucose 
to amino acid oxidation thus reducing the accumulation of glycolytic intermediates. 
Finally, rapamycin was demonstrated to prevent the increase in retinal transcripts of 
innate immune system and inflammatory response pathway genes (Yu, Song et al. 
2015). These findings are compatible with the observed increase in GFAP staining in 
RGC + IPL (this study) and other brain sections of late-stage Ndufs4-/- mice (Quintana, 
Kruse et al. 2010), indicating astroglial activation as a next step in the process of 
neurodegeneration. The present finding that chronic Trolox treatment prevents the 
loss of retinal ganglion cells without reducing the increased level of GFAP staining is 
surprising but leaves the intriguing question of whether this treatment can prevent 
the development of blindness in these complex I deficient mice. Electroretinography 
measurements (Kruse, Watt et al. 2008, Yu, Song et al. 2015) are likely to provide an 
answer to this question.
Using the Ndufs4-/- mouse, we here show that the water-soluble vitamin E analog, 
Trolox, may have therapeutic potential in human CI deficiency. Only recently, this 
conclusion was corroborated by a study showing that daily intraperitoneal injection 
of the blood-brain-barrier penetrating antioxidant, N-acetyl cysteine amide (AD4), 
between PD21 and PD28, significantly improved the rotarod performance of Ndufs4-/- 
mice (Kruse, Watt et al. 2008). Based on the data presented in the present paper, 
a number of Trolox variants was developed and tested in primary fibroblasts from 
patients with isolated CI deficiency (Blanchet, Smeitink et al. 2015).The most promising 
of these variants was selected for further therapy development. 
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Patients with dysfunction of the OXPHOS system may present at any age with a 
wide variety of signs and symptoms affecting any organ of the body (Chinnery 
1993).The genetic basis of these diseases is complex. Assembly and maintenance of 
a fully functional OXPHOS system is under dual genetic control of the nDNA and the 
mtDNA and any mutation in any gene that affects the functionality of the OXPHOS 
system might lead to OXPHOS dysfunction-related clinical symptoms (Koopman, 
Willems et al. 2012, Koopman, Distelmaier et al. 2013). Mutations in nuclear genes 
are inherited in a Mendelian manner, whereas mutations in mitochondrial genes 
are inherited maternally. Organs with high energy demand are especially afflicted, 
predominantly the brain (Kirby and Thorburn 2008, Tucker, Compton et al. 2010, 
Schapira 2012). Neurons are gradually destroyed, resulting in a progressive loss 
of nervous system structure and function (Przedborski, Vila et al. 2003, Deuschl 
and Elble 2009). The pathological picture in neurodegenerative disorders is 
heterogeneous, affecting unique areas of the nervous system. In the brain, Purkinje 
cells and neurons of the dentate nuclei of the cerebellum as well as neurons of the 
inferior olivary nuclei of the medulla are considered to be most energy demanding, 
and thus most susceptible to damage (Breuer, Koopman et al. 2013). Symptoms 
range from acute and rapid in progression to subtle and chronic (Koopman, 
Distelmaier et al. 2013). The critical function of the neuronal OXPHOS system in 
maintaining bioenergetic needs is illustrated by the fact that OXPHOS dysfunction 
leads to defects in growth and trafficking, as well as to apoptosis and neuronal 
death (Fukui and Moraes 2008). This, in turn, can lead to microglial activation, 
a pathophysiological consequence that can trigger catastrophic events such as 
further oxidative and nitrosative stress, ultimately leading to further neuronal 
damage and death (Di Filippo, Chiasserini et al. 2010). Supplementary Table 1 in 
Koopman, Distelmaier et al. lists the many genes in the nDNA and mtDNA that have 
been demonstrated to carry mutations resulting in dysfunction of the OXPHOS 
system associated with neurodegeneration (Koopman, Distelmaier et al. 2013). 
The products of these genes include (i) structural OXPHOS subunits, (ii) OXPHOS 
assembly factors, (iii) Fe-S biogenesis enzymes, (iv) enzymes involved in the synthesis 
of CoQ10 and cyt-c, (v) mt-rRNAs, (vi) mt-tRNAs, (vii) mtDNA repair enzymes, (viii) 
mtDNA replication, transcription and translation factors, (ix) enzymes involved 
in the maintenance of the mitochondrial dNTP pool, (x) mitochondrial ribosomal 
proteins, (xi) mt-tRNA synthetases and (xii) nucleoid-associated proteins. However, 
this list is far from complete because proper function of the OXPHOS system will 
also be hampered by mutations in nuclear genes encoding the mitochondrial 
phosphate carrier, the adenine nucleotide translocator, the mitochondrial protein 
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import system, the mitochondrial quality control system, the integrity of the inner 
mitochondrial membrane, etc. 
*   *   *
The aim of this thesis was to obtain a better understanding of the pathophysiological 
consequences of isolated mitochondrial CI deficiency using the WB Ndufs4-/- mouse 
model (Kruse, Watt et al. 2008) and to contribute to a relevant therapeutic strategy to 
alleviate and/or ameliorate this disease. To this end, we characterized the phenotypic 
manifestations of the Ndufs4 deletion by monitoring signs and symptoms from 
postnatal day 0 until their predefined humane endpoint (Chapter 1). In agreement 
with other studies, we found that Ndufs4-/- mice replicated several clinical milestones 
observed in children with isolated CI deficiency including hypotonia, progressive 
muscle weakness, epileptic episodes (seizures) and ataxia (de Haas, Russel et al. 2016). 
Based on these findings it was concluded that the WB Ndufs4-/- mouse could be a 
relevant model to evaluate therapeutic strategies intended for translation to man.
*   *   *
Given the dramatic phenotypic of the WB Ndufs4-/- mouse, we were intrigued by the 
observation that these mice displayed no deficit in maximal rate of ATP production 
when assessed in the ischemic hind limb paradigm in vivo (Kruse, Watt et al. 2008). 
Similarly, in vitro analysis of the maximal rate of mitochondrial ATP production in 
a mitochondria-enriched fraction from heart tissue of a conditional heart-specific 
Ndufs4-/- mouse showed only a tendency to decrease when determined in the 
presence of either glutamate and malate or pyruvate and malate and when expressed 
per unit of mitochondrial mass after normalization to the maximal activity of citrate 
synthase (Sterky, Hoffman et al. 2012). This result shows that, despite the virtual 
absence of CI activity, there is only a small, if any, decrease in maximal mitochondrial 
ATP production capacity per unit of mitochondrial mass. These observations urged 
us to measure the maximal rate of mitochondrial ATP production in a mitochondria-
enriched fraction from three tissues of high energy demand, namely skeletal muscle, 
heart and brain and compare the values obtained between WB Ndufs4-/- mice and their 
wild type littermates (Chapter 2). We show that the maximal rate of mitochondrial 
ATP production was significantly decreased in skeletal muscle and brain and close to 
significantly in heart by 51%, 25% and 32%, respectively, in WB Ndufs4-/- mice when 
expressed per unit of mitochondrial mass after normalization to the maximal activity 
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of citrate synthase. The maximal activity of CI, expressed per unit of mitochondrial 
mass, was much more dramatically reduced in all three tissues. These results are in 
agreement with those of Sterky and Hoffman et al. (Sterky, Hoffman et al. 2012) in 
that all three tissues, despite the virtual absence of CI activity, show a decreased 
though still substantial mitochondrial ATP production capacity when expressed per 
unit of mitochondrial mass. Most importantly, in contrast to brain, skeletal muscle 
and heart showed no differences in maximal rate of mitochondrial ATP production 
when expressed per mg of protein. This indicates that the total mitochondrial ATP 
production capacity per unit of tissue mass was decreased in brain but not in the 
latter two organs. Skeletal muscle and heart, but not brain, showed a significant 
increase in maximal citrate synthase activity (values of 72%; p=0.017 and 49%; 
p=0.002), respectively, indicating that these two tissues, in sharp contrast to brain, 
had been able to perform an adaptive increase in mitochondrial mass to compensate 
for the decrease in mitochondrial ATP production capacity per unit of mitochondrial 
mass. In agreement with this idea, we observed that, when expressed per unit of 
tissue mass, the maximal activity of CII was significantly increased by 56% (p=0.033) 
in skeletal muscle with a tendency to increase in heart, that of CIII showed a tendency 
to increase by 45% (p=0.069) in skeletal muscle and by 11% (p=0.071) in heart and 
that of CIV was significantly increased in both skeletal muscle by 70% (p=0.024) and 
in heart by 51% (p=0.005), whereas, in sharp contrast, for none of the complexes 
the maximal activity was altered in brain. From these results it was concluded that 
the brain, which lacks the adaptive response, is most probably the most vulnerable 
tissue in WB complex I deficiency involving a disease causing mutation in the Ndufs4 
gene. This conclusion is substantiated by the increased degeneration observed in 
olfactory bulb, brainstem and cerebellum of WB Ndufs4-/- mice and conditional brain-
specific Ndufs4-/- mice display the same clinical phenotype (Quintana, Kruse et al. 
2010, Kayser, Sedensky et al. 2016) Together, these results strongly favor the brain as 
primary target for therapeutic intervention (Koopman, Beyrath et al. 2016).
*   *   *
In Chapter 3 we employed an in silico strategy to try and understand the mechanism 
by which Ndufs4-/- skeletal muscle mitochondria, despite an ~80% decrease in 
maximal CI activity when expressed per unit of tissue mass, are still able to produce 
ATP from CI-specific substrates (pyruvate and malate) at a maximal rate that is similar 
to that obtained with wild type skeletal muscle mitochondria when expressed per 
unit of tissue mass (see, Chapter 2). To this end, we adapted a mathematical model 
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of mitochondrial metabolism that was validated for skeletal muscle mitochondria by 
Beard and co-workers (Wu, Yang et al. 2007) to match our experimental conditions. 
Thus, mitochondria were considered as an input–output system, converting 
pyruvate (input) into ATP (output) via the integrated action of transporters, pyruvate 
dehydrogenase, citric acid cycle enzymes and the OXPHOS system. By including the 
percent change in maximal activity of the complexes I, II, III and IV expressed per 
unit of tissue mass, the wild type skeletal muscle-specific model was transformed 
into an Ndufs4-/- skeletal muscle-specific model, which allowed calculating the 
maximal rates of pyruvate oxidation and ATP production per unit of tissue mass. 
Our calculations predicted that the experimentally measured changes in maximal 
activity of the complexes I, II, III and IV expressed per unit of tissue mass resulted in 
control maximal rates of mitochondrial pyruvate oxidation and ATP production in 
Ndufs4-/- skeletal muscle when expressed per unit of tissue mass. This prediction was 
in complete agreement with our experimental results. In silico analysis furthermore 
predicted that CI deficiency alters the concentration of intermediate metabolites, 
modestly increases the mitochondrial NADH/NAD+ ratio and stimulates the lower 
half of the citric acid cycle, including CII. Several of these predicted changes were 
previously reported in experimental models of CI deficiency. Interestingly, our model 
predictions suggested that CI deficiency only has major metabolic consequences 
when, in adapted skeletal muscle tissue, the maximal activity of CI decreases below 
90% of normal levels. This result is compatible with the idea of a biochemical 
threshold effect.
*   *   *
Children with mitochondrial disorders involving the energy generating system are 
frequently anaesthetized for a wide range of operations. However, these disorders 
may alter the response to anaesthesia. It has been shown that the volatile anaesthetic 
isoflurane inhibits the activity of CI (Kayser, Suthammarak et al. 2011). Moreover, CI 
deficient C. Elegans have been shown to be hypersensitive to volatile anaesthetics 
(Kayser, Suthammarak et al. 2011). Together with reports that WB Ndufs4-/- mice 
develop progressive respiratory dysfunction i.e. bradypnea and apnea, leading to 
premature death (Quintana, Zanella et al. 2012), these findings urged us to examine 
the sensitivity of these mice to isoflurane. Chapter 4 shows that WB Ndufs4-/- mice 
displayed a progressive increase with age of both isoflurane sensitivity and respiratory 
depression. In a recent study, Zimin and co-workers knocked out the Ndufs4 gene in 
GABAergic neurons (GABA-specific knock-out mice), VGLUT2-positive glutamatergic 
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neurons (VGLUT2-specific knock-out mice) and cholinergic neurons (CHAT-specific 
knock-out mice) and observed that VGLUT2-specific knock-out mice and WB Ndufs4-/- 
mice were equally sensitive to isoflurane and halothane, whereas GABA-specific 
knock-out mice and CHAT-specific knock-out mice were no longer hypersensitive 
to these anaesthetics, indicating that excitatory glutamatergic transmission is a major 
contributor to volatile anaesthetic hypersensitivity in Ndufs4-/- mice (Zimin, Woods 
et al. 2016).
*   *   *
Since the pathology of CI deficiency appears to occur mainly in the central nervous 
system (Distelmaier, Koopman et al. 2009), we conducted a specific investigation 
towards the effects of isoflurane anaesthesia on brain mitochondrial function. In 
Chapter 2 we reported that the mitochondrial ATP production capacity per unit of 
tissue mass is significantly decreased by 26% (p=0.028) in WB Ndufs4-/- brain. Based 
on this finding, it was hypothesized that a decrease in mitochondrial ATP production 
capacity might underly the observed hypersensitivity of WB Ndufs4-/- mice to volatile 
anaesthetics such as isoflurane and halothane. Surprisingly, the data presented in 
Chapter 5 demonstrate that isoflurane anaesthesia significantly increased the 
maximal rate of mitochondrial ATP production by 52% (p<0.05) and 69% (p<0.01) 
when expressed per unit of tissue mass in a mitochondria-enriched preparation 
of wild type and WB Ndufs4-/- brain, respectively. Remarkably, in agreement with 
literature findings, isoflurane anaesthesia decreased the maximal activity of CI by 
30% (p<0.001) in wild type brain. This result is in agreement with our conclusion 
in Chapter 3 that CI activity can be lowered to a tissue-specific threshold before 
this lowering starts to affect the mitochondrial ATP production capacity. In sharp 
contrast, isoflurane anaesthetics increased the activity of CII by 37 % (p<0.001) and 
50 % (p<0.001) and that of CIII by 37 % (p<0.001) and 40 % (p<0.001) in wild type and 
WB Ndufs4-/- brain, respectively, whereas it tended to increase that of CIV in both 
wild type and WB Ndufs4-/- brain. Together, these findings indicate that isoflurane 
anaesthesia interferes positively rather than negatively with the ability of CI deficient 
mice brain mitochondria to convert their main substrate pyruvate into ATP. It 
remains to be established whether this isoflurane anaesthesia-induced increase in 
mitochondrial ATP production capacity might exert unwanted effects in brain cells 
relevant for the observed respiratory depression. A major limitation of our study 
is that we used a mitochondria-enriched fraction from whole brain, whereas many 
studies report regional differences in susceptibility to mitochondrial dysfunction 
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within the central nervous system (Leong, Komen et al. 2012, Pinto, Pickrell et al. 
2012, Quintana, Zanella et al. 2012). Kayser and co-workers recently observed that 
the respiratory capacity of synaptosomes from degeneration prone regions of the 
brain, namely olfactory bulb, brainstem and cerebellum was significantly reduced 
in Ndufs4-/- mice (Kayser, Sedensky et al. 2016). Crucially, this decrease was already 
observed before the onset of the neurological symptoms. Importantly, these 
authors failed to show any reduction in respiratory capacity of synaptosomes from 
degeneration resistant parts of the brain. These results corroborate previous findings 
of region specific brain damage in Ndufs4-/- mice (Quintana, Kruse et al. 2010) and 
indicate that local insufficiencies in ATP production capacity of nerve terminals may 
underlie the occurrence of specific brain areas where neurodegeneration takes place. 
It remains to be established whether volatile anaesthetics act on these CI deficiency 
susceptible brain regions and/or on other regions in the Ndufs4-/- brain.
*   *   *
In the same study, Kayser and co-workers addressed the presence of 4-hydroxy-2-
nonenal (HNE)-modified proteins as evidence for increased formation of reactive 
oxygen species (ROS) (Kayser, Sedensky et al. 2016). The authors observed an 
increased expression of HNE-modified proteins in CI deficiency susceptible brain 
areas and not in CI deficiency resistant brain areas. However, this observation was 
reached in both wild type and Ndufs4-/- mice, suggesting that ROS-induced HNE-
modification does not play a role in region specific neurodegeneration. In sharp 
contrast, Quintana and co-workers reported a significant increase in protein 
carbonylation in the olfactory bulb of the conditional brain specific Ndufs4-/- 
mouse, suggesting a role for ROS-induced protein carbonylation in region specific 
neurodegeneration (Quintana, Kruse et al. 2010). In Chapter 6, we discuss those 
neurons which because of their presumed susceptibility to oxidative damage 
contribute most to the neurological phenotype in the Ndufs4-/- mouse models. 
Neurons have very high energy demands and it is calculated that the brain, which only 
accounts for ~ 2% of the total body mass, is responsible for 20% of the total oxygen 
consumption by the body. In the brain, the vast majority of energy consumption 
takes place in the neurons, whereas astrocytes are responsible for only 5-15% of the 
total energy requirement of the brain (Attwell and Laughlin 2001). This immense 
energy demand of neurons results from the fact that they are highly differentiated 
cells that require large amounts of ATP to maintain the ionic gradients across the 
cell membrane that are necessary for proper neurotransmission (Kann and Kovacs 
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2007). Neurons completely depend on the OXPHOS system for their ATP needs and, 
importantly, a switch to glycolysis, when OXPHOS becomes limited, will not generate 
sufficient ATP (Knott, Perkins et al. 2008). Neurons are long lived, which is important 
because their synaptic contacts carry essential information for the organism. These 
two properties of neurons may pose a serious problem, as mitochondrial oxidative 
ATP production is inevitably associated with the production of toxic oxygen radicals 
at CI and CIII (Brand 2010, Forkink, Smeitink et al. 2010, Koopman, Nijtmans et al. 
2010, Distelmaier, Valsecchi et al. 2012). It is for this reason that neurons are thought 
to not oxidize fatty acids because for every Acetyl-CoA that is generated during 
fatty acid breakdown, a step catalysed by Acyl-CoA dehydrogenase, one FADH
2
 
and one NADH is produced. This results in a by far larger increase in the amount of 
FADH
2
 than during the oxidation of glucose and it is this FADH
2
 that is oxidized by the 
electron transfer flavoprotein: ubiquinone oxidoreductase (ETF:QO) thus competing 
with CI for the reduction of ubiquinone to ubiquinol (Watmough and Frerman 2010, 
Speijer 2011). As a consequence, NADH will build up increasing the probability of 
increased ROS production by CI itself and/or mitochondrial NADH hydrogenases 
such as α-glycerophosphate dehydrogenase located on the outer surface of the 
mitochondrial inner membrane and α-ketoglutarate dehydrogenase (Adam-Vizi and 
Tretter 2013). Thus neurons do not use beta oxidation (Yang, He et al. 1987, Speijer 
2011, Schonfeld and Reiser 2013) but, instead, rely on glucose and ketone bodies for 
their energy supply, even though fatty acids have about twice the energy content of 
glucose. Despite the banishment of fatty acids from the menu, neurons still produce 
ROS during mitochondrial ATP production from glucose and ketone bodies. It is 
speculated that this lifelong ROS production, despite the presence of numerous 
antioxidant systems, gradually damages neurons resulting in a progressive loss of 
neuron function. If this process is somehow accelerated it may contribute to brain 
diseases in the elderly such as Alzheimer’s disease, Amyotrophic Lateral Sclerosis 
(ALS) and Parkinson’s disease. 
*   *   *
Having characterized the phenotypic consequences of the WB Ndufs4 deletion 
in Chapter 1 and biochemical consequences in organs of high energy demand in 
Chapter 2, we investigated the in vivo therapeutic potential of the water soluble 
Vitamin E analogue Trolox in the WB Ndufs4-/- mouse. Trolox was chosen because 
thorough in vitro testing had shown that many of the cell biological aberrations 
observed in primary skin fibroblasts from patients with isolated CI deficiency could 
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be reversed or partially reversed with this antioxidant (see Chapter 1). In Chapter 7 
we show that twice daily intraperitoneal injection of Trolox starting from week 3 of 
life retarded the progressive decline in muscle endurance and motor coordination in 
WB Ndufs4-/- mice as demonstrated by improved rope grip and rotarod performance, 
reaching statistical significance (p<0.05) and close to statistical significance (p=0.07), 
respectively, at week 6 of life. Animals were sacrificed at week 6 of life and analysis 
of the maximal rate of mitochondrial ATP production per unit of tissue mass in a 
mitochondria-enriched fraction of hind limb muscle revealed a significant decrease 
in vehicle-treated WB Ndufs4-/- mice. In sharp contrast, the work presented in 
Chapter 2 showed the absence of any difference in maximal rate of mitochondrial ATP 
production per unit of tissue mass between WB Ndufs4-/- mice at days 31-34 of life and 
their wild type littermates. Analysis of the maximal citrate synthase activity revealed 
a significant increase in WB Ndufs4-/- mice at days 31-34 of life but not in WB Ndufs4-/- 
mice at week 6 of life, suggesting that the proposed adaptive increase in mitochondrial 
mass at days 31-34 of life is no longer present in end stage WB Ndufs4-/- mice. Analysis 
of a mitochondria-enriched fraction of hind limb muscle from Trolox-treated WB 
Ndufs4-/- mice revealed a close to significant (p=0.054) increase in maximal CI activity. 
However, this tentative increase in CI activity was not accompanied by an increase in 
maximal rate of mitochondrial ATP production. These findings suggested that Trolox 
might not exert its effect at the level of the skeletal muscle but rather at the level 
of the brain. The area of the granular layer of the cerebral cortex occupied by GFAP 
positive cells did not differ between vehicle-treated wild type and Ndufs4-/- mice 
and was not influenced by Trolox-treatment. The same observation was reached for 
the number of Purkinje cells in the cerebellum. Regarding the retina, layer thickness 
tended to be decreased for RGC (p=0.06), IPL (p=0.06) and INL (p=0.06) in vehicle-
treated Ndufs4-/- mice. The same layers showed no tendency for decreased thickness 
between Trolox-treated Ndufs4-/- and wild type mice. Trolox-treated Ndufs4-/- mice 
showed a significant increase in EPL thickness as compared to Trolox-treated wild 
type mice. GFAP staining was increased in RGC+IPL of Ndufs4-/- mice and remained 
increased following Trolox treatment. Finally, Trolox-treatment fully restored the 
decrease in the number of NeuN positive cells observed in the RGC of vehicle-treated 
Ndufs4-/- mice. Taking into account the rapidly progressive, lethal phenotype of the 
Ndufs4-/- mice, the present finding that Trolox has some beneficial effect on neuro-
motor function and retinal integrity might warrant translation to the human situation. 
*   *   *
189
8
G
en
er
a
l su
m
m
a
ry
 a
n
d
 Fu
t
u
r
e per
spec
tiv
es
Using the Ndufs4-/- mouse, we here show that the water-soluble vitamin E analog, 
Trolox, may have therapeutic potential in human CI deficiency. Only recently, this 
conclusion was corroborated by a study showing that daily intraperitoneal injection 
of the blood-brain-barrier penetrating antioxidant, N-acetyl cysteine amide (AD4), 
between PD21 and PD28, significantly improved the rotarod performance of Ndufs4-/- 
mice (Kruse, Watt et al. 2008). Based on the data obtained in our cell biological 
studies, a number of Trolox variants was developed and tested in primary fibroblasts 
from patients with isolated CI deficiency (Blanchet, Smeitink et al. 2015). The most 
promising of these variants was selected for further therapy development. Together 
with the date presented in the literature, the findings presented in Chapter 7 of this 
thesis warrant a multipronged therapeutic intervention strategy consisting of 1) a 
blood-brain barrier permeant antioxidant activity to dampen the induction of ROS, 
especially in regions such as the olfactory bulb, vestibular nuclei, inferior olive, 
cerebellum and brain stem, 2) an immunosuppressant activity to prevent the innate 
immune response against self-antigens and 3) a mitochondrial biogenesis activity to 
increase the ATP production capacity in the afflicted regions of the brain.
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De oxidatieve fosforylering (OXFOS) staat (samen met de citroenzuurcyclus) 
centraal in de stofwisseling van alle organismen die zuurstof gebruiken. Dit 
metabole proces vindt plaats in de mitochondriën, waar speciale enzymen 
(o.a. complexen I-IV) voedingsstoffen oxideren en de hierbij vrijgekomen energie 
opslaan in de vorm van adenosinetrifosfaat (ATP). Patiënten met een disfunctioneel 
OXFOS systeem, wat leidt tot een verstoorde cellulaire energiehuishouding, 
kunnen ongeacht hun leeftijd diverse tekenen en symptomen van orgaanschade 
vertonen. De genetische basis van deze ziekten is complex. Het nucleair en 
mitochondrieel DNA zijn samen verantwoordelijk voor de genetische controle van 
de assemblage en het onderhoud van een volledig functioneel OXFOS systeem. 
Iedere mutatie in een gen dat de functionaliteit van het OXFOS systeem beïnvloedt, 
kan leiden tot OXFOS disfunctie gerelateerde klinische symptomen. Mutaties in 
nucleaire genen worden op een Mendeliaanse wijze overgeërfd, terwijl mutaties 
in de mitochondriale genen maternaal worden overgeërfd. Organen met een 
hoog energieverbruik worden het hardst getroffen, in het bijzonder de hersenen. 
De neuronen gaan geleidelijk ten onder, wat tot een progressief verlies van de 
structuur en functie van het zenuwstelsel leidt. De progressie van de symptomen 
varieert van acuut en snel tot subtiel en chronisch. De essentiële functie van het 
neuronale OXFOS systeem in het handhaven van bioenergetische behoeften wordt 
geïllustreerd door het feit dat OXFOS disfunctie leidt tot defecten in neuronale 
groei en transport, alsook apoptose en neuronale dood. Dit kan op zijn beurt 
microgliale activering veroorzaken, wat desastreuse gevolgen kan hebben zoals 
verdere oxidatieve en nitrosatieve stress, met additionele neuronale beschadiging 
en de dood tot gevolg.
*   *   *
Het doel van dit proefschrift was om, met behulp van het Ndufs4-/- muismodel, een 
beter inzicht in de pathofysiologische gevolgen van geïsoleerde mitochondriële 
complex I (CI) deficiëntie te krijgen en om bij te dragen aan een relevante 
therapeutische strategie voor het verlichten en/of afzwakken van deze ziekte. 
Daartoe hebben we de fenotypische uitingen van de Ndufs4 deletie gekarakteriseerd, 
door de tekenen en symptomen vanaf postnataal dag 0 tot het  humane eindpunt bij 
te houden (Hoofdstuk 1). In overeenstemming met andere studies vonden we dat 
Ndufs4-/- muizen verschillende klinische kenmerken vertoonden zoals waargenomen 
bij kinderen met geïsoleerde CI deficiëntie waaronder hypotonie, progressieve 
spierzwakte, epileptische aanvallen en ataxie. Op basis van deze bevindingen 
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werd geconcludeerd dat de Ndufs4-/- muis een relevant model zou kunnen zijn om 
therapeutische strategieën die bestemd zijn voor vertaling naar de mens te evalueren.
*   *   *
Gezien het ernstige fenotype van de Ndufs4-/- muis, waren we geïntrigeerd door 
onze in vivo waarneming dat de maximale snelheid van de ATP productie niet 
aangedaan was in deze muizen, ondanks het vrijwel geheel ontbreken van CI-
activiteit. Dit motiveerde ons om mitochondria verrijkte fracties van specifieke 
weefsels in deze muizen te bestuderen (Hoofdstuk 2). De maximale snelheid 
van de mitochondriële ATP productie bleek aanzienlijk afgenomen te zijn in 
skeletspierweefsel, de hersenen en het hart per eenheid mitochondriale massa na 
normalisatie ten opzichte van de maximale citraat synthase activiteit. De maximale 
activiteit van CI bleek nog veel sterker verminderd te zijn in deze weefsels. Echter, 
wanneer de maximale mitochondriale ATP productie snelheid uitgedrukt werd 
per mg eiwit, bleek deze niet afgenomen te zijn in het skeletspierweefsel en het 
hart, in tegenstelling tot de hersenen. Dit betekent dat de totale mitochondriale 
ATP productiecapaciteit per eenheid weefselmassa enkel verlaagd is in dit laatste 
orgaan. Verder onderzoek demonstreerde een toename in de maximale citraat 
synthase, CII, III en IV activiteit in skeletspierweefsel en het hart, indicatief voor een 
adaptieve verhoging van de mitochondriale massa in deze weefsels. Het ontbreken 
van dezelfde adaptieve verhoging in de hersenen, toont aan dat dit waarschijnlijk 
het meest kwetsbare weefsel is in CI deficiëntie veroorzaakt door een mutatie in 
het Ndufs4 gen.
*   *   *
In Hoofdstuk 3 hebben we een in silico strategie gebruikt om te trachten het 
mechanisme te achterhalen waarmee Ndufs4-/- skeletspierweefsel mitochondriën, 
ondanks een ~80% daling van de maximale CI activiteit, nog steeds in staat zijn 
om ATP te produceren uit CI-specifieke substraten met een maximale snelheid die 
vergelijkbaar is met die verkregen met wildtype skeletspierweefsel mitochondriën 
per eenheid weefselmassa (zie Hoofdstuk 2). Hiervoor hebben we een eerder 
gevalideerd wiskundig model voor mitochondriale stofwisseling in skeletspierweefsel 
aangepast aan onze experimentele omstandigheden. De hieruit voortgevloeide 
berekeningen voorspelden dat de experimenteel gemeten veranderingen in 
maximale activiteit van CI, II, III en IV per eenheid weefselmassa resulteerden in 
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maximale snelheden van mitochondriale pyruvaat oxidatie en ATP productie in 
Ndufs4-/- skeletspierweefsel per eenheid weefsel massa die nagenoeg identiek 
waren aan die van de controle. Deze voorspelling was in volledige overeenstemming 
met onze experimentele resultaten. 
*   *   *
Kinderen met mitochondriale aandoeningen van het energie genererende systeem 
worden vaak geanestheseerd voor een breed scala aan operaties. Echter kunnen deze 
aandoeningen de reactie van de patiënt op de anesthesie veranderen. Aangetoond 
is dat het vluchtige anesthetische isofluraan de activiteit van CI remt. Bovendien 
is gebleken dat CI deficiënt C. elegans overgevoelig is voor vluchtige anesthetica. 
Samen met eerder bewijs dat Ndufs4-/- muizen progressieve ademhalingsstoornissen 
ontwikkelen, met een vroege dood tot gevolg, hebben deze bevindingen ons 
aangespoord om de gevoeligheid van deze muizen voor isofluraan te onderzoeken. 
Hoofdstuk 4 laat zien dat Ndufs4-/- muizen een geleidelijke toename met de leeftijd 
lieten zien van zowel isofluraan gevoeligheid als ademhalingsdepressie. Onlangs 
werd aangetoond dat glutamaat gemedieerde transmissie een belangrijke rol speelt 
in de overgevoeligheid voor vluchtige anesthetica in Ndufs4-/- muizen.
*   *   *
De resultaten in Hoofdstuk 5 laten zien dat isofluraananesthesie tot een 
aanzienlijke toename van de maximale mitochondriale ATP productiesnelheid 
leidt per eenheid weefselmassa in een mitochondria verrijkte fractie van wildtype 
en Ndufs4-/- hersenen. Opvallend is dat, in overeenstemming met de literatuur, 
isofluraananesthesie de maximale activiteit van CI met 30% verlaagde in wildtype 
hersenen. Dit resultaat is in overeenstemming met de conclusie uit Hoofdstuk 3 dat 
CI activiteit kan worden verlaagd tot een weefselspecifieke drempel, zonder dat dit 
de mitochondriale ATP productiecapaciteit negatief beïnvloed. Tegenovergesteld, 
verhoogde isofluraananesthesie de activiteit van zowel CII, CIII als CIV in wildtype 
en Ndufs4-/- hersenen. Samen tonen deze bevindingen aan dat isofluraananesthesie 
een positief effect heeft op de capaciteit van hersenmitochondriën van Cl deficiënte 
muizen om hun belangrijkste substraat pyruvaat om te zetten in ATP.
*   *   *
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In Hoofdstuk 6 bespreken we neuronen die vanwege hun vermoedelijke gevoeligheid 
voor oxidatieve schade het meest bijdragen aan het neurologische fenotype in 
Ndufs4-/- muismodellen. De zeer hoge energiebehoefte van neuronen verklaart 
waarom de hersenen, die slechts ~2% van het totale lichaamsgewicht uitmaken, 
verantwoordelijk zijn voor 20% van het totale zuurstofverbruik door het lichaam. 
Neuronen zijn sterk gedifferentieerde cellen die grote hoeveelheden ATP verbruiken 
om de ionische gradiënten van hun celmembraan in stand te houden, welke vereist 
zijn voor effectieve neurotransmissie. Neuronen zijn afhankelijk van het OXFOS 
systeem voor hun ATP behoefte, aangezien een overstap naar glycolyse, wanneer 
OXFOS beperkt is, onvoldoende ATP genereert. Neuronen zijn langlevende cellen, 
wat belangrijk is omdat hun synaptische verbindingen essentieel zijn voor het goed 
blijven functioneren van het brein. Deze twee eigenschappen kunnen een ernstig 
probleem vormen, aangezien mitochondriale oxidatieve ATP productie gepaard 
gaat met de productie van toxische zuurstofradicalen. Er wordt verondersteld dat 
dit de voornaamste reden is waarom neuronen geen vetzuren oxideren, aangezien 
voor elk acetyl-CoA dat ontstaat tijdens vetzuur afbraak, een FADH
2
 en een NADH 
molecuul worden geproduceerd. Dit resulteert in een veel grotere toename van de 
hoeveelheid FADH
2
 in de cel, dan het geval is bij de oxidatie van glucose. Dit FADH
2
 
wordt geoxideerd door het enzym “electron transfer flavoprotein: ubiquinone 
oxidoreductase”, dat daardoor met CI concurreert voor de reductie van ubiquinon 
naar ubiquinol. Dit leidt tot een opstapeling van NADH en daarmee een hogere 
kans op een toename in de productie van reactieve zuurstofverbindingen (ROS) 
door CI zelf en/of door mitochondriale NADH hydrogenases. Neuronen prefereren 
daarom glucose (en ketonlichamen) voor hun energievoorziening, ondanks dat 
vetzuren ongeveer tweemaal zoveel energie genereren. Desondanks vormen 
neuronen nog steeds ROS tijdens de mitochondriale ATP productie. Er wordt 
gespeculeerd dat deze levenslange ROS productie, ondanks de aanwezigheid van 
talrijke antioxidantsystemen, een ophoping van beschadigingen en daarmee een 
progressief verlies van neuronfunctie veroorzaakt. Een mogelijke versnelling van 
dit proces zou kunnen bijdragen aan hersenziekten bij ouderen zoals de ziekte van 
Alzheimer, amyotrofische laterale sclerose (ALS) en de ziekte van Parkinson.
*   *   *
Trolox is een wateroplosbare analoog van vitamine E met vergelijkbare 
antioxidanteigenschappen. In Hoofdstuk 7 tonen we aan dat tweemaal daagse 
intraperitoneale injectie van Trolox vanaf week 3 na de geboorte, de geleidelijke 
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afname van het spieruithoudingsvermogen en de motorische coördinatie van 
Ndufs4-/- muizen vertraagde. Analyse van de maximale snelheid van de mitochondriale 
ATP productie per eenheid weefselmassa in een mitochondria verrijkte fractie van 
de achterpootspieren van 6 weken oude dieren liet een afname zien in vehikel-
behandelde Ndufs4-/- muizen ten opzichte van controle dieren. Dit in tegenstelling 
tot onze bevindingen in Hoofdstuk 2, waar geen verschil in de maximale snelheid van 
mitochondriële ATP productie tussen 31-34 dagen oude WB Ndufs4-/- en hun wildtype 
nestgenoten gevonden werd. De eerder aangetoonde toename in de maximale 
citraat synthase activiteit in 31-34 dagen oude Ndufs4-/- muizen, bleek afwezig te 
zijn in 6 weken oude Ndufs4-/- muizen. Dit suggereert dat de eerder voorgestelde 
adaptieve verhoging van mitochondriale massa niet meer aanwezig is in eindstadium 
Ndufs4-/- muizen. Analyse van de mitochondria verrijkte fracties van achterpoot 
spierweefsel van Trolox-behandelde Ndufs4-/- muizen liet tevens een ogenschijnlijke 
toename van de maximale CI activiteit zien. Deze toename bleek niet gepaard te 
gaan met een verhoging van de maximale mitochondriale ATP productiesnelheid. 
Deze bevindingen suggereren dat Trolox geen effect heeft op de skeletspieren, maar 
juist op de hersenen. Het door GFAP positieve cellen gepopuleerde deel van de 
granulaire laag van de cerebrale cortex, alsmede het aantal Purkinje cellen in het 
cerebellum van Ndufs4-/- muizen werd niet beïnvloed door Trolox-behandeling.  In 
het netvlies zagen we een afname in de apoptose van neuronale nuclei wanneer 
Ndufs4-/- muizen behandeld werden met Trolox, tot een niveau gelijk aan dat van 
wildtype muizen. Desalniettemin zal de analyse van een of meerdere functionele 
parameters uit moeten wijzen of deze inhibitie van neuronale celdood door Trolox 
resulteert in een toename van het gezichtsvermogen.
*   *   *
Naar aanleiding van onze celbiologische studies zijn er een aantal Trolox varianten 
ontwikkeld en getest op primaire fibroblasten van patiënten met geïsoleerde 
CI deficiëntie. De meest veelbelovende varianten zijn reeds geselecteerd voor 
de ontwikkeling van nieuwe behandelingen voor deze ziekte. Samen met reeds 
gepubliceerde data, rechtvaardigen onze bevindingen in Hoofdstuk 7 een 
therapeutische strategie bestaande uit 1) antioxidanten die de bloed-hersenbarrière 
kunnen passeren en zo de inductie van ROS kunnen temperen; 2) immunosuppressiva 
om de humorale immuunrespons tegen lichaamseigen antigenen te voorkomen; en 
3) stimulatie van de mitochondriale biogenese om de ATP productiecapaciteit in de 
getroffen gebieden van de hersenen te verhogen.
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